




INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification ⁶ : C07D 487/04, A61K 31/55 // (C07D 487/04, 243:00, 209:00) (C07D 487/04, 243:00, 231:00)</p>	<p>A1</p>	<p>(11) International Publication Number: WO 97/49707 (43) International Publication Date: 31 December 1997 (31.12.97)</p>
<p>(21) International Application Number: PCT/US97/10736 (22) International Filing Date: 20 June 1997 (20.06.97) (30) Priority Data: 08/672,150 27 June 1996 (27.06.96) US (71) Applicant: AMERICAN CYANAMID COMPANY [US/US]; Five Giralda Farms, Madison, NJ 07940-0874 (US). (72) Inventors: ALBRIGHT, Jay, Donald; 5 Clifford Court, Nanuet, NY 10954 (US). VENKATESAN, Aranapakam, Mudum- bai; Apartment 9K, 97-07 63rd Road, Rego Park, NY 11374 (US). DUSZA, John, Paul; 24 Convent Road, Nanuet, NY 10954 (US). SUM, Fuk-Wah; 16 Chamberlain Court, Pomona, NY 10970 (US). (74) Agents: ALICE, Ronald, W.; American Home Products Corpo- ration, Five Giralda Farms, Madison, NJ 07940-0874 (US) et al.</p>		<p>(81) Designated States: AL, AU, BA, BB, BG, BR, CA, CN, CU, CZ, EE, GE, GH, HU, IL, IS, JP, KP, KR, LC, LK, LR, LT, LV, MG, MK, MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TR, TT, UA, UZ, VN, YU, ZW, ARIPO patent (GH, KE, LS, MW, SD, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG).</p> <p>Published <i>With international search report.</i> <i>Before the expiration of the time limit for amending the</i> <i>claims and to be republished in the event of the receipt of</i> <i>amendments.</i></p>
<p>(54) Title: TRICYCLIC BENZAZEPINE VASOPRESSIN ANTAGONISTS</p> <p>(57) Abstract</p> <p>Tricyclic compound of general Formula (I), as defined herein which exhibit antagonist activity at V₁ and/or V₂ receptors and exhibit <i>in vivo</i> vasopressin antagonist activity, methods for using such compounds in treating diseases characterized by excess renal reabsorption of water, and process for preparing such compounds.</p> <div style="text-align: right;">  <p>(I)</p> </div>		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece			TR	Turkey
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MN	Mongolia	UA	Ukraine
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NE	Niger	VN	Viet Nam
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	NZ	New Zealand		
CM	Cameroon			PL	Poland		
CN	China	KR	Republic of Korea	PT	Portugal		
CU	Cuba	KZ	Kazakhstan	RO	Romania		
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation		
DE	Germany	LI	Liechtenstein	SD	Sudan		
DK	Denmark	LK	Sri Lanka	SE	Sweden		
EE	Estonia	LR	Liberia	SG	Singapore		

5

10 Title: TRICYCLIC BENZAZEPINE VASOPRESSIN
ANTAGONISTS

This case is a continuation-in-part of Serial
No. 08/373,132, filed January 17, 1995.

1. Field of the Invention

15 This invention relates to new tricyclic non-
peptide vasopressin antagonists which are useful in
treating conditions where decreased vasopressin levels
are desired, such as in congestive heart failure, in
disease conditions with excess renal water reabsorption
20 and in conditions with increased vascular resistance and
coronary vasoconstriction.

2. Background of the Invention

Vasopressin is released from the posterior
25 pituitary either in response to increased plasma
osmolarity detected by brain osmoreceptors or decreased
blood volume and blood pressure sensed by low-pressure
volume receptors and arterial baroreceptors. The
hormone exerts its action through two well defined
30 receptor subtypes: vascular V₁ and renal epithelial V₂
receptors. Vasopressin-induced antidiuresis, mediated
by renal epithelial V₂ receptors, helps to maintain
normal plasma osmolarity, blood volume and blood
pressure.

35 Vasopressin is involved in some cases of
congestive heart failure where peripheral resistance is

increased. V₁ antagonists may decrease systemic vascular resistance, increase cardiac output and prevent vasopressin induced coronary vasoconstriction. Thus, in conditions with vasopressin induce increases in total
5 peripheral resistance and altered local blood flow, V₁-antagonists may be therapeutic agents. V₁ antagonists may decrease blood pressure, induced hypotensive effects and thus be therapeutically useful in treatment of some types of hypertension.

10 The blockage of V₂ receptors is useful in treating diseases characterized by excess renal reabsorption of free water. Antidiuresis is regulated by the hypothalamic release of vasopressin (antidiuretic hormone) which binds to specific receptors on renal
15 collecting tubule cells. This binding stimulates adenylyl cyclase and promotes the cAMP-mediated incorporation of water pores into the luminal surface of these cells. V₂ antagonists may correct the fluid retention in congestive heart failure, liver cirrhosis,
20 nephritic syndrome, central nervous system injuries, lung disease and hyponatremia.

Elevated vasopressin levels occur in congestive heart failure which is more common in older patients with chronic heart failure. In patients with
25 hyponatremic congestive heart failure and elevated vasopressin levels, a V₂ antagonist may be beneficial in promoting free water excretion by antagonizing the action of antidiuretic hormone. On the basis of biochemical and pharmacological effects of the hormone,
30 antagonists of vasopressin are expected to be therapeutically useful in the treatment and/or prevention of hypertension, cardiac insufficiency, coronary vasospasm, cardiac ischemia, renal vasospasm, liver cirrhosis, congestive heart failure, nephritic
35 syndrome, brain edema, cerebral ischemia, cerebral

hemorrhage-stroke, thrombosis-bleeding and abnormal states of water retention.

The following prior art references describe peptide vasopressin antagonists: M. Manning et al.,
5 J. Med. Chem., 35, 382(1992); M. Manning et al., J. Med. Chem., 35, 3895(1992); H. Gavras and B. Lammek, U.S. Patent 5,070,187 (1991); M. Manning and W.H. Sawyer, U.S. Patent 5,055,448(1991) F.E. Ali, U.S. Patent 4,766,108(1988); R.R. Ruffolo et al., Drug
10 News and Perspective, 4(4), 217, (May)(1991). P.D. Williams et al., have reported on potent hexapeptide oxytocin antagonists [J. Med. Chem., 35, 3905(1992)] which also exhibit weak vasopressin antagonist activity in binding to V₁ and V₂ receptors. Peptide vasopressin
15 antagonists suffer from a lack of oral activity and many of these peptides are not selective antagonists since they also exhibit partial agonist activity.

Non-peptide vasopressin antagonists have recently been disclosed, Y. Yamamura et al., Science,
20 252, 579(1991); Y. Yamamura et al., Br. J. Pharmacol., 105, 787(1992); Ogawa et al., (Otsuka Pharm Co., LTD.) EP 0514667-A1; EPO 382185-A2; WO9105549 and U.S.5,258,510; WO 9404525 Yamanouchi Pharm.Co.,Ltd., WO 9420473; WO 9412476; WO 9414796; Fujisawa Co. Ltd.,
25 EP 620216-A1 Ogawa et al, (Otsuka Pharm. Co.) EP 470514A disclose carbostyryl derivatives and pharmaceutical compositions containing the same. Non-peptide oxytocin and vasopressin antagonist have been disclosed by Merck and Co.; M.G. Bock and P.D. Williams, EP 0533242A; M.G. Bock et al., EP 0533244A; J.M. Erb, D.F. Verber, P.D. Williams, EP 0533240A; K. Gilbert et al., EP 0533243A.
30


Premature birth can cause infant health problems and mortality and a key mediator in the mechanism of labor is the peptide hormone oxytocin. On
35 the basis of the pharmacological action of oxytocin, antagonists of this hormone are useful in the prevention

of preterm labor, B.E. Evans et al., J. Med. Chem. 35, 3919(1992), J. Med. Chem., 36, 3993(1993) and references therein. The compounds of this invention are
 5 useful in the control of premature birth.


The present invention relates to novel tricyclic derivatives which exhibit antagonist activity at V₁ and/or V₂ receptors and exhibit in vivo vasopressin antagonist activity. The compounds also
 10 exhibit antagonist activity at oxytocin receptors.

SUMMARY OF THE INVENTION


This invention relates to new compounds selected from those of the general formula I:



15 wherein Y is a moiety selected from; $-(CH_2)_n-$ wherein n is an integer from 0 to 2,




A-B is a moiety selected from



20 wherein m is an integer from 1 to 2 provided that when Y is $-(CH_2)_n-$ and n is 2, m may also be zero and when n is zero, m may also be three, provided also that when Y is $-(CH_2)_n-$ and n is 2, m may not be two; and the moiety:









represents: (1) phenyl or substituted phenyl optionally substituted by one or two substituents selected from (C₁-C₃)lower alkyl, halogen, amino, (C₁-C₃)lower alkoxy
 5 or (C₁-C₃)lower alkylamino; (2) a 5-membered aromatic (unsaturated) heterocyclic ring having one heteroatom selected from O, N or S; (3) a 6-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom; (4) a 5 or 6-membered aromatic (unsaturated)
 10 heterocyclic ring having two nitrogen atoms; (5) a 5-membered aromatic (unsaturated) heterocyclic ring having one nitrogen atom together with either one oxygen or one sulfur atom; wherein the 5 or 6-membered heterocyclic rings are optionally substituted by (C₁-C₃)lower alkyl,
 15 halogen or (C₁-C₃)lower alkoxy;
 the moiety:



is a five membered aromatic (unsaturated) nitrogen containing heterocyclic ring wherein D, E and F are
 20 selected from carbon and nitrogen and wherein the carbon atoms may be optionally substituted by a substituent selected from halogen, (C₁-C₃)lower alkyl, hydroxy, -COCCl₃, -COCF₃,

-6-



-CHO, amino, (C₁-C₃) lower alkoxy, (C₁-C₃) lower
 5 alkylamino, CONH-lower alkyl (C₁-C₃), and -CON[lower

alkyl(C₁-C₃)]₂; q is one or two; R_b is independently selected from hydrogen, -CH₃ or -C₂H₅;


R_e is H, lower alkyl(C₁-C₃), hydroxyethyl, -CH₂CO₂R⁵⁰, -CH₂C(CH₂OH)₃;

5 R⁵⁰ is H, lower alkyl(C₁-C₄);

R³ is a moiety of the formula:



wherein Ar is a moiety selected from the group consisting of












10

wherein R⁴ is selected from hydrogen, lower alkyl(C₁-C₃), -CO lower alkyl(C₁-C₃);


R¹ and R² are independently selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, hydroxy and

15 halogen; R⁵ is selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen; R⁶ is selected from (a) moieties of the formulae:


-8-




wherein cycloalkyl is defined as C₃-C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently selected from hydrogen, -CH₃, -C₂H₅,



- 5 - (CH₂)_q-O-lower alkyl (C₁-C₃) and -CH₂CH₂OH, q is one or two, and R₁, R₂ and R_b are as hereinbefore defined;
 (b) moieties of the formula:




- 10 wherein R⁷ is lower alkyl (C₃-C₈), lower alkenyl (C₃-C₈), - (CH₂)_p-cycloalkyl (C₃-C₆),






-10-

wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R¹ and R² are as hereinbefore defined;
 (c) a moiety of the formula:




- 5 wherein J is R_a, lower alkyl(C₃-C₈) branched or unbranched, lower alkenyl(C₃-C₈) branched or unbranched, O-lower alkyl(C₃-C₈) branched or unbranched, -O-lower alkenyl(C₃-C₈) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties:



10


or -CH₂-K' wherein K' is (C₁-C₃) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:






-11-

wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C₁-C₃)lower alkyl, hydroxy, -CO-lower alkyl(C₁-C₃), CHO, (C₁-C₃)lower alkoxy, -CO₂-
 5 lower alkyl(C₁-C₃), and R_a and R_b are as hereinbefore defined;

(d) a moiety of the formula:




wherein R_c is selected from halogen, (C₁-C₃) lower alkyl, -O-lower alkyl(C₁-C₃), OH,




wherein R_a and R_b are as hereinbefore defined and Ar' is
 10 selected from moieties of the formula:

-12-




wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);

- 5 R⁸ and R⁹ are independently selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),






- 10 -N(R_b)(CH₂)_vN(R_b)₂, and CF₃ wherein v is one to three and;
R¹⁰ is selected from hydrogen, halogen and lower alkyl(C₁-C₃); R¹⁴ is

-O- lower alkyl (C_3-C_8) branched or unbranched ,






-NH lower alkyl (C_3-C_8) branched or unbranched ,






wherein n is 0 or 1; q is 1 or 2; R_a is hydrogen, $-\text{CH}_3$ or $-\text{C}_2\text{H}_5$; R^1 is hydrogen, (C1-C3)lower alkyl, (C1-C3)lower alkoxy and halogen; R^{45} is hydrogen, (C1-C3)lower alkyl, (C1-C3)-lower alkoxy and halogen; R^{20} is hydrogen, halogen, (C1-C3)lower alkyl, (C1-C3)lower alkoxy, NH_2 , $-\text{NH(C1-C3)lower alkyl}$, $-\text{N-[(C1-C3)lower alkyl]}_2$.



and the pharmaceutically acceptable salts thereof.


DETAILED DESCRIPTION OF THE INVENTION

- Within the group of the compounds defined by
- 5 Formula I, certain subgroups of compounds are broadly preferred. Broadly preferred are those compounds wherein R₃ is the moiety:




and Ar is selected from the moieties:

-16-




Y is (CH₂)_n and n is one or zero;
 wherein R¹, R², R⁴, R⁵, R⁶ and R¹⁴ are as hereinbefore defined.

- 5 Especially preferred are compounds wherein R³ is the moiety:




Ar is selected from the moieties:



- 10 Y is -(CH₂)_n and n is one and m is one;
 wherein R¹, R², R⁴, R⁶ and R¹⁴ are as hereinbefore defined.


Especially preferred are compounds wherein R³ is the moiety:



15


Ar is selected from the moieties:

-17-




Y is $-(CH_2)_n$ and n is one or zero;

R^6 is




- 5 wherein cycloalkyl is defined as C₃-C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; and wherein X, R_a , R_b and R^{14} are as hereinbefore defined; and Ar' is selected from the moieties:



- 10 wherein R^8 , R^9 and W' are as hereinbefore defined.


Also especially preferred are compounds wherein Y in Formula I is $-(CH_2)_n-$ and n is zero or one; A-B is

-18-




and R^1 , R^2 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} and R^{14} are as hereinbefore defined; and m is an integer from 1-2.


The most preferred of the compounds of Formula
 5 I are those wherein Y is $-(\text{CH}_2)_n-$ and n is one; A-B is:



R_3 is the moiety:




Ar is selected from the moieties:




10

R^6 is



(CH₂)_n-cycloalkyl wherein cycloalkyl is defined as C₃-C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; wherein X, R_a, R_b and R¹⁴ are as hereinbefore defined; and Ar' is:



5

wherein R⁵, R⁸ and R⁹ are as previously defined.


The most highly broadly preferred of the compounds of Formula I are those wherein Y is -(CH₂)_n- and n is zero or one; wherein the moiety:



10


is a phenyl, substituted phenyl, thiophene, furan, pyrrole or pyridine ring;

A-B is:




15 m is one when n is one and m is two when n is zero; D, E, F, R¹, R², R⁴, R⁵, R⁷, R⁸, R⁹, R¹⁰ are as previously defined;


R₃ is the moiety:




20 wherein Ar is selected from the moieties:



and R_6 is selected from the group:



where Ar' is selected from the group:




5

and R^{14} , X , W' , R_a , R_b and cycloalkyl are as previously described.

More particularly preferred are compounds of the formulae:

-21-




wherein the moiety:



is selected from a phenyl, thiophene, furan, pyrrole, or
 5 pyridine ring;
 R^3 is the moiety:




wherein Ar is selected from the moieties:




10 R^6 is


-22-



and Ar' is selected from the moieties:




wherein X, R_a, R_b, R⁵, R⁷, R⁸, R⁹, R¹⁴, cycloalkyl and
 5 W' are as hereinbefore described;
 R¹¹ is selected from hydrogen, halogen, (C₁-C₃) lower
 alkyl, hydroxy,




-CHO, and (C₁-C₃) lower alkoxy; and R¹² is selected from
 10 hydrogen, (C₁-C₃) lower alkyl, halogen and (C₁-C₃) lower
 alkoxy.

Also particularly preferred are compounds of
 the formulae:

-23-



and




wherein m is one or two;
the moiety:




5

is selected from a phenyl, thiophene, furan, pyrrole or
pyridine ring;


R³ is the moiety:




10 wherein Ar is selected from the moieties:




R⁶ is



$(CH_2)_n$ cycloalkyl; Ar' is selected from the moieties:




- wherein X , R_a , R_b , R^5 , R^6 , R^8 , R^9 , R^{14} , cycloalkyl and
 5 W' are as hereinbefore defined;
 R^{11} is selected from hydrogen, halogen, (C_1-C_3) lower
 alkyl, hydroxy,



- $-CHO$, and (C_1-C_3) lower alkoxy; and
 10 R^{12} is selected from hydrogen, (C_1-C_3) lower alkyl,
 halogen and (C_1-C_3) lower alkoxy.

More particularly preferred are compounds of
 the formulae:


-25-



R^3 is the moiety:




wherein Ar is selected from the moieties:









5



R^6 is




R^{14} is



- wherein n is 0 or 1; R_a is hydrogen, $-CH_3$ or $-C_2H_5$; R' is hydrogen, (C1-C3)lower alkyl, (C1-C3)lower alkoxy and halogen; R^{20} is hydrogen, halogen, (C1-C3)lower alkyl, (C1-C3)lower alkoxy, NH_2 , $-NH(C_1-C_3)lower\ alkyl$, $-N-[(C_1-C_3)lower\ alkyl]_2$,



wherein cycloalkyl is defined as C₃-C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; R_b is hydrogen; R_a is independently selected from hydrogen, -CH₃, -C₂H₅ or -(CH₂)_qN(CH₃)₂; Ar' is selected from the moieties:




5

wherein q, X, R_a, R_b, R⁵, R⁷, R⁸, R⁹, R¹⁰, R¹¹ and W' are as hereinbefore described;

R¹² and R¹³ are independently selected from hydrogen, (C₁-C₃) lower alkyl, halogen, amino, (C₁-C₃) lower alkoxy or (C₁-C₃) lower alkylamino.

10

Also particularly preferred are compounds of the formulae:




wherein m is one or two;


15 R³ is the moiety:




wherein Ar is selected from the moieties:



R⁶ is




wherein cycloalkyl is defined as C₃-C₆ cycloalkyl,
 5 cyclohexenyl or cyclopentenyl; R_b is hydrogen; R_a is
 independently selected from hydrogen, -CH₃, -C₂H₅ or
 -(CH₂)_qN(CH₃)₂; and Ar' is selected from the moieties:




wherein q, X, R_a, R_b, R⁵, R⁷, R⁸, R⁹, R¹¹, R¹⁴ and W'
 10 are as hereinbefore defined;
 R¹² and R¹³ are independently selected from hydrogen,
 (C₁-C₃) lower alkyl, halogen, amino, (C₁-C₃) lower
 alkoxy or (C₁-C₃) lower alkylamino.

The most highly broadly preferred of the
 15 compounds are those of the formula:




wherein Y is a moiety $-(CH_2)-$;


A-B is a moiety:




5 the moiety:




is a five membered aromatic (unsaturated) nitrogen
containing heterocyclic ring optionally substituted by
halogen, (C_1-C_3) lower alkyl, and $-(CH_2)_q-N(R_b)_2$ wherein
10 D is carbon; q is 1 or 2; R_b is independently selected
from hydrogen, $-CH_3$, and C_2H_5 ;
 R^3 is a moiety of the formula:



wherein Ar is a moiety selected from the group
15 consisting of




R^1 and R^2 are independently selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen; R^{14} is selected from a moiety of the formula:



5

wherein R_a is hydrogen; R^{10} is selected from hydrogen, halogen, and (C₁-C₃)lower alkyl; R^8 is selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃), CF₃, and




and the pharmaceutically acceptable salts, esters and pro-drug forms thereof.

15


-31-

Preferred group I. Among the more preferred compounds of this invention are those selected from the
 5 formula:



wherein Y is CH₂;


A-B is a moiety selected from



10 and the moiety:











represents phenyl or substituted phenyl optionally substituted by one or two substituents selected from (C₁-C₃)lower alkyl, halogen, amino, (C₁-C₃)lower alkoxy
 15 or (C₁-C₃)lower alkylamino;
 the moiety:



is a five membered aromatic (unsaturated) nitrogen containing heterocyclic ring wherein D, E and F are
 20 selected from carbon and nitrogen and wherein the carbon atoms may be optionally substituted by a substituent selected from halogen, (C₁-C₃)lower alkyl, hydroxy, -COCCl₃, -COCF₃,

-32-




5 -CHO, amino, (C₁-C₃)lower alkoxy, (C₁-C₃)lower
alkylamino, CONH-lower alkyl(C₁-C₃), and -CON{lower
alkyl(C₁-C₃)₂; q is one or two;

R_b is independently selected from hydrogen, $-CH_3$ or $-C_2H_5$;


R_e is H, lower alkyl(C1-C3), hydroxyethyl, $-CH_2CO_2R^{50}$, $-CH_2C(CH_2OH)_3$;

5 R^{50} is H or lower alkyl(C1-C4);

R^3 is a moiety of the formula:



wherein Ar is a moiety selected from the group consisting of




10

R^4 is selected from hydrogen, lower alkyl(C1-C3); $-CO-$ lower alkyl(C1-C3);


R^1 and R^2 are independently selected from hydrogen, (C1-C3)lower alkyl, (C1-C3)lower alkoxy, hydroxy and

15 halogen; R^5 is selected from hydrogen, (C1-C3)lower alkyl, (C1-C3)lower alkoxy and halogen;


R^6 is selected from (a) moieties of the formula:





wherein cycloalkyl is defined as C₃ to C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently selected from hydrogen, -CH₃, -C₂H₅,



- 5 $-(CH_2)_q-O$ -lower alkyl (C₁-C₃) and $-CH_2CH_2OH$, q is one or two, and R₁, R₂ and R_b are as hereinbefore defined;
(b) moieties of the formula:




- 10 wherein R⁷ is lower alkyl (C₃-C₈), lower alkenyl (C₃-C₈), $-(CH_2)_p$ -cycloalkyl (C₃-C₆),






-36-

wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R¹ and R² are as hereinbefore defined;
 (c) a moiety of the formula:




- 5 wherein J is R_a, lower alkyl(C₃-C₈) branched or unbranched, lower alkenyl(C₃-C₈) branched or unbranched, O-lower alkyl(C₃-C₈) branched or unbranched, -O-lower alkenyl(C₃-C₈) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties:




10

or -CH₂-K' wherein K' is (C₁-C₃) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:






-37-

wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C₁-C₃)lower alkyl, hydroxy, -CO-lower alkyl(C₁-C₃), CHO, (C₁-C₃)lower alkoxy, -CO₂-
 5 lower alkyl(C₁-C₃), and R_a and R_b are as hereinbefore defined;
 (d) a moiety of the formula:




wherein R_c is selected from halogen, (C₁-C₃) lower alkyl, -O-lower alkyl(C₁-C₃), OH,




and R_a and R_b are as hereinbefore defined wherein Ar' is
 10 selected from moieties of the formula:

-38-



wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);


- 5 R⁸ and R⁹ are independently selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),






- 10 -N(R_b)(CH₂)_vN(R_b)₂, and CF₃ wherein v is one to three and;
R¹⁰ is selected from hydrogen, halogen and lower alkyl(C₁-C₃);









R¹⁴ is

-O-lower alkyl (C₃-C₈) branched or unbranched ,



-NH-lower alkyl (C₃-C₈) branched or unbranched ,









q is 1 or 2;

wherein n is 0 or 1;

R_a is hydrogen, $-CH_3$ or $-C_2H_5$; R' is hydrogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy and halogen;
 R^{45} is hydrogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy and halogen;

- 5 R^{20} is hydrogen, halogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy, NH_2 , $-NH(C_1-C_3)$ lower alkyl, $-N-[(C_1-C_3)$ lower alkyl] $_2$,




and the pharmaceutically acceptable salts, esters and
 10 pro-drug forms thereof.

Within preferred group I above are the following preferred sub-groups 1, 2 and 3 of compounds:

1. wherein the moiety A-B is:

-42-




wherein R^3 is as defined in preferred group I above;

2. wherein R^3 is the moiety:



5 and Ar is




wherein R^1 , R^2 and R^{14} are as defined in preferred group I above;

3. wherein R^3 is the moiety:



10


and Ar is




wherein R^1 , R^2 , and R^6 are as defined in preferred group I above.

-43-

Preferred group II. Among the most preferred compounds of this invention are those selected from the formula:




- 5 wherein Y is CH₂;
A-B is a moiety selected from









and the moiety:



- 10 represents phenyl or substituted phenyl optionally substituted by one or two substituents selected from (C₁-C₃)lower alkyl, halogen, amino, (C₁-C₃)lower alkoxy or (C₁-C₃)lower alkylamino;
the moiety:



- 15 is a five membered aromatic (unsaturated) nitrogen containing heterocyclic ring wherein D, E and F are carbon and wherein the carbon atoms may be optionally substituted by a substituent selected from halogen, (C₁-
20 C₃)lower alkyl, hydroxy, -COCCl₃, -COCF₃,




5 -CHO, amino, (C₁-C₃)lower alkoxy, (C₁-C₃)lower
alkylamino, CONH-lower alkyl(C₁-C₃), and -CON[lower
alkyl(C₁-C₃)]₂; q is one or two;

R_b is independently selected from hydrogen, $-CH_3$ or $-C_2H_5$;


R_e is H, lower alkyl(C1-C3), hydroxyethyl, $-CH_2CO_2R^{50}$, $-CH_2C(CH_2OH)_3$;

5 R^{50} is H or lower alkyl(C1-C4);

R^3 is a moiety of the formula:



wherein Ar is a moiety selected from the group consisting of













10

R^4 is selected from hydrogen, lower alkyl(C1-C3); $-CO-$ lower alkyl(C1-C3);


R^1 and R^2 are independently selected from hydrogen, (C1-C3)lower alkyl, (C1-C3)lower alkoxy, hydroxy and

15 halogen; R^5 is selected from hydrogen, (C1-C3)lower alkyl, (C1-C3)lower alkoxy and halogen;


R^6 is selected from (a) moieties of the formula:




wherein cycloalkyl is defined as C₃ to C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently selected from hydrogen, -CH₃, -C₂H₅,



- 5 - (CH₂)_q-O-lower alkyl (C₁-C₃) and -CH₂CH₂OH, q is one or two, and R₁, R₂ and R_b are as hereinbefore defined;
 (b) moieties of the formula:




- 10 wherein R⁷ is lower alkyl (C₃-C₈), lower alkenyl (C₃-C₈), - (CH₂)_p-cycloalkyl (C₃-C₆),








wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R¹ and R² are as hereinbefore defined;

(c) a moiety of the formula:




- 5 wherein J is R_a, lower alkyl(C₃-C₈) branched or unbranched, lower alkenyl(C₃-C₈) branched or unbranched, O-lower alkyl(C₃-C₈) branched or unbranched, -O-lower alkenyl(C₃-C₈) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties:




10

or -CH₂-K' wherein K' is (C₁-C₃) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:






wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C₁-C₃)lower alkyl, hydroxy, -CO-lower alkyl(C₁-C₃), CHO, (C₁-C₃)lower alkoxy, -CO₂-
 5 lower alkyl(C₁-C₃), and R_a and R_b are as hereinbefore defined;

(d) a moiety of the formula:




wherein R_c is selected from halogen, (C₁-C₃) lower alkyl, -O-lower alkyl(C₁-C₃), OH,




and R_a and R_b are as hereinbefore defined wherein Ar' is
 10 selected from moieties of the formula:

-50-



wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);


- 5 R^8 and R^9 are independently selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),






- 10 $-N(R_b)(CH_2)_vN(R_b)_2$, and CF₃ wherein v is one to three and;

R^{10} is selected from hydrogen, halogen and lower alkyl(C₁-C₃); R^{14} is









-O-lower alkyl (C_3-C_8) branched or unbranched ,



-NH lower alkyl (C_3-C_8) branched or unbranched ,



-52-







q is 1 or 2;

wherein n is 0 or 1;

R_a is hydrogen, $-CH_3$ or $-C_2H_5$; R' is hydrogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy and halogen;
 R^{45} is hydrogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy and halogen;

- 5 R^{20} is hydrogen, halogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy, NH_2 , $-NH(C_1-C_3)$ lower alkyl, $-N-[(C_1-C_3)$ lower alkyl] $_2$,




- and the pharmaceutically acceptable salts, esters and
 10 pro-drug forms thereof.


Within preferred group II above are the following preferred sub-groups 1 and 2 of compounds:

1. wherein R^3 is the moiety:

-54-



and Ar is




wherein R¹, R² and R¹⁴ are as defined in preferred group
5 II above;

2. wherein R³ is the moiety:




and Ar is



10 wherein R¹, R² and R⁶ are as defined in in preferred group II above.

Preferred group III. Among the preferred compounds of this invention are those selected from those of the formulae:




15

-55-

wherein Y is CH₂;

A-B is a moiety selected from




and the moiety:



5







represents phenyl or substituted phenyl optionally substituted by one or two substituents selected from (C₁-C₃)lower alkyl, halogen, amino, (C₁-C₃)lower alkoxy or (C₁-C₃)lower alkylamino;

10 the moiety:



is a five membered aromatic (unsaturated) nitrogen containing heterocyclic ring wherein D, E and F are carbon and wherein the carbon atoms may be optionally substituted by a substituent selected from halogen, (C₁-C₃)lower alkyl, hydroxy, -COCCl₃, -COCF₃,

15




- CHO, amino, (C₁-C₃)lower alkoxy, (C₁-C₃)lower
 5 alkylamino, CONH-lower alkyl(C₁-C₃), and -CON[lower
 alkyl(C₁-C₃)]₂; q is one or two;

R_b is independently selected from hydrogen, -CH₃ or -C₂H₅;


R_e is H, lower alkyl(C₁-C₃), hydroxyethyl, -CH₂CO₂R⁵⁰, -CH₂C(CH₂OH)₃;

5 R⁵⁰ is H or lower alkyl(C₁-C₄);

R³ is a moiety of the formula:



wherein Ar is a moiety selected from the group consisting of




10


R⁴ is selected from hydrogen, lower alkyl(C₁-C₃); -CO-lower alkyl(C₁-C₃);

R² is selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, hydroxy and halogen; R⁵ is selected
15 from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;


R⁶ is selected from (a) moieties of the formula:




wherein cycloalkyl is defined as C₃ to C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently selected from hydrogen, -CH₃, -C₂H₅,



- 5 - (CH₂)_q-O-lower alkyl (C₁-C₃) and -CH₂CH₂OH, q is one or two, and R₁, R₂ and R_b are as hereinbefore defined;
 (b) moieties of the formula:




- 10 wherein R⁷ is lower alkyl (C₃-C₈), lower alkenyl (C₃-C₈), - (CH₂)_p-cycloalkyl (C₃-C₆),








-60-

wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R¹ and R² are as hereinbefore defined;
 (c) a moiety of the formula:




- 5 wherein J is R_a, lower alkyl(C₃-C₈) branched or unbranched, lower alkenyl(C₃-C₈) branched or unbranched, O-lower alkyl(C₃-C₈) branched or unbranched, -O-lower alkenyl(C₃-C₈) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties:



10


or -CH₂-K' wherein K' is (C₁-C₃) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:





-61-

wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C₁-C₃)lower alkyl, hydroxy, -CO-lower alkyl(C₁-C₃), CHO, (C₁-C₃)lower alkoxy, -CO₂-
 5 lower alkyl(C₁-C₃), and R_a and R_b are as hereinbefore defined;

(d) a moiety of the formula:




wherein R_c is selected from halogen, (C₁-C₃) lower alkyl, -O-lower alkyl(C₁-C₃), OH,




and R_a and R_b are as hereinbefore defined wherein Ar' is
 10 selected from moieties of the formula:

-62-




wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);

- 5 R^8 and R^9 are independently selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),




- 10 -N(R_b)(CH₂)_vN(R_b)₂, and CF₃ wherein v is one to three and;
 R^{10} is selected from hydrogen, halogen and lower alkyl(C₁-C₃); R^{14} is


-O-lower alkyl (C_3-C_8) branched or unbranched ,



-NH lower alkyl (C_3-C_8) branched or unbranched ,



-64-



q is 1 or 2;






wherein n is 0 or 1;

R_a is hydrogen, -CH₃ or -C₂H₅; R' is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;

R⁴⁵ is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy

5 and halogen;

R²⁰ is hydrogen, halogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, NH₂, -NH(C₁-C₃)lower alkyl, -N-[(C₁-C₃)lower alkyl]₂,




10 and the pharmaceutically acceptable salts, esters and pro-drug forms thereof.

Within the preferred group III above are the following preferred sub-groups 1, 2 and 3 of compounds:


-66-

1. wherein A-B is a moiety:



where R^3 is as defined in preferred group III above;

2. wherein A-B is the moiety:




5

R^3 is a moiety of the formula:




wherein Ar is:




10 wherein R^2 and R^6 are defined in in preferred group III above;

3. wherein A-B is the moiety:




R^3 is a moiety of the formula:



15


wherein Ar is:

-67-




wherein R^2 and R^{14} are defined in preferred group III above.

Preferred group IV. Among the preferred
5 compounds of this invention are those selected from those of the formula:



wherein Y is CH_2 ;

A-B is a moiety selected from




10

and the moiety:



represents phenyl or substituted phenyl optionally
substituted by one or two substituents selected from
15 $(\text{C}_1\text{-C}_3)$ lower alkyl, halogen, amino, $(\text{C}_1\text{-C}_3)$ lower alkoxy
or $(\text{C}_1\text{-C}_3)$ lower alkylamino;
the moiety:









-68-

is a five membered aromatic (unsaturated) nitrogen containing heterocyclic ring where D is carbon and E and F are selected from carbon and nitrogen and wherein the carbon atoms may be optionally substituted by a

5 substituent selected from halogen, (C₁-C₃) lower alkyl, hydroxy, -COCCl₃, -COCF₃,

-69-




-CHO, amino, (C₁-C₃)lower alkoxy, (C₁-C₃)lower
 5 alkylamino, CONH-lower alkyl(C₁-C₃), and -CON[lower
 alkyl(C₁-C₃)]₂; q is one or two;

R_b is independently selected from hydrogen, $-CH_3$ or $-C_2H_5$;


R_e is H, lower alkyl(C_1-C_3), hydroxyethyl, $-CH_2CO_2R^{50}$, $-CH_2C(CH_2OH)_3$;

5 R^{50} is H or lower alkyl(C_1-C_4);

R^3 is a moiety of the formula:



wherein Ar is a moiety selected from the group consisting of



10






R^4 is selected from hydrogen, lower alkyl(C_1-C_3); $-CO-$ lower alkyl(C_1-C_3);

R^2 is selected from hydrogen, (C_1-C_3)lower alkyl, (C_1-C_3)lower alkoxy, hydroxy and halogen; R^5 is selected from hydrogen, (C_1-C_3)lower alkyl, (C_1-C_3)lower alkoxy and halogen;



R^6 is selected from (a) moieties of the formula:

15

-71-




wherein cycloalkyl is defined as C₃ to C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently selected from hydrogen, -CH₃, -C₂H₅,





- 5 $-(CH_2)_q-O$ -lower alkyl(C₁-C₃) and $-CH_2CH_2OH$, q is one or two, and R₁, R₂ and R_b are as hereinbefore defined;

(b) moieties of the formula:




- 10 wherein R⁷ is lower alkyl(C₃-C₈), lower alkenyl(C₃-C₈), $-(CH_2)_p$ -cycloalkyl(C₃-C₆),






-73-

wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R¹ and R² are as hereinbefore defined;

(c) a moiety of the formula:




- 5 wherein J is R_a, lower alkyl(C₃-C₈) branched or unbranched, lower alkenyl(C₃-C₈) branched or unbranched, O-lower alkyl(C₃-C₈) branched or unbranched, -O-lower alkenyl(C₃-C₈) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties:




10

or -CH₂-K' wherein K' is (C₁-C₃) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:






wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C₁-C₃)lower alkyl, hydroxy, -CO-lower alkyl(C₁-C₃), CHO, (C₁-C₃)lower alkoxy, -CO₂-
 5 lower alkyl(C₁-C₃), and R_a and R_b are as hereinbefore defined;

(d) a moiety of the formula:




wherein R_c is selected from halogen, (C₁-C₃) lower alkyl, -O-lower alkyl(C₁-C₃), OH,




and R_a and R_b are as hereinbefore defined wherein Ar' is
 10 selected from moieties of the formula:

-75-



wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);


- 5 R^8 and R^9 are independently selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),






- 10 $-N(R_b)(CH_2)_vN(R_b)_2$, and CF₃ wherein v is one to three and;
 R^{10} is selected from hydrogen, halogen and lower alkyl(C₁-C₃); R^{14} is

g









-O- lower alkyl (C_3-C_8) branched or unbranched ,



-NH lower alkyl (C_3-C_8) branched or unbranched ,



-77-






q is 1 or 2;

wherein n is 0 or 1;

R_a is hydrogen, $-CH_3$ or $-C_2H_5$; R' is hydrogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy and halogen;
 R^{45} is hydrogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy and halogen;

- 5 R^{20} is hydrogen, halogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy, NH_2 , $-NH(C_1-C_3)$ lower alkyl, $-N-[(C_1-C_3)$ lower alkyl] $_2$,




- and the pharmaceutically acceptable salts, esters and
 10 pro-drug forms thereof.


Within the preferred group IV above are the following preferred sub-groups 1 and 2 of compounds:.

1. wherein A-B is the moiety:


-79-



R^3 is a moiety of the formula:




wherein Ar is:




5

wherein R^2 and R^{14} are defined in preferred group IV above;


2. wherein A-B is the moiety:



10 R^3 is a moiety of the formula:




wherein Ar is:



-80-


wherein R^2 and R^{14} are defined in preferred group IV above.

Preferred group V. Among the more preferred compounds of this invention are those selected from the
5 formula:



wherein Y is CH_2 ;


A-B is






10 and the moiety:



represents phenyl or substituted phenyl optionally substituted by one or two substituents selected from (C₁-C₃)lower alkyl, halogen, amino, (C₁-C₃)lower alkoxy
15 or (C₁-C₃)lower alkylamino;
the moiety:



is a five membered aromatic (unsaturated) nitrogen containing heterocyclic ring wherein D, E and F are
20 carbon wherein the carbon atoms may be optionally substituted by a substituent selected from




-CHO, and (C₁-C₃)lower alkylamino;


q is one or two;

- 5 R_b is independently selected from hydrogen, -CH₃ or -C₂H₅;

R³ is a moiety of the formula:




10 wherein Ar is a moiety selected from the group consisting of




R⁴ is selected from hydrogen, lower alkyl(C₁-C₃); -CO-lower alkyl(C₁-C₃);

R^1 and R^2 are independently selected from hydrogen, (C1-C3)lower alkyl, (C1-C3)lower alkoxy, hydroxy and halogen; R^5 is selected from hydrogen, (C1-C3)lower alkyl, (C1-C3)lower alkoxy and halogen;

5 R^6 is selected from (a) moieties of the formula:




Ar' is selected from moieties of the formula:



wherein W' is selected from O, S, NH, N-lower alkyl(C1-C3), NHCO-lower alkyl(C1-C3), and NSO₂lower alkyl(C1-C3);

R^8 and R^9 are independently selected from hydrogen, lower alkyl(C1-C3), -S-lower alkyl(C1-C3), halogen, -NH-lower alkyl(C1-C3), -N-[lower alkyl(C1-C3)]₂, -OCF₃,
 15 -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C1-C3),




$-\text{N}(\text{R}_b)(\text{CH}_2)_v\text{N}(\text{R}_b)_2$, and CF_3 wherein v is one to three and;

R^{10} is selected from hydrogen, halogen and lower


5 alkyl(C_1-C_3);

wherein cycloalkyl is defined as C_3 to C_6 cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently selected from hydrogen, $-\text{CH}_3$, $-\text{C}_2\text{H}_5$,




10 $-(\text{CH}_2)_q-\text{O}$ -lower alkyl(C_1-C_3) and $-\text{CH}_2\text{CH}_2\text{OH}$, q is one or two, and R_1 , R_2 and R_b are as hereinbefore defined;

(b) moieties of the formula:




15 wherein R^7 is lower alkyl(C_3-C_8), lower alkenyl(C_3-C_8), $-(\text{CH}_2)_p$ -cycloalkyl(C_3-C_6),



wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R^1 and R^2 are as hereinbefore defined;

(c) a moiety of the formula:




5


wherein J is R_a , lower alkyl(C₃-C₈) branched or unbranched, lower alkenyl(C₃-C₈) branched or unbranched, O-lower alkyl(C₃-C₈) branched or unbranched, -O-lower alkenyl(C₃-C₈) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties:

10

-85-



or $-CH_2-K'$ wherein K' is (C₁-C₃) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:




5

wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C₁-C₃) lower alkyl, hydroxy, -CO-lower alkyl(C₁-C₃), CHO, (C₁-C₃) lower alkoxy, -CO₂-

10 lower alkyl(C₁-C₃), and R_A and R_B are as hereinbefore defined;




(d) a moiety of the formula:

-86-




wherein R_c is selected from halogen, (C_1-C_3)

lower alkyl, -O-lower alkyl (C_1-C_3) , OH,




and R_a and R_b are as hereinbefore defined;



wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);


- R⁸ and R⁹ are independently selected from hydrogen,
 5 lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen,
 -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃,
 -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),






- N(R_b)(CH₂)_vN(R_b)₂, and CF₃ wherein v is one to three
 10 and;
 R¹⁰ is selected from hydrogen, halogen and lower
 alkyl(C₁-C₃);









R¹⁴ is

-O-lower alkyl (C₃-C₈) branched or unbranched ,



-NH lower alkyl (C₃-C₈) branched or unbranched ,





q is 1 or 2;






wherein n is 0 or 1;

R_a is hydrogen, -CH₃ or -C₂H₅; R' is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;

R⁴⁵ is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy

5 and halogen;


R²⁰ is hydrogen, halogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, NH₂, -NH(C₁-C₃)lower alkyl, -N-[(C₁-C₃)lower alkyl]₂,



10 and the pharmaceutically acceptable salts, esters and pro-drug forms thereof.


Within preferred group V above are the following preferred sub-groups 1 and 2 of compounds:

1. wherein Ar is:




wherein R¹, R² and R⁶ are defined in preferred group V above;

5 2. wherein Ar is:




wherein R¹, R² and R¹⁴ are defined in preferred group V above.

10 Preferred group VI. Among the preferred compounds of this invention are those selected from those of the formula:



wherein Y is CH₂;

A-B is



15


and the moiety:






-92-

represents phenyl or substituted phenyl optionally substituted by one or two substituents selected from (C₁-C₃)lower alkyl, halogen, amino, (C₁-C₃)lower alkoxy or (C₁-C₃)lower alkylamino;

5 the moiety:



is a five membered aromatic (unsaturated) nitrogen containing heterocyclic ring wherein D, E and F are carbon wherein the carbon atoms may be optionally substituted by a substituent selected from




-CHO, and (C₁-C₃)lower alkylamino;


q is one or two;

15 R_b is independently selected from hydrogen, -CH₃ or -C₂H₅;


R³ is a moiety of the formula:




wherein Ar is a moiety selected from the group consisting of



- 5 R^4 is selected from hydrogen, lower alkyl(C₁-C₃); -CO-lower alkyl(C₁-C₃);
 R^1 and R^2 are independently selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, hydroxy and
 halogen; R^5 is selected from hydrogen, (C₁-C₃)lower
 10 alkyl, (C₁-C₃)lower alkoxy and halogen;
 R^6 is selected from (a) moieties of the formula:




Ar' is selected from moieties of the formula:




wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);

- 5 R^8 and R^9 are independently selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),




- 10 $-N(R_b)(CH_2)_vN(R_b)_2$, and CF₃ wherein v is one to three and;
 R^{10} is selected from hydrogen, halogen and lower alkyl(C₁-C₃);
 wherein cycloalkyl is defined as C₃ to C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently
 15 selected from hydrogen, -CH₃, -C₂H₅,

-95-




- (CH₂)_q-O-lower alkyl(C₁-C₃) and -CH₂CH₂OH, q is one or two, and R₁, R₂ and R_b are as hereinbefore defined;

(b) moieties of the formula:




5

wherein R⁷ is lower alkyl(C₃-C₈), lower alkenyl(C₃-C₈),
 -(CH₂)_p-cycloalkyl(C₃-C₆),








10 wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R¹ and R² are as hereinbefore defined;
 (c) a moiety of the formula:


-96-



wherein J is R_a , lower alkyl(C₃-C₈) branched or unbranched, lower alkenyl(C₃-C₈) branched or unbranched, O-lower alkyl(C₃-C₈) branched or unbranched, -O-lower
 5 alkenyl(C₃-C₈) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties:



or -CH₂-K' wherein K' is (C₁-C₃) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic
 10 ring moiety:




wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C₁-C₃)lower alkyl, hydroxy,

-97-




-CO-lower alkyl(C₁-C₃), CHO, (C₁-C₃)lower alkoxy, -CO₂-lower alkyl(C₁-C₃), and R_a and R_b are as hereinbefore defined;

(d) a moiety of the formula:




wherein R_c is selected from halogen, (C₁-C₃)

lower alkyl, -O-lower alkyl(C₁-C₃), OH,




and R_a and R_b are as hereinbefore defined;



wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);

R^8 and R^9 are independently selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),




-N(R_b)(CH₂)_vN(R_b)₂, and CF₃ wherein v is one to three and;




R^{10} is selected from hydrogen, halogen and lower alkyl(C₁-C₃);

R^{14} is









-O-lower alkyl (C_3-C_8) branched or unbranched ,



-NH lower alkyl (C_3-C_8) branched or unbranched ,



-100-



q is 1 or 2;




wherein n is 0 or 1;

R_a is hydrogen, -CH₃ or -C₂H₅; R' is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;

R⁴⁵ is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy

5 and halogen;


R²⁰ is hydrogen, halogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, NH₂, -NH(C₁-C₃)lower alkyl, -N-[(C₁-C₃)lower alkyl]₂,



10 and the pharmaceutically acceptable salts, esters and pro-drug forms thereof.


Within preferred group VI above are the following preferred sub-groups 1 and 2 of compounds:

1. wherein Ar is:




5 and R² and R⁶ are defined in preferred group VI above;

2. wherein Ar is:




and R² and R¹⁴ are as defined in preferred group VI above.

10 Preferred group VII. Among the preferred compounds of this invention are those selected from the formula:



wherein Y is CH₂;

15 A-B is a moiety selected from




and the moiety:




-103-

represents phenyl or substituted phenyl optionally substituted by one or two substituents selected from (C₁-C₃)lower alkyl, halogen, amino, (C₁-C₃)lower alkoxy or (C₁-C₃)lower alkylamino;

5 the moiety:



is a five membered aromatic (unsaturated) nitrogen containing heterocyclic ring wherein D, E and F are carbon and wherein the carbon atoms may be optionally substituted by a substituent selected from ,
 10 -CH=CH-NO₂, -(CH₂)_qNO₂,



q is one or two;


R_b is independently selected from hydrogen, -CH₃ or

15 -C₂H₅;


R_e is H, lower alkyl(C₁-C₃), hydroxyethyl, -CH₂CO₂R⁵⁰,
 -CH₂C(CH₂OH)₃;

R⁵⁰ is H or lower alkyl(C₁-C₄);











R³ is a moiety of the formula:




wherein Ar is a moiety selected from the group consisting of




- 5 R⁴ is selected from hydrogen, lower alkyl(C₁-C₃); -CO-lower alkyl(C₁-C₃);
 R¹ and R² are independently selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, hydroxy and
 halogen; R⁵ is selected from hydrogen, (C₁-C₃)lower
 10 alkyl, (C₁-C₃)lower alkoxy and halogen;
 R⁶ is selected from (a) moieties of the formula:




wherein cycloalkyl is defined as C₃ to C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently selected from hydrogen, -CH₃, -C₂H₅,



- 5 - (CH₂)_q-O-lower alkyl (C₁-C₃) and -CH₂CH₂OH, q is one or two, and R₁, R₂ and R_b are as hereinbefore defined;
 (b) moieties of the formula:




- 10 wherein R⁷ is lower alkyl (C₃-C₈), lower alkenyl (C₃-C₈), - (CH₂)_p-cycloalkyl (C₃-C₆),






-107-

wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R¹ and R² are as hereinbefore defined;

(c) a moiety of the formula:




- 5 wherein J is R_a, lower alkyl(C₃-C₈) branched or unbranched, lower alkenyl(C₃-C₈) branched or unbranched, O-lower alkyl(C₃-C₈) branched or unbranched, -O-lower alkenyl(C₃-C₈) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties:



10


or -CH₂-K' wherein K' is (C₁-C₃) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:






-108-

wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C₁-C₃)lower alkyl, hydroxy, -CO-lower alkyl(C₁-C₃), CHO, (C₁-C₃)lower alkoxy, -CO₂-
 5 lower alkyl(C₁-C₃), and R_a and R_b are as hereinbefore defined;


(d) a moiety of the formula:



wherein R_c is selected from halogen, (C₁-C₃) lower alkyl, -O-lower alkyl (C₁-C₃), OH,




and R_a and R_b are as hereinbefore defined wherein Ar' is
 10 selected from moieties of the formula:



wherein W' is selected from O, S, NH, N-lower alkyl(C1-C3), NHCO-lower alkyl(C1-C3), and NSO₂lower alkyl(C1-C3);


- 5 R^8 and R^9 are independently selected from hydrogen, lower alkyl(C1-C3), -S-lower alkyl(C1-C3), halogen, -NH-lower alkyl(C1-C3), -N-[lower alkyl(C1-C3)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C1-C3),






- 10 $-N(R_b)(CH_2)_vN(R_b)_2$, and CF₃ wherein v is one to three and;
 R^{10} is selected from hydrogen, halogen and lower alkyl(C1-C3);

R¹⁴ is


-O-lower alkyl (C₃-C₈) branched or unbranched ,



-NH lower alkyl (C₃-C₈) branched or unbranched ,



-111-








q is 1 or 2;

wherein n is 0 or 1;

R_a is hydrogen, $-CH_3$ or $-C_2H_5$; R' is hydrogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy and halogen;
 R^{45} is hydrogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy and halogen;


- 5 R^{20} is hydrogen, halogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy, NH_2 , $-NH(C_1-C_3)$ lower alkyl, $-N-[(C_1-C_3)$ lower alkyl] $_2$,




and the pharmaceutically acceptable salts, esters and
 10 pro-drug forms thereof.

-113-

Preferred group VIII. Among the more preferred compounds of this invention are those selected from the formula:




- 5 wherein Y is CH₂;
A-B is a moiety selected from



and the moiety:




- 10 represents phenyl or substituted phenyl optionally substituted by one or two substituents selected from (C₁-C₃)lower alkyl, halogen, amino, (C₁-C₃)lower alkoxy or (C₁-C₃)lower alkylamino;
the moiety:



- 15 is a five membered aromatic (unsaturated) nitrogen containing heterocyclic ring wherein D, is carbon and E and F are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted by a
20 substituent selected from

-114-




q is one or two;

5 R_b is independently selected from hydrogen, $-\text{CH}_3$ or $-\text{C}_2\text{H}_5$;


R_e is H, lower alkyl ($\text{C}_1\text{-C}_3$), hydroxyethyl, $-\text{CH}_2\text{CO}_2\text{R}^{50}$, $-\text{CH}_2\text{C}(\text{CH}_2\text{OH})_3$;

R^{50} is H or lower alkyl ($\text{C}_1\text{-C}_4$);

10 R^3 is a moiety of the formula:




wherein Ar is a moiety selected from the group consisting of



R^4 is selected from hydrogen, lower alkyl(C₁-C₃); -CO-lower alkyl(C₁-C₃);

- R^1 and R^2 are independently selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, hydroxy and
5 halogen; R^5 is selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;
 R^6 is selected from (a) moieties of the formula:




-117-



wherein cycloalkyl is defined as C₃ to C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently selected from hydrogen, -CH₃, -C₂H₅,




- 5 $-(\text{CH}_2)_q\text{-O-lower alkyl (C}_1\text{-C}_3\text{)}$ and $-\text{CH}_2\text{CH}_2\text{OH}$, q is one or two, and R₁, R₂ and R_b are as hereinbefore defined;
(b) moieties of the formula:






- 10 wherein R⁷ is lower alkyl (C₃-C₈), lower alkenyl (C₃-C₈), $-(\text{CH}_2)_p\text{-cycloalkyl (C}_3\text{-C}_6\text{)}$,



wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R¹ and R² are as hereinbefore defined;
 (c) a moiety of the formula:




- 5 wherein J is R_a, lower alkyl(C₃-C₈) branched or unbranched, lower alkenyl(C₃-C₈) branched or unbranched, O-lower alkyl(C₃-C₈) branched or unbranched, -O-lower alkenyl(C₃-C₈) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties:



10


or -CH₂-K' wherein K' is (C₁-C₃) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:






-119-

wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C₁-C₃)lower alkyl, hydroxy, -CO-lower alkyl(C₁-C₃), CHO, (C₁-C₃)lower alkoxy, -CO₂-
 5 lower alkyl(C₁-C₃), and R_a and R_b are as hereinbefore defined;

(d) a moiety of the formula:




wherein R_c is selected from halogen, (C₁-C₃) lower alkyl, -O-lower alkyl (C₁-C₃), OH,




and R_a and R_b are as hereinbefore defined wherein Ar' is
 10 selected from moieties of the formula:

-120-







wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);









- 5 R⁸ and R⁹ are independently selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),



- 10 -N(R_b)(CH₂)_vN(R_b)₂, and CF₃ wherein v is one to three and;
R¹⁰ is selected from hydrogen, halogen and lower alkyl(C₁-C₃);

-121-

 R^{14} is-O-lower alkyl (C_3-C_8) branched or unbranched,-NH-lower alkyl (C_3-C_8) branched or unbranched,



q is 1 or 2;





wherein n is 0 or 1;

R_a is hydrogen, -CH₃ or -C₂H₅; R' is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;

R⁴⁵ is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy

5 and halogen;

R²⁰ is hydrogen, halogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, NH₂, -NH(C₁-C₃)lower alkyl, -N-[(C₁-C₃)lower alkyl]₂,



10 and the pharmaceutically acceptable salts, esters and pro-drug forms thereof.

Among the more preferred compounds of this invention are those selected from:

[4-(3-Dimethylaminomethyl-3-hydroxy-5H,11H-pyrrolo
[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl]-
5 biphenyl-2-carboxylic acid amide.

[4-(3-[1,4']Bipiperidiny1-1'-ylmethyl-5H,11H-
pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-3-
chloro-phenyl]-biphenyl-2-carboxylic acid amide.

10 (3-Chloro-4-(3-((2-hydroxy-1,1-bis-hydroxymethyl-
ethylamino)-methyl)-5H,11H-pyrrolo[2,1-c][1,4]benzo-
diazepine-10-carbonyl)-phenyl)-biphenyl-2-carboxylic
acid amide.

15 [3-chloro-4-(3-((2-dimethylamino-ethyl)-methyl-amino)-
methyl)-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-
carbonyl)-phenyl]-biphenyl-2-carboxylic acid amide.

20 {3-chloro-4-[3-(4-dimethylamino-piperidin-1-ylmethyl)-
5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl]-
phenyl}-biphenyl-2-carboxylic acid amide.

N-[3-Chloro-4-(5H,11H-pyrrolo[2,1-c][1,4]benzo-
25 diazepine-10-carbonyl)-phenyl]-2-pyrrol-1-yl-benzamide.


Quinoline-8-carboxylic acid [4-(5H,11H-pyrrolo[2,1-c]
[1,4]benzodiazepine-10-carbonyl)-3-phenyl]-amide.


30 [3-Chloro-4-(3-dimethylaminomethyl-5H,11H-pyrrolo[2,1-c]
[1,4]benzodiazepine-10-carbonyl)-phenyl]-2-phenyl-
cyclopent-1-enecarboxylic acid amide.

Biphenyl-2-carboxylic acid {3-chloro-4-[3-(2-nitro-
35 ethyl)-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-
carbonyl]-phenyl}-amide.



Compounds of this invention may be prepared as shown in Scheme I by reaction of tricyclic derivatives of Formula 3a and 3b with a substituted or unsubstituted 6-nitropyridine-3-carbonyl chloride 4 to give the intermediates 5a and 5b. Reduction of the nitro group in intermediates 5a and 5b gives the 6-aminopyridine derivatives 6a and 6b. The reduction of the nitro group in intermediates 5a and 5b may be carried out under catalytic reduction conditions (hydrogen-Pd/C; Pd/C-hydrazine-ethanol) or under chemical reduction conditions (SnCl₂-ethanol; Zn-acetic acid TiCl₃) and related reduction conditions known in the art for converting a nitro group to an amino group. The conditions for conversion of the nitro group to the amino group are chosen on the basis of compatability with the preservation of other functional groups in the molecule.

Reaction of compounds of Formula 6a and 6b with aroyl chloride or related activated aryl carboxylic acids in solvents such as chloroform, dichloromethane, dioxane, tetrahydrofuran, toluene and the like in the presence of a tertiary base such as triethylamine and diisopropylethylamine or pyridine and the like, affords the compounds 8a and 8b which are vasopressin antagonists.


Scheme 1

Scheme 1 (cont'd)


-128-




Reaction of tricyclic derivatives of Formula 6a and 6b with either a carbamoyl derivative 2 or a
 5 isocyanate derivative 10 gives compounds (Scheme 2) of formula 11a and 11b which are vasopressin antagonists of Formula I wherein R^6 is




Scheme 2



Reaction of tricyclic derivatives of Formula 6a and 6b with arylacetic acids, activated as the acid chlorides 12, anhydrides, mixed anhydrides or activated with known activating reagents, gives compounds 13a and 13b (Scheme 3).


Scheme 3

The compounds of Formula I wherein Y, A-B, Z, R^1 , R^2 and R^3 are as defined and the Ar moiety of R^3 (-COAr) is




may be prepared, as shown in Scheme 4, by reacting an activated ester of the pyridine-3-carboxylic acid 14

with tricyclic derivatives 3a and 3b. The pyridine-3-carboxylic acids 14 may be activated by preparing the anhydride, a mixed anhydride or reacting with diethyl cyanophosphonate, *N,N*-carbonyldiimidazole or related peptide coupling reagents. Alternatively, the acid chloride derivatives 15 may be prepared from the acid derivatives 14 and oxalyl chloride or thionyl chloride in an inert solvent. The solvent is removed and the derivative reacted with 3a or 3b at 0°C to 25°C in dichloromethane as solvent and a tertiary amine such as triethylamine as a base. The activating reagent for the pyridine-3-carboxylic acids 14 is chosen on the basis of its compatibility with other substituent groups and the reactivity of the activated derivative toward the tricyclic derivatives 3a and 3b to give the vasopressin antagonists 16a and 16b.

Scheme 4

Alternatively, the compounds of Formula I wherein Y, A-B, Z, R¹, R² and R³ are as defined and the Ar moiety of R³ (-COAr) is




wherein R^6 is the moiety

$-X-R^7$ and X is S, NH, NCH_3


may be prepared as shown in Scheme 5 by first converting
 5 tricyclic derivatives 3a and 3b into the intermediates
17a and 17b and then reacting these intermediates with
 potassium, sodium, or lithium anions (R^7-X^-) to give the
 products 16a and 16b. The symbol M^+ is a metal cation
 derived from reacting a compound HXR^7 with a metal
 10 hydride (sodium or potassium hydride, for example) or
 LDA, n-butyl lithium, lithium bis(trimethylsilyl)amide
 and the like.

The reaction of intermediates 17a and 17b with
 the moieties R^7-NH_2 and R^7-NHCH_3 may also be carried
 15 without first forming the corresponding anions. Thus,
 heating intermediates 17a and 17b with excess R^7-NH_2 or
 R^7-NHCH_3 in an inert solvent or without solvent gives
 the products 16a and 16b wherein X is NH or NCH_3 .


Scheme 5

Alternatively, the intermediates 17a and 17b may be converted to the more reactive fluoride derivatives 18a and 18b as shown in Scheme 6. Reaction of the fluoride intermediates 18a and 18b with amines NH_2R^7 and

5 CH_3NHR^7 gives the 6-aminonicotinoyl derivatives 19a and 19b.

Scheme 6

As an alternative method for synthesis of compounds of this invention as depicted in Formula I wherein Y, A-B, D, E, F and Z are as previously
 5 described and R³ is





is the coupling of pyridinyl carboxylic acids 20 with the tricyclic derivatives 3a and 3b to give 21a and 21b.

The pyridine carboxylic acids are activated
 10 for coupling by conversion to an acid chloride, bromide or anhydride or by first reacting with an activating reagent such as *N,N*-dicyclocarbodiimide, diethyl cyanophosphonate and related "peptide type" activating reagents. The method of activating the acids 20 for
 15 coupling to the tricyclic derivatives 3a and 3b is chosen on the basis of compatibility with other substituent groups in the molecule. The method of choice is the conversion of the 3-pyridinyl carboxylic acids 20 to the corresponding 3-pyridinylcarbonyl
 20 chlorides. The 3-pyridinylcarbonyl chlorides 22 may be prepared by standard procedures known in the art, such as reaction with thionyl chloride, oxalyl chloride and the like. The coupling reaction is carried out in solvents such as halogenated hydrocarbons, toluene,
 25 xylene, tetrahydrofuran, or dioxane in the presence of pyridine or tertiary bases such as triethylamine and the like (Scheme 7). Alternatively, the 3-pyridinylcarbonyl chlorides 22, prepared from the carboxylic acids 20, may be reacted with derivatives 3a and 3b in
 30 pyridine with or without 4-(dimethylamino)pyridine.

In general, when the 3-pyridinyl carboxylic acids 20 are activated with "peptide type" activating reagents, higher temperatures are required than when the 3-pyridinylcarbonyl chlorides are used.

5

Scheme 7

Scheme 8

The starting materials **3a** and **3b** in the foregoing Schemes 1-7 may be prepared as follows. In accordance with Scheme 8, alkylation of heterocycles of structural type **24** with an alkylating moiety such as **23** gives intermediates **25**. The heterocycle **24** may contain an α -

carboxaldehyde function or an α -carboxylic and/or ester function as shown in Scheme 8. Where the intermediate 25 ($R^{15}=H$) contains an α -carboxaldehyde group, hydrogenation with palladium-on-carbon gives reduction and ring closure in one step to give 29.


In derivatives 25 where R^{15} is an α -carboxylic and/or an α -carboxylic ester function, the intermediate amino acid derivative 27 is first isolated and then ring closed. The ring closure of derivatives 27 may be carried out by heating or by activation of the acid function (27: $R^{15}=H$) for ring closure. The cyclic lactams 28 are conveniently reduced with diborane or lithium aluminum hydride to give intermediates 29. Reaction of tricyclic derivatives 29 with aroyl chlorides ($ArCOCl$), where Ar is as hereinbefore defined, gives diazepines 26.

Tricyclic derivatives of structural type 36 may be prepared as shown in Scheme 9. Formylation of 32 under known conditions in the literature, such as Vilsmeier formylation, gives intermediates 35 which on reduction and ring closure affords tricyclics 37.


Where the ring containing the symbol Z is a substituted or unsubstituted phenyl group, the procedure gives 4,5-dihydropyrrolo[1,2-a]-quinoxalines 36. These derivatives 36 and 37 may be reacted with aroyl chlorides ($ArCOCl$) wherein Ar is as previously defined or with a substituted or unsubstituted 6-nitropyridine-3-carbonyl chloride or with a nitrogen protecting group, such as benzyloxycarbonyl chloride to give compounds 38 and 39. The compounds 38 and 39 may be reacted with chlorine, bromine or halogenating reagents such as N-chlorosuccinimide, N-bromosuccinimide and the like to give compounds 40 and 41 wherein R^{17} is a halogen atom. The derivatives 38 and 39 may be formylated and acetylated to give products 40 and 41 wherein R^{17} is a

-141-


CHO or a -COCH₃ group. Halogenation, formylation and acetylation of derivatives 36 gives 1-substituted 4,5-dihydropyrrolo[1,2-a]quinoxalines. The derivatives 38, 39, 40 and 41 wherein R¹⁶ is a substituted or unsubstituted 6-nitro-3-pyridinylcarbonyl group are reduced to give the 6-amino-3-pyridinylcarbonyl derivatives 42d and 43d which are reacted with reagents Ar'COCl, Ar'CH₂COCl or




10 wherein Ar' and R_b are as previously hereinbefore defined, to give tricyclic diazepines 44 and 45.


Scheme 9

Scheme 9 (cont'd)




Scheme 9 (cont'd)

The compounds of this invention wherein R³ is the moiety:




5 and the Ar group is the moiety:

-145-



and R^6 , R_a , R_b , Y , R^1 , R^2 , Z and Ar' are as previously defined and wherein R^{11} is selected from the moieties:



5


may be synthesized as shown in Scheme 10.

The tricyclic pyrrolodiazepines 46 and 47 are reacted with appropriate amines in the presence of formaldehyde to give the aminomethylene derivatives 48 and 49. The reaction may be carried out with aqueous formaldehyde or its equivalent in the presence of the appropriate amine in a lower alkanol at room temperature or preferably at temperatures of 50°C-100°C. The


10

aminomethylene derivatives 48 and 49 may be converted to hydrochloride salts or succinic acid and maleic acid salts as well as other pharmaceutically acceptable acid salts.

Scheme 10




Scheme 10 (cont'd)




The compounds of this invention wherein R³ is
5 the moiety:


-148-



and the Ar group is the moiety:



and R^{14} , R_a , R_b , Y , R^1 , R^2 , Z and Ar' are as previously
 5 defined and wherein R^{11} is selected from the moieties:









may be synthesized as shown in Scheme 10b.


The tricyclic pyrrolodiazepines 146 and 147
 10 are reacted with appropriate amines in the presence of
 formaldehyde to give the aminomethylene derivatives 148

and 149. The reaction may be carried out with aqueous formaldehyde or its equivalent in the presence of the appropriate amine in a lower alkanol at room temperature or preferably at temperatures of 50°C-100°C. The
5 aminomethylene derivatives 148 and 149 may be converted to hydrochloride salts or succinic acid and maleic acid salts as well as other pharmaceutically acceptable acid salts.


In the schemes 10c and 10d that follow, X^- indicates an anion selected from a halogen, preferably I^- , or a sulfate or nitrate.

Scheme 10b (cont'd)


Scheme 10c

Scheme 10c (cont'd)


-154-

Scheme 10d


-155-

Scheme 10d (cont'd)

The aminomethylene derivatives of the formulas 49a or 153, wherein R^1 , R^2 , R^3 , R^6 , R^8 , R^{10} , R^{11} , R^{14} , R^{45} , R' , R_a , R_b , R_e are hereinbefore defined, Y is equal to CH_2 and Z is phenyl or substituted phenyl and R^6 is selected from a moiety of the formula:




10 wherein J is independently selected from the moieties:



wherein further q is 1 or 2; n is 0 or 1; and R^{14} is independently selected from the moieties:

5



can be reacted as described in Schemes 10c and 10d with an excess of an alkyl halide such as methyl iodide, ethyl bromide, to give the corresponding quarternary ammonium derivatives 150 and 154. Reaction of the


5 quarternary ammonium derivatives 150 and 154 with ammonia, a primary amine such as methylamine, glycine methyl ester, tris(hydroxymethylaminomethane, or a secondary amine such as dimethylamine, sarcosine methyl ester, ethanolamine in an inert solvent such as

10 dimethylsulfoxide, tetrahydrofuran, or dichloromethane at room temperature to the reflux temperature of the solvent affords the corresponding aminomethyl derivatives 151 and 155. Alternately, reaction of the quarternary ammonium derivatives 150 and 154 with

15 nitromethane in the presence of an alkali metal alkoxide in a solvent such as methanol, ethanol, tetrahydrofuran or dimethylsulfoxide at temperatures ranging between 40-100°C gives the nitro derivatives 152 and 156.


The 3-aminoethyl and 3-dialkylaminoethyl compounds

20 of Formula 157,




wherein R^1 , R^2 , R^3 , R^6 , R^8 , R^{10} , R^{14} , R' , R_a , and R_b , are

25 defined hereinabove; and R^6 , is selected from a moiety of the formula:




-158-

wherein J is independently selected from the moieties:



5


wherein further q is 1 or 2; n is 0 or 1; and R^{14} is independently selected from the moieties:



wherein n is 0, can be prepared by procedures recognized in the art from known or readily prepared intermediates.


A detailed description of preferred compounds is described in exemplary procedure (Scheme 10e) as follows:

-160-

Scheme 10e


-161-

wherein R^1 and R^2 are defined hereinabove; and R^6 , is selected from a moiety of the formula:



5


wherein J is independently selected from the moieties:




10 and; R^8 is hydrogen.

A detailed description of especially preferred compounds is described further in procedure (Scheme 10f) as follows:

-162-

Scheme 10f

wherein R^1 and R^2 are defined hereinabove; and R^{14} is selected from the moiety:



5

wherein R_a , R' , R^8 , and R^{10} are defined hereinabove; and n is 0.





More specifically, a compound of Formula 158 or
 10 Formula 162, wherein R^1 , R^2 , R^6 , and R^{14} are defined
 hereinabove, is reacted with 1-dimethylamino-2-
 nitroethylene according to the procedure described by
 Buchi and Mak in the Journal of Organic Chemistry, Vol.
 42, No. 10, 1784 (1977), to prepare a compound of
 15 Formula 159 or Formula 163, respectively; wherein R^1 , R^2 ,
 R^6 , and R^{14} are defined hereinabove. Reaction
 temperatures may range from -20°C to 45°C , and reaction
 times may vary from five minutes to three hours. The
 reaction may be carried out in acidic media or under
 20 acid catalyzed conditions employing neutral solvent
 media. The acidic media include, but are not limited
 to, glacial acetic acid, formic acid, trifluoroacetic
 acid, and the like. Solvents include, but are not
 limited to ethanol, methanol, and the like. Acid
 25 catalysts include, but are not limited to, hydrogen
 halides, sulfonic or phosphoric acids, and the like.

A compound of Formula 159 or Formula 163, wherein
 R^1 , R^2 , R^6 , and R^{14} are defined hereinabove, is reacted


with alkali metal borohydride or alkyl metal trialkoxyborohydride reagents according to the procedure described by Kardos and Genet in *Tetrahedron: Asymmetry*, Vol 5., No.8, 1525 (1994), and also by Kruse and Hilbert in *Heterocycles*, Vol. 20, No.7, 1373 (1983), to prepare a compound of Formula 152 or Formula 156, respectively; wherein R^1 , R^2 , R^6 , and R^{14} are defined hereinabove. Reaction temperatures may range from -40°C to the reflux temperature of the solvent. The reaction times may vary from five minutes to three hours. The reaction may be carried out in various protic or aprotic solvents, or mixtures thereof, which include, but are not limited to, methanol, ethanol, 2-propanol, tetrahydrofuran, 1,4-dioxane, diethyl ether, and the like. A compound of Formula 152 or Formula 156, wherein R^1 , R^2 , R^6 , and R^{14} are defined hereinabove, is reacted with reducing metals which include, but are not limited to, zinc, tin, iron, sodium, potassium, or copper, and the like, in protic solvents to prepare a compound of Formula 160 or Formula 164, respectively; wherein R^1 , R^2 , R^6 , and R^{14} are defined hereinabove. Such protic solvents include, but are not limited to, methanol, ethanol, 2-propanol, acetic acid, formic acid, or trifluoroacetic acid, and the like. Such reducing metals may or may not be promoted by acid catalysts. Such acid catalysts include, but are not limited to, hydrogen halides, sulfonic acids, phosphoric acids, or organic carboxylic acids, and the like. Reaction temperatures may range from -20°C to the reflux temperature of the solvent. The reaction times may vary from five minutes to three hours.

Alternatively, a compound of Formula 159 or Formula 163, wherein R^1 , R^2 , R^6 , and R^{14} are defined hereinabove, can be reacted with lithium borohydride and trimethylchlorosilane, according to the procedure described by Giannis and Sandhoff, *Angewante Chemie. International*

- Edition in English, Vol. 28, No.2, 218 (1989), or reacted with diborane-tetrahydrofuran complex, to prepare a compound of Formula 160 or Formula 164, respectively; wherein R^1 , R^2 , R^6 , and R^{14} are defined
- 5 hereinabove. Reaction temperatures may range from 0°C to the reflux temperature of the solvent. The reaction times may vary from one hour to 48 hours. The reaction may be carried out in various aprotic inert solvents. Solvents may include, but are not limited to, diethyl
- 10 ether, tetrahydrofuran, 1-4 dioxane, and the like.
- A compound of Formula 161 or Formula 165, wherein R^1 , R^2 , R^6 , R^{14} , and R_b , are defined hereinabove, can be prepared from a compound of Formula 160 or Formula 164, respectively; wherein R^1 , R^2 , R^6 , and R^{14} are defined
- 15 hereinabove, by reacting with paraformaldehyde, 37% aqueous formaldehyde (Formalin), or acetaldehyde, and sodium cyanoborohydride within a pH range of 3.0 to 6.0. The reaction temperature may range from -20°C to the reflux temperature of the solvent. The reaction times
- 20 may vary from five minutes to several hours. The pH range may be maintained with organic carboxylic acids. Such organic carboxylic acids include, but are not limited to, glacial acetic acid, trifluoroacetic acid, formic acid, 4-toluene-sulfonic acid, and the like.

Scheme 10g166168167169






- The hydroxy derivatives of the formulas 168 and 169, wherein R¹, R¹, R⁶, R⁸, R¹⁰, R¹¹, R¹⁴, R⁴⁵, D, E, F, R_a, R_b, Y, and Z are hereinbefore defined and R² is lower alkoxy may be prepared by reaction of 166 or 167 with boron tribromide in an inert solvent, such as dichloromethane or chloroform at or between -20°C to the reflux temperature of the solvent at from between 30 minutes to overnight.






Scheme 11

-168-

As shown in Scheme 11, reaction of tricyclic derivatives of Formula 3a and 3b with substituted and unsubstituted arylcarbonyl chlorides 50, wherein R¹, R² and R¹⁴ are hereinbefore defined gives compounds 51 and

5 52 which are vasopressin antagonists.

Scheme 123a3b5354a54b


Scheme 12 (cont'd)

Reaction of tricyclic derivatives of Formula 3a and 3b with a substituted or unsubstituted phenyl carbonyl chloride 53 gives intermediates 54a and 54b. The reduction of the nitro group in intermediates 54a and 54b may be carried out under catalytic reduction conditions (hydrogen-Pd/C; Pd/C-hydrazine-ethanol) or under chemical reduction conditions (SnCl₂-ethanol; Zn-acetic acid TiCl₃ and related reduction conditions known in the art for converting a nitro group to an amino group. The conditions for conversion of the nitro group to the amino group are chosen on the basis of compatability with the preservation of other functional groups in the molecule.

Reaction of compounds of Formula 55a and 55b with acid chlorides, R²⁵COCl or related activated acid carboxylic acids in solvents such as chloroform, dichloromethane, dioxane, tetrahydrofuran, toluene and the like in the presence of a tertiary base such as triethylamine and diisopropylethylamine or pyridine and the like, affords the compounds 56a and 56b which are vasopressin antagonists.




The acid chlorides R²⁵COCl are those wherein R²⁵ is selected from the group

-172-




Wherein n is 0 or 1; R_a is hydrogen, $-CH_3$ or $-C_2H_5$; R' is hydrogen, (C1-C3)lower alkyl, (C1-C3)lower alkoxy and halogen; R^{20} is hydrogen, halogen, (C1-C3)-lower alkyl, (C1-C3)lower alkoxy, NH_2 , $-NH(C1-C3)$ -lower alkyl, $-N-[(C1-C3)lower alkyl]_2$,

-173-




Preparation of some tricyclic diazepines useful for starting materials for the synthesis of compounds of this invention are shown in Schemes 8 and 9. Other tricyclic diazepines are prepared by literature procedures or by methods known in the art or by procedures reported for the synthesis of specific known tricyclic diazepines. These diazepine ring systems discussed below when subjected to reaction conditions shown in Schemes 1, 2, 3, 4, 5, 6, 7, 9 and 10 give the compounds of this invention.

The tricyclic diazepine ring system, 10,11-dihydro-5H-imidazo[2,1-c][1,4]benzodiazepine,



5


is reported by G. Stefancich, R. Silvestri and M. Artico, J. Het. Chem. **30**, 529(1993); ring substitution on the same ring system is reported by G. Stefancich, M. Artico, F. Carelli, R. Silvestri, G. deFeo, G. Mazzanti, I. Durando, M. Palmery, IL Farmaco, Ed. Sc., **40**, 429(1985).




The synthesis of 9,10-dihydro-4H-furo[2,3-e]-pyrrolo[1,2-a][1,4]diazepin-9-one

15


-175-




is reported by F. Povazunec, B. Decroix and J. Morel, *J. Het. Chem.* **29**, 1507(1992) and is reduced to give the tricyclic heterocycle 9,10-dihydro-4H-furo[2,3-
 5 elpyrrolo[1,2-a][1,4]diazepine.




The tricyclic 5,10-dihydro-4H-pyrazolo[5,1-c][1,4]benzodiazepine ring system is reported by L. Cecchi and G. Filacchioni, *J. Het. Chem.*, **20**, 871(1983);




The synthesis of 9-oxo-9,10-dihydro-4H-pyrrolo[1,2-a]-thieno[2,3-e][1,4]diazepine is reported by A. Daich and B. Decroix, Bull. Soc. Chim. Fr 129, 360(1992);



- 5 and is reduced with boron-dimethylsulfide to give 9,10-dihydro-4H-pyrrolo[1,2-a]thieno[2,3-e][1,4]diazepine.




Also reported by A. Daich and B. Decroix is 5-oxo-4,5-dihydropyrrolo[1,2-a]thieno[3,2-e][1,4]diazepine




10

which is also reduced to give 4,10-dihydro-5H-pyrrolo-[1,2-a]thieno[3,2-e][1,4]diazepine

-177-



Reported by B. Decroix and J. Morel, J. Het. Chem., **28**, 81(1991) are 5H-pyrrolo[1,2-a]thieno[3,2-e][1,4]diazepine;




5


and 4H-pyrrolo[1,2-a]thieno[2,3-e][1,4]diazepine. The 10H-pyrrolo[1,2-a]thieno[3,4-e][1,4]diazepine is reported by A. Daich, J. Morel and B. Decroix, J. Heterocyclic Chem., **31**, 341(1994). Reduction by

10 hydrogen-Pd/C or chemical reduction with reagents such as sodium cyanoborohydride and acetic acid gives the dihydro tricyclic heterocycles

-178-




The synthesis of the tricyclic 1,5-benzodiazepine ring system, 6,7-dihydro-5H-pyrrolo[1,2-a][1,5]benzodiazepine, has been reported by F. Chimenti, S. Vomero, R. Giuliano and M. Artico, *IL Farmaco, Ed. Sc.*, **32**, 339 (1977). Annelated 1,5-benzodiazepines containing five membered rings have been reviewed by A. Chimirri, R. Gitto, S. Grasso, A.M. Monforte, G. Romeo and M. Zappala, *Heterocycles*, **36**, No. 3, 604 (1993), and the ring system 6,7-dihydro-5H-pyrrolo[1,2-a][1,5]benzodiazepine is described.



The preparation of 5,6-dihydro-4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepin-5-ones from 1,2-dihydro-3H-4-dimethylamino-1,5-benzodiazepin-2-ones has been described by M. DiBroccio, G. Roma, G. Grossi, M. Ghia, and F. Mattioli *Eur. J. Med. Chem.*, **26**, 489 (1991). Reduction of 5,6-dihydro-4H-[1,2,4]triazolo[4,3-a]-

[1,5]benzodiazepin-5-ones with diborane or lithium hydride gives the tricyclic 5,6-dihydro derivatives.



The compounds of this invention and their preparation can be understood further by the following examples, but should not constitute a limitation thereof.

Reference Example 1

1-(2-Nitrophenyl)-1H-pyrrole-2-carboxaldehyde

To a solution of 3.76 g of 1-(2-nitro-phenyl)pyrrole in 20 ml of N,N-dimethylformamide at 0°C is added dropwise with stirring 3 ml of phosphorus oxychloride. Stirring is continued for 30 minutes and the reaction mixture is heated at 90°C for 1 hour. After cooling to room temperature the mixture is treated with crushed ice and the pH adjusted to 12 with 2 N sodium hydroxide. The resulting suspension is filtered, washed with water and dried to give 5.81 g of the desired product as a light yellow solid, m.p. 119°-122°C.

Reference Example 2

4,5-Dihydro-pyrrolo-[1,2-a]quinoxaline

To a solution of 1.0 g of 1-(2-nitrophenyl)-1H-pyrrole-2-carboxaldehyde in 40 ml of ethyl alcohol and 40 ml of ethyl acetate, under argon, is added 40 mg of 10% Pd/C. The mixture is hydrogenated at 40 psi for

-180-

2 hours and filtered through diatomaceous earth. The filtrate is concentrated in vacuo to a residue which is dissolved in ether and treated with hexanes to give 0.35 g of the desired product as a beige solid, m.p. 108°-110°C.

Reference Example 3

N-(2-Nitrobenzoyl)pyrrole-2-carboxaldehyde

To an ice bath cooled solution of 5.6 g of 2-pyrrolecarboxaldehyde in 40 ml of tetrahydrofuran is added 2.4 g of 60% sodium hydride in mineral oil. The temperature elevates to 40°C. After stirring for 20 minutes a solution of 11.0 g of 2-nitrobenzoyl chloride in 20 ml of tetrahydrofuran is added dropwise over 20 minutes. After stirring in the cold for 45 minutes, the reaction mixture is poured into ice water and ether then filtered. The cake is washed with additional ether. The two phase filtrate is separated and the ether layer dried and concentrated in vacuo to give 10 g of a residue as a dark syrup which is scratched with ethanol to give crystals which are collected by filtration, washed with ether and then dried to afford 3.2 g of solid, m.p. 95-99°C.

Reference Example 4

10,11-Dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-5-one

A mixture of 1.5 g of N-(2-nitrobenzoyl)-pyrrole-2-carboxaldehyde in 50 ml of ethyl acetate, 2 drops of concentrated HCl and 0.3 g of 10% Pd/C is shaken in a Parr apparatus under hydrogen pressure for 1.75 hours. The mixture is filtered, 0.4 g of 10% Pd/C added and the mixture shaken in a Parr apparatus under hydrogen pressure for 2 hours. The reaction mixture is filtered through diatomaceous earth and the filtrate concentrated in vacuo to give 1.0 g of a yellow oil. The residue is purified on thick layer chromatography plates by elution with 4:1 ethyl acetate:hexane to give 107 mg of the desired product as an oily solid.

-181-

Reference Example 51-(2-Nitrobenzyl)-2-pyrrolicarboxaldehyde

To 5.56 g of 60% sodium hydride in mineral oil, washed three times with hexane, is added 300 ml of N,N-dimethylformamide under argon. The reaction mixture is cooled in an ice-bath and 13.2 g of pyrrole-2-carboxaldehyde is added slowly. The reaction mixture becomes a complete solution and is stirred for an additional 10 minutes. While stirring, 30.0 g of 2-nitrobenzyl bromide is added slowly. After complete addition, the reaction mixture is stirred for 30 minutes, the ice bath is removed and the reaction mixture stirred at room temperature for 24 hours. The N,N-dimethylformamide is concentrated in vacuo to give a residue which is stirred with ice water for 1 hour. The resulting solid is collected, air dried, then vacuum dried to give 30.64 g of the desired product as a tan solid, m.p. 128-132°C.

Reference Example 610,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine

A mixture of 30.6 g of 1-(2-nitrobenzyl)-2-pyrrolicarboxaldehyde and 3.06 g of 10% Pd/C in 400 ml of ethyl acetate and 400 ml of ethyl alcohol is hydrogenated over 18 hours. The reaction mixture is filtered through diatomaceous earth and the filtrate is treated with activated carbon and filtered through diatomaceous earth. The filtrate is concentrated in vacuo to give a residue which is dissolved in methylene chloride containing ethyl alcohol. The solution is passed through a pad of silica gel and the pad washed with a 7:1 hexane-ethyl acetate solution to give 16.31 g of the desired product as solid, m.p. 145-148°C.

Reference Example 73-Methylbenzo[b]thiophene-2-acetyl chloride

A mixture of 2.0 g of 3-methylbenzo[b]-thiophene-2-acetic acid and 19.4 ml of thionyl chloride is heated at reflux for 1 hour. The volatiles are evaporated in vacuo to give a residue which is concentrated from toluene three times and dried under vacuum to give 2.25 g of the desired product as a residue.

10

Reference Example 84-Chloro-2-methoxybenzoyl chloride

A solution of 2.0 g of 4-chloro-o-anisic acid in 22 ml of thionyl chloride is heated at reflux for 1 hour. The volatiles are evaporated in vacuo to give a residue which is concentrated from toluene three times and dried under vacuum to give 2.0 g of the desired product as a residue.

15

Reference Example 92-(Trifluoromethyl)benzoyl chloride

A solution of 2.0 g of o-trifluoromethylbenzoic acid in 21 ml of thionyl chloride is heated at reflux for 1 hour. The volatiles are evaporated in vacuo to give a residue which is concentrated from toluene three times and dried under vacuum to give 2.1 g of the desired product as a residue.

20

25

Reference Example 102-Methylphenylacetyl chloride

A solution of 2.0 g of o-tolylacetic acid in 27 ml of thionyl chloride is heated at reflux for 1 hour. The volatiles are evaporated in vacuo to give a residue which is concentrated from toluene three times and dried under vacuum to give 2.1 g of the desired product as a light brown oil.

30

Reference Example 113-Methyl-4-nitro-benzoyl chloride

A mixture of 1.81 g of 3-methyl-4-nitrobenzoic acid and 1.25 g of thionyl chloride in 75 ml of chloro-
5 form is heated at reflux under argon for 48 hours. The volatiles are removed in vacuo to a residue which is evaporated with toluene several times in vacuo. The residue is partially dissolved in methylene chloride and filtered free of solids and the filtrate evaporated in
10 vacuo to give 1.47 g of the desired acid chloride.

Reference Example 121-(o-Nitrobenzyl)-imidazole-2-carboxaldehyde

A 2.0 g portion of sodium hydride (60% in oil) is washed with pentane two times. To the residue is
15 added 110 ml of N,N-dimethylformamide under argon. With stirring and external cooling, 4.80 g of 2-imidazole-carboxaldehyde is added and the cooling bath removed. Slight external heating results in a yellow solution. The reaction mixture is chilled in ice and 10.8 g of 2-
20 nitrobenzyl bromide is added. The reaction mixture is stirred at 0°C for 18 hours. The volatiles are removed in vacuo to a residue which is stirred with ice water, filtered and the cake washed well with water and suction dried to give 10.9 g of the desired product as a solid,
25 m.p. 141-144°C. MH+ 232.

Reference Example 1310,11-Dihydro-5H-imidazo[2,1-cl][1,4]benzodiazepine

A 5.0 g sample of 1-(o-nitrobenzyl)-imidazole-2-carboxaldehyde is dissolved in 150 ml of hot ethyl
30 alcohol, cooled to room temperature and filtered. To the filtrate is added 0.5 g of 10% Pd/C and the mixture hydrogenated at 48 psi for 4 hours. An additional 0.5 g of 10% Pd/C is added and hydrogenation continued for 25 hours at 65 psi. The mixture is filtered through
35 diatomaceous earth and the cake washed with ethyl acetate. The filtrate is evaporated in vacuo to a

residue which is dissolved in methylene chloride, treated with activated carbon, filtered through diatomaceous earth and hexanes added to the filtrate at the boil to give 1.86 g of the desired product as a
5 crystalline solid, m.p. 164-170°C.

Reference Example 14

10,11-Dihydro-5H-imidazo[2,1-c][1,4]benzodiazepine

To a suspension of 4 mmol of lithium aluminum hydride in 20 ml of anhydrous tetrahydrofuran is added a
10 1 mmol solution of 10,11-dihydro-11-oxo-5H-imidazo-[2,1-c][1,4]benzodiazepine and the mixture is refluxed for 24 hours and cooled at 0°C. To the mixture is added dropwise 0.12 ml of water and 6 ml of 1 N sodium hydroxide. The mixture is extracted with ethyl acetate
15 and the solvent removed to give the desired product as a solid. Recrystallization from methylene chloride-hexane gives crystals, m.p. 164-170°C.

Reference Example 15

9,10-Dihydro-4H-furo[2,3-e]pyrrolo[1,2-a][1,4]diazepine

To a suspension of 4 mmol of lithium aluminum hydride in 25 ml of anhydrous tetrahydrofuran is added 1
20 mmol of 9,10-dihydro-4H-furo[2,3-e]pyrrolo[1,2-a][1,4]-diazepin-9-one. The mixture is refluxed for 12 hours and allowed to stand overnight. To the mixture is added
25 dropwise 0.12 ml of water and then 6 ml of 1 N sodium hydroxide. The mixture is extracted with ethyl acetate and the extract dried (Na₂SO₄). The volatiles are removed in vacuo to give the desired product as a solid.

Reference Example 16

30 9,10-Dihydro-4H-furo[2,3-e]pyrrolo[1,2-a][1,4]diazepine

A solution of 1 mmol of 4H-furo[2,3-e]pyrrolo-[1,2-a][1,4]diazepine and 0.2 g of 10% Pd/C in 10 ml of ethanol is hydrogenated for 18 hours. The reaction mixture is filtered through diatomaceous earth and the
35 filtrate is evaporated in vacuo to give the desired product as a solid.

Reference Example 179,10-Dihydro-4H-pyrrolo[1,2-a]thieno[2,3-e]-
[1,4]diazepine

To a mixture of 7.0 g of 9-oxo-9,10-dihydro-
5 4H-pyrrolo[1,2-a]thieno[2,3-e][1,4]diazepin in 25 ml of
anhydrous tetrahydrofuran is added 9 ml of 10 molar
boron-dimethylsulfide in tetrahydrofuran. The mixture
is refluxed for 6 hours. The solution is cooled to room
temperature and 25 ml of methanol added dropwise. The
10 volatiles are removed under vacuum. To the residue is
added 100 ml of 2 N NaOH. The mixture is refluxed 5
hours and filtered. The solid is extracted with di-
chloromethane and the extract is washed with 2 N citric
acid, water and dried (Na₂SO₄). The solvent is removed
15 in vacuo to give the desired product as a solid.

Reference Example 184,10-Dihydro-5H-pyrrolo[1,2-a]thieno[3,2-e]-
[1,4]diazepine

To a suspension of 7.0 g of 5-oxo-4,5-dihydro-
20 pyrrolo[1,2-a]thieno[3,2-e][1,4]diazepine in 25 ml of
anhydrous tetrahydrofuran is added 9 ml of 10 M borane-
dimethylsulfide in tetrahydrofuran. The mixture is
refluxed for 6 hours. The solution is cooled to room
temperature and 25 ml of methanol added dropwise. The
25 volatiles are removed under vacuum. To the residue is
added 100 ml of 2 N NaOH. The mixture is refluxed 5
hours and filtered. The solid is extracted with di-
chloromethane and the extract is washed with 2 N citric
acid, water and dried (Na₂SO₄). The solvent is removed
30 to give a solid.

Reference Example 195,6-Dihydro-4H-[1,2,4]triazolo[4,3-a][1,5]benzodiazepine

A mixture of 7.0 g of 5,6-dihydro-4H-[1,2,4]-
triazolo-[4,3-a][1,5]benzodiazepin-5-one in 25 ml of
35 tetrahydrofuran is added 9 ml of 10 M borane-
dimethylsulfide in tetrahydrofuran. The mixture is

refluxed for 6 hours, cooled to room temperature and 25 ml of methanol added dropwise. The volatiles are removed under vacuum and to the residue is added 100 ml of 2 N sodium hydroxide. The mixture is refluxed for 5 hours, chilled and extracted with dichloromethane. The extract is washed with 2 N citric acid, water and dried (Na_2SO_4). The solvent is removed under vacuum to give a solid. The solid is purified by chromatography on silica gel to give the desired product.

10

Reference Example 20

1-(2-Nitrophenyl)-1H-pyrrole-2-carboxaldehyde

A sample of 4.7 g of sodium hydride (60% in oil) is washed with hexane (under argon). To the sodium hydride is added 200 ml of dry N,N-dimethylformamide and the mixture is chilled to 0°C. To the mixture is added 10.11 g of pyrrole-2-carboxaldehyde in small portions. The mixture is stirred 10 minutes and 15.0 g of 1-fluoro-2-nitrobenzene added dropwise. After the addition, the mixture is stirred at room temperature 16 hours and the mixture concentrated (65°C) under high vacuum. To the residue is added 400 ml of dichloromethane and the mixture washed with 150 ml each of H_2O , brine and dried (Na_2SO_4). The solvent is removed in vacuo to give a yellow solid. Crystallization from ethyl acetate-hexane (9:1) gives 17.0 g of light yellow crystals, m.p. 119°-122°C.

15

20

25

Reference Example 21

4,10-Dihydro-5H-pyrrolo[1,2-a]thieno[3,2-e]-[1,4]diazepine

To an ice cooled mixture of 2.1 g of pyrrole-2-carboxylic acid and 2.3 g of methyl 3-aminothiophene-2-carboxylate in 40 ml of dry dichloromethane is added 4 g of N,N-dicyclohexylcarbodiimide. The mixture is stirred at room temperature for 3 hours and filtered. The filter cake is washed with dichloromethane and then extracted twice with 60 ml of acetone. The acetone

30

35

-187-

extract is concentrated to dryness to give 0.8 g of solid, m.p. 214-218°C. To a suspension of the preceding compound (1.19 g) in 20 ml of dry tetrahydrofuran is added 0.2 g of sodium hydride (60% in oil). After the
5 hydrogen evolution, the mixture is stirred and refluxed for 4.5 hours, cooled and poured into ice-water. The precipitated solid is filtered and the solid triturated with petroleum ether (bp 30-60°C) to give 0.75 g of
10 4,10-dihydro-4,10-dioxo-5H-pyrrolo-[1,2-a]thieno[3,2-e][1,4]diazepine as a solid, m.p. 280-290°C. The preceding compound (0.362 g) is added to an ice-water cooled solution of 1 M diborane in tetrahydrofuran. The mixture is stirred at room temperature for 65 hours. The solution is concentrated to dryness and ice-water
15 added to the residue. The mixture is acidified with dilute HCl, stirred and then basified with solid NaHCO₃. The mixture is filtered to give 0.223 g of a solid (foam) m.p. 80-85°C.

Reference Example 22

20 10,11-Dihydro-5H-1,2,4-triazolo[3,4-c]-
[1,4]benzodiazepine

A mixture of 2.2 g of 2-cyanoaniline, 2.0 g of methyl bromoacetate and 1.3 g of potassium carbonate in 12 ml of dry N,N-dimethylformamide is heated at 150-
25 155°C for 40 minutes. The cooled mixture is poured into ice-water and the mixture filtered to give 2 g of methyl [N-(2-cyanophenyl)amino]acetate as a yellow solid, m.p. 70-78°C. The preceding compound (2.0 g) is added to a solution of 0.5 g of sodium methoxide in 50 ml of
30 methanol. The mixture is shaken under an atmosphere of hydrogen with the catalyst Raney-Ni for 19 hours. The mixture is filtered through diatomaceous earth and the filtrate evaporated. Water is added to the residue and the mixture filtered to give 2,3,4,5-tetrahydro-1H-1,4-
35 benzodiazepin-3-one as a yellow solid, m.p. 167-170°C.

A mixture of the preceding compound (1.6 g) and 0.84 g of phosphorus pentasulfide in 10 ml of dry (dried over KOH) pyridine is stirred and heated at 80-85°C for 15 minutes. The mixture is poured into water and stirred for 30 minutes. Filtration gives 1.0 g of 1,2,4,5-tetrahydro-3H-1,4-benzodiazepin-3-thione as yellow solid, m.p. 150-153°C.

The preceding compound (0.5 g) and 0.5 g of N-formylhydrazine in 6 ml of dry n-butanol is refluxed for 16 hours and the solvent removed. The gummy residue is triturated with cold water and the mixture filtered. The solid is triturated with acetone to give 0.19 g of yellow solid, m.p. 232-237°C.

Reference Example 23

4,5-Dihydro-6H-[1,2,4]triazolo[4,3-a][1,5]-benzodiazepine

A mixture of 2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-thione (0.8 g) and 0.80 g of N-formylhydrazine in 8 ml of n-butanol is stirred and refluxed for 18 hours and the solvent removed under vacuum. Ice water is added to the residual solid and the mixture filtered to give 0.312 g of a gray solid, m.p. 162-165°C.

Reference Example 24

4,5-Dihydro-6H-imidazo[1,2-a][1,5]benzodiazepine

A mixture of 30 g of acrylic acid, 33 g of o-phenylenediamine is heated on a steam bath for 1.5 hours and the cooled black mixture triturated with ice-water. The aqueous phase is decanted and ice and aqueous ammonium hydroxide added to the residue. The mixture is extracted with dichloromethane and the extract concentrated to dryness. The residue is triturated with carbon tetrachloride and filtered. The oily solid is triturated with a small amount of ethanol to give 9.7 g of a solid. Trituration of the solid with ethyl acetate

gives 2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-one as an impure solid, m.p. 75-107°C.

A mixture of the preceding compound (11.3 g) and 5.9 g of phosphorus pentasulfide in 70 ml of dry
5 pyridine is stirred and heated at approximately 80°C for 20 minutes. The mixture is poured into water and the mixture stirred for 30 minutes. Filtration gives 8.6 g of 2,3,4,5-tetrahydro-1H-1,5-benzodiazepin-2-thione as a solid, m.p. 154-157°C.

10 A mixture of the preceding compound (0.70 g), 1.0 g of aminoacetaldehyde dimethyl acetal and 15 mg of 4-methylbenzenesulfonic acid monohydrate in 6 ml of dry n-butanol is refluxed for 4 hours and the solvent removed under vacuum. The residue is heated (refluxed)
15 with 10 ml of 3 N hydrochloric acid for 55 minutes. Ice is added to the cooled mixture and the mixture made basic with solid NaHCO₃. The mixture is extracted with dichloromethane and the extract dried (Na₂SO₄). The solvent is removed to give an orange syrup which solidi-
20 fied on standing. The oily solid is triturated with acetone to give a light yellow solid (0.185 g) m.p. 119-122°C.

Reference Example 25

1-(2-Nitrophenyl)-2-pyrroleacetic acid, ethyl ester

25 To a stirred mixture of 1.88 g of 1-(2-nitrophenyl)pyrrole, 4.80 g of ethyl iodoacetate and 2.22 g of FeSO₄·7H₂O in 40 ml of dimethyl sulfoxide is added dropwise 10 ml of 30% hydrogen peroxide while keeping the reaction mixture at room temperature with a
30 cold water bath. The mixture is stirred at room temperature for one day. An additional 2.4 g of ethyl iodoacetate, 1.1 g of FeSO₄·7H₂O and 5 ml of 30% hydrogen peroxide is added and the mixture stirred at room temperature for 1 day. The mixture is diluted with
35 water and extracted with diethyl ether. The organic extract is washed with water, brine and dried (Na₂SO₄).

The solvent is removed and the residue (2.12 g) chromatographed on silica gel with ethyl acetate-hexane (1:4) as solvent to give 0.30 g of product as a brown gum.

Reference Example 26

5 6,7-Dihydro-5H-pyrrolo[1,2-a][1,5]benzodiazepin-6-one

To a solution of 0.8 mmol of 1-(2-nitro-phenyl)-2-pyrroleacetic acid, ethyl ester in 3 ml of ethanol is added stannous chloride dihydrate ($\text{SnCl}_2 \cdot 2\text{H}_2\text{O}$) in 2 ml of concentrated hydrochloric acid (with cooling
10 in water bath). The mixture is stirred at room temperature for 5 hours and chilled in an ice bath. To the mixture is added slowly saturated sodium carbonate solution. The solid which precipitates is filtered and the solid washed with water and then extracted with
15 ethyl acetate. The ethyl acetate extract is dried (Na_2SO_4) and the solvent removed to give 0.16 g of solid which is triturated with ether to give 0.11 g of product as an off-white solid.

Reference Example 27

20 6,7-Dihydro-5H-pyrrolo[1,2-a][1,5]benzodiazepine

To a solution of 0.070 g of 6,7-dihydro-5H-pyrrolo[1,2-a][1,5]benzodiazepin-6-one in 2 ml of tetrahydrofuran is added 0.45 ml of a 2.0 M solution of diborane-dimethylsulfide in tetrahydrofuran. The
25 mixture is refluxed for 3 hours, poured into water and made basic with 2 N NaOH. The tetrahydrofuran is removed under vacuum and the residual aqueous mixture extracted with diethyl ether. The extract is washed with brine, dried (Na_2SO_4) and the solvent removed to
30 give 0.065 g of a colorless oil; one spot by thin layer chromatography (silica gel) with ethyl acetate-hexane (1:2) as solvent (R_f 0.81).

Reference Example 281-[2-Nitro-5-(ethoxycarbonyl)benzyl]-pyrrole-2-carboxaldehyde

To a stirred slurry of 2.2 g of sodium hydride (60% in oil, washed with hexane) in tetrahydrofuran is added at 0°C a solution of 4.5 g of pyrrole-2-carboxaldehyde in 25 ml of tetrahydrofuran. After the addition is complete, a solution of 15 g of ethyl 4-nitro-3-bromomethylbenzoate in 30 ml of dry tetrahydrofuran is slowly added under nitrogen. The reaction mixture is stirred at 20°C for 8 hours and carefully quenched with water. The reaction mixture is extracted with chloroform which is washed with water, dried with Na₂SO₄ and concentrated in vacuo to give 12 g of the desired product as a solid; mass spectrum (M⁺H) 349.

Reference Example 291-[2-Nitro-4-(ethoxycarbonyl)benzyl]-pyrrole-2-carboxaldehyde

The conditions of Example 28 are used with ethyl 3-nitro-4-bromomethylbenzoate to give 13.0 g of the desired product as a solid; mass spectrum (M⁺H) 349.

Reference Example 30Ethyl 10,11-Dihydro-5H-pyrrolo[2,1-c][1,4]-benzodiazepine-7-carboxylate

A solution of 10.0 g of 1-[2-nitro-5-(ethoxycarbonyl)benzyl]-pyrrole-2-carboxaldehyde in 150 ml of absolute ethanol containing 1.0 g of 10% Pd/C is hydrogenated in a Parr apparatus for 16 hours under 40 psi of hydrogen. The reaction mixture is filtered through a pad of diatomaceous earth and the filtrate concentrated in vacuo to a residue of 5.5 g of the desired product as a solid; mass spectrum (M⁺H) 255.

Reference Example 31Ethyl 10,11-Dihydro-5H-pyrrolo[2,1-c][1,4]-
benzodiazepine-8-carboxylate

The hydrogenation conditions of ethyl 10,11-
5 dihydro-5H-pyrrolo[2,1-c][1,4]-benzodiazepine-7-car-
boxylate are used with 1-[2-nitro-4-(ethoxycarbonyl)-
benzyl]-pyrrole-2-carboxaldehyde to give 5.0 g of the
desired product as a solid; mass spectrum (M⁺H)255.

Reference Example 3210 2-Methylfuran-3-carbonyl chloride

A mixture of 4.0 g of methyl-2-methylfuran-3-
carboxylate, 30 ml of 2 N NaOH and 15 ml methanol is
refluxed for 1.5 hours. The solvent is removed under
vacuum to give a solid. The solid is extracted with
15 dichloromethane (discarded). The solid is dissolved in
water and the solution acidified with 2 N citric acid to
give a solid. The solid is washed with water and dried
to give crystals 1.05 g of crystals of 2-methylfuran-3-
carboxylic acid. The preceding compound (0.95 g) and 3
20 ml of thionyl chloride is refluxed for 1 hour. The
solvent is removed, toluene added (20 ml, three times)
and the solvent removed to give the product as an oil.

Reference Example 332-[2-(Tributylstannyl)-3-thienyl]-1,3-dioxolane

25 To a stirred solution of 15.6 g (0.10 mol) of
2-(3-thienyl)-1,3-dioxolane in 100 ml of anhydrous
ether, n-butyl-lithium (1.48 N, in hexane, 74.3 ml) is
added dropwise under nitrogen at room temperature.
After being refluxed for 15 minutes, the reaction
30 mixture is cooled to -78°C and tri-n-butyltin chloride
(34.18 g, 0.105 mol) in 100 ml of dry tetrahydrofuran is
added dropwise. After the addition is complete, the
mixture is warmed to room temperature and the solvent
evaporated. To the oily residue 100 ml of hexane is
35 added, and the resulting precipitate (LiCl) is filtered
off. The filtrate is evaporated and the residue dis-

tilled at reduced pressure, giving 34.16 g (77%) of the desired product.

Reference Example 34

Methyl 6-aminopyridine-3-carboxylate

5 Dry methanol (400 ml) is cooled in an ice bath and HCl gas is bubbled into the mixture for 25 minutes. To the MeOH-HCl is added 30 g of 6-aminopyridine-3-carboxylic acid and then the mixture is stirred and heated at 90°C for 2 hours (all the solid dissolved).

10 The solvent is removed under vacuum and the residual solid dissolved in 100 ml of water. The acidic solution is neutralized with saturated sodium bicarbonate (solid separated) and the mixture chilled and filtered to give 30 g of white crystals, m.p. 150°-154°C.

15 Reference Example 35

6-[[5-fluoro-2-methylbenzoyl]amino]pyridine-3-carboxylic acid

To a mixture of 4.5 g of methyl 6-amino-
pyridine-3-carboxylate and 5.53 ml of triethylamine in
20 40 ml of dichloromethane (cooled in an ice bath) is added 6.38 g of 5-fluoro-2-methylbenzoyl chloride in 10 ml of dichloromethane. The mixture is stirred at room temperature under argon for 18 hours and an additional 3.4 g of 5-fluoro-2-methylbenzoyl chloride added. After
25 stirring at room temperature for 3 hours, the mixture is filtered to give 3.0 g of methyl 6-[[bis(5-fluoro-2-methylbenzoyl)]amino]pyridine-3-carboxylate. The filtrate is concentrated to dryness and the residue triturated with hexane and ethyl acetate to give an
30 additional 9.0 g of bis acylated compound.

A mixture of 12.0 g of methyl 6-[[bis(5-fluoro-2-methylbenzoyl)]amino]pyridine-3-carboxylate, 60 ml of methanol-tetrahydrofuran (1:1) and 23 ml of 5 N NaOH is stirred at room temperature for 16 hours. The
35 mixture is concentrated under vacuum, diluted with 25 ml of water, cooled and acidified with 1 N HCl. The mix-

ture is filtered and the solid washed with water to give 6.3 g of the product as a white solid.

As described for Reference Example 35, but substituting the appropriate aroyl chloride, heteroaroyl chloride, cycloalkanoyl chlorides, phenylacetylchlorides and related appropriate acid chlorides, the following 6-[(aroylamino)pyridine-3-carboxylic acids, 6-[(heteroaroyl)amino]pyridine-3-carboxylic acids and related 6-[(acylated)amino]pyridine-3-carboxylic acids are prepared.

Reference Example 36

6-[(3-Methyl-2-thienylcarbonyl)aminopyridine-3-carboxylic acid

Reference Example 37

6-[(2-Methyl-3-thienylcarbonyl)aminopyridine-3-carboxylic acid

Reference Example 38

6-[(3-Methyl-2-furylcarbonyl)aminopyridine-3-carboxylic acid

Reference Example 39

6-[(2-Methyl-3-furylcarbonyl)aminopyridine-3-carboxylic acid

Reference Example 40

6-[(3-fluoro-2-methylbenzoyl)aminopyridine-3-carboxylic acid

Reference Example 41

6-[(2-Methylbenzoyl)aminopyridine-3-carboxylic acid

Reference Example 42

6-[(2-chlorobenzoyl)aminopyridine-3-carboxylic acid

Reference Example 43

6-[(2-Fluorobenzoyl)aminopyridine-3-carboxylic acid

Reference Example 44

6-[(2-Chloro-4-fluorobenzoyl)aminopyridine-3-carboxylic acid

Reference Example 45

6-[(2,4-Dichlorobenzoyl)aminopyridine-3-carboxylic acid

Reference Example 46

6-[(4-Chloro-2-fluorobenzoyl)aminolpyridine-3-carboxylic acid

Reference Example 47

5 6-[(3,4,5-Trimethoxybenzoyl)aminolpyridine-3-carboxylic acid

Reference Example 48

6-[(2,4-Difluorobenzoyl)aminolpyridine-3-carboxylic acid

Reference Example 49

10 6-[(2-Bromobenzoyl)aminolpyridine-3-carboxylic acid

Reference Example 50

6-[(2-Chloro-4-nitrobenzoyl)aminolpyridine-3-carboxylic acid

Reference Example 51

15 6-[(Tetrahydrofuran-2-yl)aminolpyridine-3-carboxylic acid

Reference Example 52

6-[(Tetrahydrothien-2-yl)aminolpyridine-3-carboxylic acid

20 Reference Example 53

6-[(Cyclohexylcarbonyl)aminolpyridine-3-carboxylic acid

Reference Example 54

6-[(cyclohex-3-enecarbonyl)aminolpyridine-3-carboxylic acid

25 Reference Example 55

6-[(5-Fluoro-2-methylbenzeneacetyl)aminolpyridine-3-carboxylic acid

Reference Example 56

30 6-[(2-Chlorobenzeneacetyl)aminolpyridine-3-carboxylic acid

Reference Example 57

6-[(cyclopentylcarbonyl)aminolpyridine-3-carboxylic acid

Reference Example 58

6-[(cyclohexylacetyl)aminolpyridine-3-carboxylic acid

Reference Example 59

6-[(3-Methyl-2-thienylacetyl)aminolpyridine-3-carboxylic acid]

Reference Example 60

5 6-[(2-Methyl-3-thienylacetyl)aminolpyridine-3-carboxylic acid]

Reference Example 61

6-[(3-Methyl-2-furanylacetyl)aminolpyridine-3-carboxylic acid]

10

Example 62

6-[(2-Methyl-3-furanylacetyl)aminolpyridine-3-carboxylic acid]

Reference Example 63

15 6-[(3-Methyl-2-tetrahydrothienylacetyl)aminolpyridine-3-carboxylic acid]

Reference Example 64

6-[(2-Methyl-3-tetrahydrothienylacetyl)aminolpyridine-3-carboxylic acid]

Reference Example 65

20 6-[(2,5-Dichlorobenzoyl)aminolpyridine-3-carboxylic acid]

Reference Example 66

6-[(3,5-Dichlorobenzoyl)aminolpyridine-3-carboxylic acid]

Reference Example 67

25 6-[(2-Methyl-4-chlorobenzoyl)aminolpyridine-3-carboxylic acid]

Reference Example 68

6-[(2,3-Dimethylbenzoyl)aminolpyridine-3-carboxylic acid]

Reference Example 69

30 6-[(2-Methoxybenzoyl)aminolpyridine-3-carboxylic acid]

Reference Example 70

6-[(2-Trifluoromethoxybenzoyl)aminolpyridine-3-carboxylic acid]

Reference Example 71

35 6-[(4-Chloro-2-methoxybenzoyl)aminolpyridine-3-carboxylic acid]

Reference Example 72

6-[(2-(Trifluoromethyl)benzoyl)aminolpyridine-3-carboxylic acid

Reference Example 73

5 6-[(2,6-Dichlorobenzoyl)aminolpyridine-3-carboxylic acid

Reference Example 74

6-[(2,6-Dimethylbenzoyl)aminolpyridine-3-carboxylic acid

Reference Example 75

6-[(2-Methylthiobenzoyl)aminolpyridine-3-carboxylic acid

10 Reference Example 76

6-[(4-Fluoro-2-(trifluoromethyl)benzoyl)aminolpyridine-3-carboxylic acid

Reference Example 77

6-[(2,3-Dichlorobenzoyl)aminolpyridine-3-carboxylic acid

15 Reference Example 78

6-[(4-Fluoro-2-methylbenzoyl)aminolpyridine-3-carboxylic acid

Reference Example 79

6-[(2,3,5-Trichlorobenzoyl)aminolpyridine-3-carboxylic acid

20

Reference Example 80

6-[(5-Fluoro-2-chlorobenzoyl)aminolpyridine-3-carboxylic acid

Reference Example 81

25 6-[(2-Fluoro-5-(trifluoromethyl)benzoyl)aminolpyridine-3-carboxylic acid

Reference Example 82

6-[(5-Fluoro-2-methylbenzoyl)aminolpyridine-3-carbonyl chloride

30

A mixture of 6.2 g of 6-[(5-fluoro-2-methylbenzoyl)amino]pyridine-3-carboxylic acid and 23 ml of thionyl chloride is refluxed for 1 hour. An additional 12 ml of thionyl chloride is added and the mixture refluxed for 0.5 hour. The mixture is concentrated to dryness under vacuum and 30 ml of toluene added to the residue. The toluene is removed under vacuum and the

35

process (add toluene and remove) is repeated to give 7.7 g of crude product as a solid.

As described for Reference Example 82, the following 6-(acyl)aminopyridine-3-carbonyl chlorides are prepared.

Reference Example 83

6-[(3-Methyl-2-thienylcarbonyl)aminopyridine-3-carbonyl chloride]

Reference Example 84

6-[(2-Methyl-3-thienylcarbonyl)aminopyridine-3-carbonyl chloride]

Reference Example 85

6-[(3-Methyl-2-furylcarbonyl)aminopyridine-3-carbonyl chloride]

Reference Example 86

6-[(2-Methyl-3-furylcarbonyl)aminopyridine-3-carbonyl chloride]

Reference Example 87

6-[(3-Fluoro-2-methylbenzoyl)aminopyridine-3-carbonyl chloride]

Reference Example 88

6-[(2-Methylbenzoyl)aminopyridine-3-carbonyl chloride]

Reference Example 89

6-[(2-Chlorobenzoyl)aminopyridine-3-carbonyl chloride],
white crystals

Reference Example 90

6-[(2-Fluorobenzoyl)aminopyridine-3-carbonyl chloride]

Reference Example 91

6-[(2-Chloro-4-fluorobenzoyl)aminopyridine-3-carbonyl chloride]

Reference Example 92

6-[(2,4-Dichlorobenzoyl)aminopyridine-3-carbonyl chloride]

Reference Example 93

6-[(4-Chloro-2-fluorobenzoyl)aminopyridine-3-carbonyl chloride]

Reference Example 94

6-[(3,4,5-Trimethoxybenzoyl)aminolpyridine-3-carbonyl
chloride

Reference Example 95

5 6-[(2,4-Difluorobenzoyl)aminolpyridine-3-carbonyl
chloride

Reference Example 96

6-[(2-Bromobenzoyl)aminolpyridine-3-carbonyl chloride

Reference Example 97

10 6-[(2-Chloro-4-nitrobenzoyl)aminolpyridine-3-carbonyl
chloride

Reference Example 98

6-[(Tetrahydrofuran-2-carbonyl)aminolpyridine-3-
carbonyl chloride

15 Reference Example 99

6-[(Tetrahydrothienyl-2-carbonyl)aminolpyridine-3-
carbonyl chloride

Reference Example 100

20 6-[(Cyclohexylcarbonyl)aminolpyridine-3-carbonyl
chloride

Reference Example 101

6-[(Cyclohex-3-enecarbonyl)aminolpyridine-3-carbonyl
chloride

Reference Example 102

25 6-[(2-Methylbenzeneacetyl)aminolpyridine-3-carbonyl
chloride

Reference Example 103

6-[(2-Chlorobenzeneacetyl)aminolpyridine-3-carbonyl
chloride

30 Reference Example 104

6-[(Cyclopentylcarbonyl)aminolpyridine-3-carbonyl
chloride

Reference Example 105

6-[(Cyclohexylacetyl)aminolpyridine-3-carbonyl chloride

Reference Example 106

6-[(3-Methyl-2-thienylacetyl)aminopyridine-3-carbonyl
chloride

Reference Example 107

5 6-[(2-Methyl-3-thienylacetyl)aminopyridine-3-carbonyl
chloride

Reference Example 108

6-[(3-Methyl-2-furanylacetyl)aminopyridine-3-carbonyl
chloride

10 Reference Example 109

6-[(2-Methyl-3-furanylacetyl)aminopyridine-3-carbonyl
chloride

Reference Example 110

15 6-[(2-Methyl-5-fluorobenzeneacetyl)aminopyridine-3-
carbonyl chloride

Reference Example 111

6-[(3-Methyl-2-tetrahydrothienylacetyl)aminopyridine-3-
carbonyl chloride

Reference Example 112

20 6-[(2-Methyl-3-tetrahydrothienylacetyl)aminopyridine-3-
carbonyl chloride

Reference Example 113

6-[(2,5-Dichlorobenzoyl)aminopyridine-3-carbonyl
chloride

25 Reference Example 114

6-[(3,5-Dichlorobenzoyl)aminopyridine-3-carbonyl
chloride

Reference Example 115

30 6-[(2-Methyl-4-chlorobenzoyl)aminopyridine-3-carbonyl
chloride

Reference Example 116

6-[(2,3-Dimethylbenzoyl)aminopyridine-3-carbonyl
chloride

Reference Example 117

35 6-[(2-Methoxybenzoyl)aminopyridine-3-carbonyl chloride

Reference Example 118

6-[(2-Trifluoromethoxybenzoyl)aminolpyridine-3-carbonyl
chloride

Reference Example 119

5 6-[(4-Chloro-2-methoxybenzoyl)aminolpyridine-3-carbonyl
chloride

Reference Example 120

6-[(2-(Trifluoromethyl)benzoyl)aminolpyridine-3-carbonyl
chloride

10

Reference Example 121

6-[(2,6-Dichlorobenzoyl)aminolpyridine-3-carbonyl
chloride

Reference Example 122

6-[(2,6-Dimethylbenzoyl)aminolpyridine-3-carbonyl
chloride

15

Reference Example 123

6-[(2-Methylthiobenzoyl)aminolpyridine-3-carbonyl
chloride

Reference Example 124

20 6-[(4-Fluoro-2-(trifluoromethyl)benzoyl)aminolpyridine-
3-carbonyl chloride

Reference Example 125

6-[(2,3-Dichlorobenzoyl)aminolpyridine-3-carbonyl
chloride

25

Reference Example 126

6-[(4-Fluoro-2-methylbenzoyl)aminolpyridine-3-carbonyl
chloride

Reference Example 127

6-[(2,3,5-Trichlorobenzoyl)aminolpyridine-3-carbonyl
chloride

30

Reference Example 128

6-[(5-Fluoro-2-chlorobenzoyl)aminolpyridine-3-carbonyl
chloride

Reference Example 129

35 6-[(2-Fluoro-5-(trifluoromethyl)benzoyl)aminolpyridine-
3-carbonyl chloride

Reference Example 1301-(3-Nitro-2-pyridinyl)-1H-pyrrole-2-carboxaldehyde

A sample (3.6 g) of sodium hydride (60% in oil) is washed with hexane under argon. To the sodium
5 hydride is added 100 ml of dry N,N-dimethylformamide. The mixture is cooled in an ice bath and 7.8 g of 1H-pyrrole-2-carboxaldehyde is added in small portions. After the addition the cooled mixture is stirred for 15 minutes and 13.0 g of 2-chloro-3-nitropyridine is added.
10 The mixture is heated at 120°C for 16 hours. The solvent is removed under vacuum at 80°C and to the dark residue is added 200 ml of ethyl acetate. The mixture is filtered and to the filtrate is added 100 ml of water. The mixture is filtered through diatomaceous
15 earth and then filtered through a thin pad of hydrous magnesium silicate. The filtrate is diluted with water, the organic layer separated, washed 2 times with 100 ml of water and once with 100 ml of brine and then dried (Na₂SO₄). The solvent is removed under vacuum to give
20 16 g of solid. The solid is chromatographed on a silica gel column with hexane-ethyl acetate (2:1) as solvent to give crystals which are recrystallized from ethyl acetate-hexane (97:3) to give 8.5 g of product as crystals, m.p. 122°-125°C.


25 Reference Example 1315,6-Dihydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine

To a suspension of 8.0 g of 1-(3-nitro-2-pyridinyl)-1H-pyrrole-2-carboxaldehyde in 150 ml of ethyl acetate is added 800 mg of 10% Pd/C. The mixture
30 is shaken in a Parr hydrogenator for 3 hours and then filtered through diatomaceous earth. The filtrate is concentrated under vacuum to give 8.5 g of solid. The solid is purified by chromatography over silica gel with solvent hexane-ethyl acetate (2:1) as solvent to give
35 2.6 g of product as white crystals, m.p. 92°-94°C and

1.6 g of pyrido[3,2-a]pyrrolo[1,2-a]pyrazine as tan needles, m.p. 88°C to 90°C.

As described for Reference Example 35, the following bis acylated products (Table A) are prepared and purified by silica gel chromatography. These compounds are then hydrolysed to the acids as described in Example 35 (Table B).

Table A




10

Ref. Ex. No.	R ₁	R ₂	R ₃	R ₄	X	M ⁺
132	CH ₃	H	H	H	H	388
133	CH ₃	H	H	F	H	424
134	CH ₃	F	H	H	H	426
135	H	OCH ₃	OCH ₃	OCH ₃	H	540
136	Cl	H	H	H	H	430
137	F	H	F	H	H	396
138	Br	H	H	H	H	520
139	Cl	H	F	H	H	412
140	Ph	H	H	H	H	512
142	Cl	H	H	Br	H	474
143	CH ₃	H	H	F	Br	
144	CH ₃	H	H	H	Br	468

M⁺ is molecular ion found from FAB mass spectrum

Table B



Ref. Ex. No.	R ₁	R ₂	R ₃	R ₄	X	M ⁺
145	CH ₃	H	H	H	H	256
146	CH ₃	H	H	F	H	274
147	CH ₃	F	H	H	H	274
148	H	OCH ₃	OCH ₃	OCH ₃	H	332
149	Cl	H	H	H	H	276
150	F	H	F	H	H	278
151	Br	H	H	H	H	322
152	Cl	H	F	H	H	294
153	Ph	H	H	H	H	318
154	Cl	H	H	Br	H	356
155	CH ₃	H	H	F	Cl	
156	CH ₃	H	H	H	Br	336

M⁺ is molecular ion found from FAB mass spectrum.

5

Reference Example 157

6-Amino-5-bromopyridine-3-carboxylic acid

To a stirred solution of 6-aminonicotinic acid (13.8 g, 0.1 mole) in glacial acetic acid (100 ml), bromine (16 g, 5 ml, 0.1 mole) in acetic acid (20 ml) is added slowly. The reaction mixture is stirred for 8 hours at room temperature and the acetic acid is removed under reduced pressure. The yellow solid residue is dissolved in water and carefully neutralized with 30%

10

NH₄OH. The separated solid is filtered and washed with water to give 18 g of solid; mass spectrum: 218 (M⁺).

Reference Example 158

Methyl 6-amino-5-bromopyridine-3-carboxylate

5 6-Amino-5-bromopyridine-3-carboxylic acid (10 g, 50 mmol) is dissolved in saturated methanolic HCl (100 ml) and refluxed for 24 hours. The solvent, methanol, is re-moved under reduced pressure and the residue is dis-solved in ice cold water. The aqueous
10 solution is neutralized with 0.1 N NaOH and the solid which separates is filtered; washed well with water and air dried to yield 10 g of product as a solid: mass spectrum 231 (M⁺).

Reference Example 159

15 10-[[6-Chloro-3-pyridinyl]carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine

To a mixture of 1.84 g of 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine and 1.52 g of tri-ethylamine in 20 ml of dichloromethane is added a solu-
20 tion of 2.11 g of 6-chloronicotinyll chloride in 5 ml of dichloromethane. The mixture is stirred at room temperature for 2 hours and quenched with 30 ml of 1 N sodium hydroxide. The mixture is diluted with 20 ml of dichloromethane and the organic layer separated. The
25 organic layer is washed twice with 20 ml of 1 N sodium hydroxide, washed with brine and dried (Na₂SO₄). The solvent is removed under vacuum and the residue tri-turated with ether to give 3.22 g of white solid; mass spectrum (CI) 324 (M+H).

30 Reference Example 160

10-[[6-[(2-dimethylaminoethyl)amino]-3-pyridinyl]carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine

A mixture of 10-[[6-chloro-3-pyridinyl]-
35 carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine (3.2 g), K₂CO₃ (5 g) and the 2-dimethylamino-

ethylamine (5 ml) is heated in dimethylsulfoxide (80 ml) for 6 hours at 100°C (with stirring). The reaction mixture is quenched with water and the solid which separates, is filtered off and washed well with water.

- 5 Examination of the TLC (CHCl₃:MeOH; 3:1) showed the products to be sufficiently pure to be used for further reactions without purification. Yield 3.2 g, 85%, mass spectrum (CI) 376 (M+1).

Reference Example 161

10 6-[(2-Methylbenzeneacetyl)aminolpyridine-3-carboxylic acid

- To a cooled (0°C) mixture of 5.0 g methyl 6-aminopyridine-3-carboxylate, 12.6 ml of N,N-diisopropylethylamine in 40 ml of dichloromethane is added a
- 15 solution of 12.2 g of 2-methylbenzeneacetyl chloride in 10 ml of dichloromethane. The mixture is stirred under argon at room temperature overnight. The mixture is diluted with 200 ml of dichloromethane and 50 ml of water and the organic layer separated. The organic
- 20 layer is washed with 50 ml each of 1 M NaHCO₃, brine and dried (Na₂SO₄). The solution is filtered through a thin pad of hydrous magnesium silicate and the filtrate concentrated to dryness. The residue (9.0 g) is chromatographed on a silica gel column with hexane-ethyl
- 25 acetate (3:1) as eluent to give 8.6 g of solid. This solid, mainly methyl 6-[[bis(2-methylbenzeneacetyl)]-aminolpyridine-3-carboxylate, is dissolved in 60 ml of tetrahydrofuran-methanol (1:1) and 23 ml of 5 N NaOH added to the solution. The mixture is stirred at room
- 30 temperature overnight and the mixture concentrated under vacuum. Water (25 ml) is added and the mixture is stirred and acidified with cold 1 N HCl. The mixture is chilled and the solid filtered and washed with water to give 5.9 g of off-white solid.

-207-

Reference Example 1626-[(2-Methylbenzeneacetyl)aminopyridine-3-carbonyl chloride

A mixture of 4.5 g of 6-[(2-methylbenzene-
5 acetyl)aminopyridine-3-carboxylic acid and 25 ml of
thionyl chloride is refluxed for 1 hour and then con-
centrated to dryness under vacuum. To the residue is
added 20 ml of toluene and the solvent removed under
vacuum. The addition and removal of toluene is repeated
10 and the residual solid dried at room temperature under
vacuum to give 5.3 g of dark brown solid.

Reference Example 1636-[(2-Methylbenzeneacetyl)aminopyridine-3-carboxylic acid

15 To a chilled solution (0°C) of 5.0 g of methyl
6-aminopyridine-3-carboxylate and 12.6 ml of diiso-
propylethylamine in 40 ml of dichloromethane under argon
is added 12.2 g of 2-methylbenzeneacetyl chloride in 10
ml of dichloromethane. The mixture is stirred at room
20 temperature 16 hours and diluted with 200 ml of di-
chloromethane and 50 ml of water. The organic layer is
separated and washed with 50 ml each of 1 M NaHCO₃,
brine and dried (Na₂SO₄). The solution is filtered
through a thin pad of hydrous magnesium silicate and the
25 filtrate concentrated to dryness. The residue (9.0 g)
is purified by chromatography on silica gel with hexane-
ethyl acetate (3:1) as eluent to give 0.70 g of methyl
6-[[bis(2-methylbenzeneacetyl)aminopyridine-3-carboxy-
late and 8.6 g of a mixture of methyl 6-[(2-methyl-
30 benzeneacetyl)aminopyridine-3-carboxylate and the bis
acylated product. The above mixture (8.6 g) of mono and
bis acylated product is dissolved in 60 ml of tetra-
hydrofuran-methanol (1:1) and 23 ml of 5 N NaOH is
added. The solution is stirred at room temperature for
35 16 hours, concentrated under vacuum, diluted with 25 ml
of H₂O and acidified with cold 1 N HCl. The precipi-

tated solid is filtered off and dried to give 5.9 g of white solid.

Reference Example 164

6-[(2-Methylbenzeneacetyl)aminopyridine-3-carbonyl chloride

5 A mixture of 4.5 g of 6-[(2-methylbenzene-acetyl)amino]pyridine-3-carboxylic acid and 17 ml of thionyl chloride is heated on a steam bath for 1/2 hour. An additional 815 ml of thionyl chloride is added and
10 the mixture refluxed for 0.5 hour. The volatiles are removed under vacuum and toluene (20 ml) added (twice) and the solvent removed under vacuum to give 5.3 g of a dark colored solid.

Reference Example 165

2-Biphenylcarbonyl chloride

15 A mixture of 5.6 g of 2-biphenylcarboxylic acid and 29 ml of thionyl chloride is heated on a steam bath for 0.5 hour and the volatiles removed under vacuum. Toluene (40 ml) is added (twice) and the
20 solvent removed under vacuum to give 6.8 g of a yellow oil.

Reference Example 166

Methyl 6-[[bis(2-biphenylcarbonyl)aminopyridine-3-carboxylate

25 To a chilled (0°C) solution of 2.64 g of methyl 6-aminopyridine-3-carboxylate and 5.5 ml of diisopropylethylamine in 30 ml of dichloromethane under argon is added 6.8 g of 2-biphenylcarbonyl chloride in 10 ml of dichloromethane. The mixture is stirred at
30 room temperature 2 days and then diluted with 120 ml of dichloromethane and 50 ml of water. The organic layer is separated, washed with 50 ml each of 1 M NaHCO₃ and brine and dried (Na₂SO₄). The solution is filtered
35 through a thin pad of hydrous magnesium silicate and the filtrate concentrated under vacuum to give a solid.

Crystallization from ethyl acetate gives 6.2 g of white crystals, m.p. 180-188°C.

Reference Example 167

6-[(2-Biphenylcarbonyl)aminopyridine-3-carboxylic acid

5 To a chilled (0°C) mixture of 6.0 g of methyl
6-[[bis(2-biphenylcarbonyl)]amino]pyridine-3-carboxylate
in 40 ml of methanol and 30 ml of tetrahydrofuran is
added slowly 18 ml of 2 N NaOH. The mixture is stirred
at room temperature overnight and brought to pH 5 with
10 glacial acetic acid. The mixture is concentrated,
acidified to pH 2-3 with 1 N HCl and extracted with 250
ml of ethyl acetate. The extract is washed with 50 ml
of brine, dried (Na₂SO₄) and the solvent removed under
vacuum. The residual white solid is triturated with 15
15 ml of ethyl acetate to give 3.35 g of white crystals,
m.p. 215-217°C.

Reference Example 168

6-[(2-Biphenylcarbonyl)aminopyridine-3-carbonyl
chloride

20 A mixture of 1.9 g of 6-[(2-biphenylcar-
bonyl)amino]pyridine-3-carboxylic acid and 9 ml of
thionyl chloride is refluxed for 1 hour and then con-
centrated to dryness under vacuum. Toluene (15 ml) is
added (twice) to the residue and the solvent removed
25 under vacuum to give 2.1 g of a light brown oil.

Reference Example 169

6-[(Cyclohexylcarbonyl)aminopyridine-3-carboxylic acid

To a chilled (0°C) solution of 5.0 g of methyl
6-aminopyridine-3-carboxylate and 12.6 ml of diiso-
30 propylethylamine in 50 ml of dichloromethane under argon
is added a solution of 9.7 ml of cyclohexylcarbonyl
chloride in 10 ml of dichloromethane. The mixture is
stirred at room temperature overnight and diluted with
200 ml of dichloromethane and 60 ml of water. The
35 organic layer is separated, washed with 60 ml of brine
and dried (Na₂SO₄). The solution is filtered through a

thin pad of hydrous magnesium silicate and the filtrate concentrated under vacuum to give 12.8 g of a solid.

The above solid (12.0 g) in a mixture of 150 ml of tetrahydrofuran-methanol (1:1) is chilled (0°C) and 62 ml of 2 N sodium hydroxide added. The mixture is stirred at room temperature for 3 hours, neutralized with 10 ml of glacial acetic acid and concentrated under vacuum. The mixture (containing solid) is acidified to pH 1 with 1 N HCl and extracted with 250 ml of ethyl acetate and twice with 100 ml of ethyl acetate. The combined extract is washed with 100 ml of brine, dried (Na₂SO₄) and concentrated to a white solid. Trituration with hexane gives 6.5 g of product as a white solid.

Reference Example 170

5-[(6-Chloro-3-pyridinyl)carbonyl]-5,10-dihydro-4H-pyrazolo[5,1-c][1,4]benzodiazepine

To a solution of 10 mmol of 5,10-dihydro-4H-pyrazolo[5,1-c][1,4]benzodiazepine and 1.5 g of triethylamine in 20 ml of dichloromethane is added a solution of 2.11 g of 6-chloropyridine-3-carbonyl chloride in 5 ml of dichloromethane. The mixture is stirred for 3 hours at room temperature diluted with 20 ml of dichloromethane and washed with 30 ml of 1 N NaOH. The organic layer is washed twice with 20 ml of 1 N NaOH, dried (Na₂SO₄) and the solvent removed. The residue is triturated with ether to give 3 g of solid.

Reference Example 171

Methyl 4-[(1,1'-Biphenyl)-2-carbonyl]aminol-3-methoxybenzoate

A mixture of 10.0 g of [1,1'-biphenyl]-2-carboxylic acid in 75 ml of methylene chloride and 12.52 g of oxalyl chloride is stirred at room temperature for 15 hours. The volatiles are evaporated in vacuo to give 11.06 g of an oil. A 2.16 g portion of the above oil in 25 ml of methylene chloride is reacted with 1.81 g of methyl 4-amino-3-methoxybenzoate and 1.30 g of N,N-

-211-

diisopropylethylamine by stirring at room temperature for 18 hours. The reaction mixture is washed with water, saturated aqueous NaHCO_3 and the organic layer dried (Na_2SO_4). The organic layer is passed through
5 hydrous magnesium silicate and hexane added to the filtrate at the boil to give 3.20 g of the desired product as a crystalline solid, m.p. 115-117°C.

Reference Example 172

10 Methyl 4-([1,1'-Biphenyl]-2-carbonyl)aminol-2-chlorobenzoate

A solution of 2.37 g of [1,1'-biphenyl]-2-carbonyl chloride in 10 ml of methylene chloride is added dropwise to an ice cold solution of 1.84 g of methyl 4-amino-2-chlorobenzoate and 1.49 g of N,N-
15 diisopropylethylamine in 50 ml of methylene chloride. The reaction mixture is stirred at room temperature for 18 hours and washed with water, saturated aqueous NaHCO_3 and the organic layer dried (Na_2SO_4). The organic layer is passed through a pad of hydrous magnesium silicate
20 and hexane added at the boil to give 1.1 g of the desired product as a crystalline solid, m.p. 132-134°C.
M⁺H=365

Reference Example 173

25 4-([1,1'-Biphenyl]-2-carbonyl)aminol-2-chlorobenzoic Acid

A mixture of 3.0 g of methyl 4-([1,1'-biphenyl]-2-carbonyl)amino]-2-chlorobenzoate in 75 ml of absolute ethanol and 2.0 ml of 10 N sodium hydroxide is heated on a steam bath for 3 hours. Water is added to
30 obtain a solution which is extracted with methylene chloride. The aqueous phase is acidified with acetic acid and the resulting solid collected and dried in vacuo at 80°C to give 0.1 g of the desired product as a crystalline solid, m.p. 217-219°C

Reference Example 1744-[[[1,1'-Biphenyl]-2-carbonyl]-amino]-3-methoxybenzoyl
Chloride

A solution of 2.69 g of 4-[[[1,1'-biphenyl]-2-
5 carbonyl]amino]-3-methoxy benzoic acid in 5 ml of
thionyl chloride is heated on a steam bath for 1 hour
under Argon. The volatiles are removed in vacuo to give
a residue which is stirred with hexane to give 2.58 g of
crystalline solid, m.p. 121-123°C. M_n=361.

10

Reference Example 175Methyl 4-[[[1,1'-Biphenyl]-2-carbonyl]aminobenzoate

A mixture of 10.0 g of [1,1'-biphenyl]-2-
carboxylic acid in 75 ml of methylene chloride and 12.52
g of oxalyl chloride is stirred at room temperature for
15 18 hours. The volatiles are evaporated in vacuo to give
11.66 g of an oil. A 7.5 g portion of the above oil in
25 ml of methylene chloride is added dropwise to a
solution of 4.53 g of methyl 4-aminobenzoate and 4.3 g
of N,N-diisopropylethylamine in 100 ml of methylene
20 chloride at 0°C. The reaction mixture is stirred at
room temperature for 18 hours and washed with water, and
saturated aqueous NaHCO₃ and the organic layer
dried (Na₂SO₄). The organic layer is passed through
hydrous magnesium silicate and hexane added to the
25 filtrate at the boil to give 8.38 g of the desired
product as a crystalline solid, m.p. 163-165°C.

Reference Example 1764-[[[1,1'-Biphenyl]-2-carbonyl]aminobenzoic Acid

A 3.15 g sample of methyl 4-[[[1,1'-biphenyl]-
30 2-carbonyl]aminobenzoate is refluxed for 8 hours in 100
ml of ethyl alcohol and 2.5 ml of 10N sodium hydroxide.
The cooled reaction mixture is acidified with [[? acid]]
and the desired product collected and dried to give 2.9
g of the desired product as a solid m.p. 246-249°C.
35 M_n+H=318.

Reference Example 1774-[[[1,1'-Biphenyl]-2-carbonyl]amino]benzoyl Chloride

A mixture of 1.39 g of 4-[[[1,1'-biphenyl]-2-carbonyl]amino]benzoic acid in 2.0 ml of thionyl chloride is heated on a steam bath for 1 hour. Cold hexane is added and the crystalline solid collected and dried to give 1.34 g of the desired product, m.p. 118-120°C.

Reference Example 1782-(Phenylmethyl)benzoyl Chloride

A mixture of 5.0 g of 2-(phenylmethyl)benzoic acid in 5.0 ml of thionyl chloride is heated on a steam bath for 1 hour. The volatiles are evaporated in vacuo to give 5.74 g of the desired product as an oil. $M^+ = 227$ as methyl ester.

Reference Example 179Methyl 4-[[2-(Phenylmethyl)benzoyl]amino]benzoate

To 3.03 g of methyl 4-aminobenzoate and 3.12 g of N,N-diisopropylethylamine in 75 ml of methylene chloride is added 5.54 g of 2-(phenylmethyl)benzoyl chloride and the reactants stirred at room temperature for 18 hours. The reaction mixture is washed with water, saturated aqueous NaHCO_3 and the organic layer dried (Na_2SO_4). The organic layer is passed through hydrous magnesium silicate two times and hexane added to the filtrate at the boil to give 5.04 g of the desired product as a crystalline solid, m.p. 138-139°C.

Reference Example 180Sodium 4-[[2-(Phenylmethyl)benzoyl]amino]benzoate

A mixture of 4.90 g of methyl 4-[[2-(phenylmethyl)benzoyl]amino]benzoate in 100 ml of absolute ethanol and 3.50 ml of 10 N sodium hydroxide is heated on a steam bath for 3 hours. The aqueous phase is filtered and the resulting solid collected and dried to give 4.25 g of the desired product m.p. 340-346°C.

Reference Example 1814-[[2-(Phenylmethyl)benzoyl]aminolbenzoic Acid

A mixture of 4.0 g sodium 4-[[2-(phenylmethyl)benzoyl]amino]benzoate is suspended in water and the pH adjusted to 5 with acetic acid. The solid is collected by filtration and dried at 80°C in vacuo to give 3.75 g of the desired product, 246-247°C. $M^+ = 332$.

Reference Example 1824-[[2-(Phenylmethyl)benzoyl]aminolbenzoyl Chloride

A mixture of 2.0 g of 4-[[2-(phenylmethyl)benzoyl]amino]benzoic acid in 2.0 ml of thionyl chloride is heated on a steam bath for 1 hour. The volatiles are evaporated in vacuo to give 1.53 g of the desired product as an oil. $M^+ = 346$ as methyl ester.

Reference Example 183Methyl 4-[[2-(phenylmethyl)benzoyl]aminol-2-chlorobenzoate

A mixture of 5.0 g of 2-(phenylmethyl)benzoic acid in 5.0 ml of thionyl chloride is heated on a steam bath for 1 hour. The volatiles are evaporated in vacuo to give 5.70 g of an oil. A 2.85 g portion of the above oil in 25 ml of methylene chloride is added to a solution of 50 ml of methylene chloride containing 1.85 g of methyl 4-amino-2-chlorobenzoate and 1.65 g of N,N-diisopropylethylamine by stirring at room temperature for 18 hours. The reaction mixture is washed with water, saturated aqueous NaHCO_3 and the organic layer dried (Na_2SO_4). The organic layer is passed through hydrous magnesium silicate two times and hexane added to the filtrate at the boil to give 2.96 g of the desired product as a crystalline solid, m.p. 133-135°C. $M^+ = 380$.

Reference Example 184Methyl 4-[[2-(Phenylmethyl)benzoyl]aminol-3-methoxybenzoate

A solution of 2.85 g of 2-(phenylmethyl)benzoyl chloride in 25 ml of methylene chloride is added

dropwise to an ice cold solution of 1.84 g of methyl 4-amino-3-methoxybenzoate and 1.61 g of N,N-diisopropylethylamine in 50 ml of methylene chloride. The reaction mixture is stirred at room temperature for 18 hours and washed with water, saturated aqueous NaHCO₃ and the organic layer dried (Na₂SO₄). The organic layer is passed through a pad of hydrous magnesium silicate and hexane added at the boil to give 2.2 g of the desired product as a crystalline solid, m.p. 129-131°C. M⁺=376.

10 Reference Example 185

2-Chloro-4-[[(2-Phenylmethyl) benzoyl] aminol benzoic Acid

A mixture of 2.8 g of methyl 2-chloro-4-[[(2-phenylmethyl) benzoyl] aminobenzoate in 75 ml of absolute ethanol and 1.84 ml of 10 N sodium hydroxide is heated on a steam bath for 3 hours. Water is added to obtain a solution which is extracted with methylene chloride. The aqueous phase is acidified with acetic acid and the resulting solid collected and dried in vacuo at 80°C to give 2.6 g of the desired product as a crystalline solid, m.p. 184-187°C. M⁺H=366.

Reference Example 186

3-Methoxy-4-[[(2-phenylmethyl) benzoyl] aminol benzoate

A mixture of 2.05 g of methyl 4-[[(2-phenylmethyl) benzoyl] amino]-3-methoxybenzoate in 75 ml of absolute ethanol and 1.4 ml of 10 N sodium hydroxide is heated on a steam bath for 3 hours. Water is added to obtain a solution which is extracted with methylene chloride. The aqueous phase is acidified with acetic acid and the resulting solid collected and dried in vacuo at 80°C to give 1.87 g of the desired product as a crystalline solid, m.p. 176-178°C. M⁺H=362.

Reference Example 187

3-Methoxy-4-[[(2-phenylmethyl) benzoyl] aminol benzoyl Chloride

35 A mixture of 1.71 g of 3-methoxy-4-[[(2-phenylmethyl) benzoyl] amino] benzoic acid in 2.0 ml of

thionyl chloride is heated on a steam bath under Argon for 1 hour and hexane added. The resulting solid is collected and dried to give 1.71 g of the desired product as a crystalline solid, m.p. 130-135°C. $M^+=376$ as the methyl ester.

Reference Example 188

4'-(Trifluoromethyl)-[1,1'-biphenyl]-2-carbonyl Chloride

A mixture of 5.0 g of 4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carboxylic acid in 5.0 ml of thionyl chloride is heated on a steam bath under Argon for 1 hour and hexane added. The resulting solid is collected and dried to give 5.36 g of the desired product as a colorless oil. $M^+=280$ as methyl ester.

Reference Example 189

Methyl 2-Chloro-4-([4'-(trifluoromethyl)[1,1'-biphenyl]carbonyl)aminobenzoate

A solution of 3.13 g of 4'-(trifluoromethyl)-[1,1'-biphenyl]-2-carbonyl chloride in 25 ml of methylene chloride is added dropwise to an ice cold solution of 1.84 g of methyl 4-aminobenzoate and 1.43 g of N,N-diisopropylethylamine in 50 ml of methylene chloride. The reaction mixture is stirred at room temperature for 18 hours and washed with water, saturated aqueous NaHCO_3 and the organic layer dried (Na_2SO_4). The organic layer is passed through a pad of hydrous magnesium silicate and hexane added at the boil to give 3.36 g of the desired product as a crystalline solid, m.p. 164-165°C. $M^+=396$.

Reference Example 190

3-Methoxy-4-([4'-(trifluoromethyl)[1,1'-biphenyl]-2-carbonyl)aminobenzoyl Chloride

A mixture of 2.0 g of 3-methoxy-4-([4'-(trifluoromethyl)[1,1'-biphenyl]-2-carbonyl)amino]benzoic acid in 20 ml of thionyl chloride is heated on a steam bath under Argon for 1 hour and hexane added. The

-217-

resulting solid is collected and dried to give 1.92 g of the desired product as a crystalline solid, m.p. 136-138°C.

Reference Example 191

5 3-Methoxy-4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-carbonyl]aminobenzoic Acid

A mixture of 3.78 g of methyl 3-methoxy-4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-carbonyl)-amino]benzoate in 75 ml of absolute ethanol and 2.20 ml
10 of 10 N sodium hydroxide is heated on a steam bath for 3 hours. Water is added to obtain a solution which is extracted with methylene chloride. The aqueous phase is acidified with acetic acid and the resulting solid collected and dried in vacuo at 80°C to give 3.49 g of
15 the desired product as a crystalline solid, m.p. 213-215°C.

Reference Example 192

Methyl 3-Methoxy-4-[(4'-trifluoromethyl)[1,1'-biphenyl]-2-carbonyl]aminobenzoate

20 A solution of 3.56 g of [4'-(trifluoromethyl)[1,1'-biphenyl]-2-carbonyl chloride in 25 ml of methylene chloride is added dropwise to an ice cold solution of 1.81 g of methyl 4-amino-3-methoxybenzoate and 1.62 g of N,N-diisopropylethylamine in 50 ml of
25 methylene chloride. The reaction mixture is stirred at room temperature for 18 hours and washed with water, saturated aqueous NaHCO₃ and the organic layer dried (Na₂SO₄). The organic layer is passed through a pad of hydrous magnesium silicate and hexane added at
30 the boil to give 3.9 g of the desired product as a crystalline solid, m.p. 112-113°C.

Reference Example 193

2-Chloro-4-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-carbonyl]aminobenzoyl Chloride

35 A mixture of 1.39 g of 2-chloro-4-[(4'-(trifluoromethyl)[1,1'-biphenyl]-2-carbonyl)amino]-

benzoic acid in 2.0 ml of thionyl chloride is heated on a steam bath for 1 hour. The reaction mixture is concentrated to a residue in vacuo to a residue. Cold hexane is added to the residue and the solid collected and dried to give 1.39 g of the desired product.

Reference Example 194

2-Chloro-4-([(4'-(trifluoromethyl)[1,1'-biphenyl]-2-carbonyl)amino]benzoic acid

A mixture of 3.83 g of methyl 2-chloro-4-
10 [([(4'-(trifluoromethyl)[1,1'-biphenyl]-2-carbonyl)-amino]benzoate in 75 ml of absolute ethanol and 2.20 ml of 10 N sodium hydroxide is heated on a steam bath for 3 hours. Water is added to obtain a solution which is extracted with methylene chloride. The aqueous phase is
15 acidified with acetic acid and the resulting solid collected and dried in vacuo at 80°C to give 3.42 g of the desired product as a crystalline solid, m.p. 187-189°C.

Reference Example 195

20 Methyl 2-Chloro-4-([(4'-(trifluoromethyl)[1,1'-biphenyl]-2-carbonyl)amino]benzoate

A solution of 3.56 g of [4'-(trifluoromethyl)[1,1'-biphenyl]-2-carbonyl chloride in 10 ml of methylene chloride is added dropwise to an ice cold
25 solution of 1.86 g of methyl 2-chloro-4-aminobenzoate and 1.6 g of N,N-diisopropylethylamine in 50 ml of methylene chloride. The reaction mixture is stirred at room temperature for 18 hours and washed with water, saturated aqueous NaHCO₃ and the organic layer
30 dried(Na₂SO₄). The organic layer is passed through a pad of hydrous magnesium silicate(3X) and hexane added to the filtrate at the boil to give 4.0 g of the desired product as a crystalline solid, m.p. 130-132°C.

Reference Example 1964-[[[4'-(Trifluoromethyl)][1,1'-biphenyl]carbonyl]aminolbenzoic Acid

A mixture of 3.0 g of methyl 4-[[[4'-(tri-
5 fluoromethyl)[1,1'-biphenyl]-2-carbonyl]amino]benzoate
in 75 ml of absolute ethanol and 2.0 ml of 10 N sodium
hydroxide is heated on a steam bath for 3 hours. Water
is added to obtain a solution which is extracted with
methylene chloride. The aqueous phase is acidified with
10 acetic acid and the resulting solid collected and dried
in vacuo at 80°C to give 2.93 g of the desired product
as a crystalline solid, m.p. 243-245°C. M⁺=385.

Reference Example 197Methyl 6-[[[3-(2-methylpyridinyl)carbonyl]aminolpyridine-3-carboxylate

To a stirred solution of 3 g of methyl 6-
aminopyridine-3-carboxylate and 4 ml of N,N-diisopro-
pylamine in 100 ml of methylene chloride is added
dropwise a solution of 6.4 g of 2-methylpyridine-3-
20 carbonyl chloride in 25 ml of methylene chloride. The
reaction mixture is stirred at room temperature for 2
hours and quenched with water. The organic layer is
washed with water, dried (MgSO₄), filtered and evaporated
in vacuo to a residue which is stirred with ether and
25 the resulting solid collected and air dried to give 6.8
g of the desired product. M⁺=390.

Reference Example 1986-[[[3-(2-methylpyridinyl)carbonyl]aminolpyridine-3-carboxylic Acid

To a solution of 6.5 g of methyl 6-[[[3-(2-
methylpyridinyl)carbonyl]aminolpyridine-3-carboxylate in
100 ml of 1:1 tetrahydrofuran:methyl alcohol is added 20
ml of 5N NaOH. The reaction mixture is stirred over-
night and evaporated in vacuo to a residue. The residue
35 is dissolved in water and neutralized with acetic acid.

-220-

The separated solid is filtered and air-dried to give 3.0 g of the desired product. $M^+ = 257$.

Reference Example 199

Methyl 6-([(1,1'-biphenyl]-2-carbonyl)amino]-pyridine-3-carboxylate

5
10
15
To a solution of 1.5 g of methyl 6-amino-pyridine-3-carboxylate in 100 ml of methylene chloride is added 3 ml of N,N-diisopropylethylamine at room temperature. To the stirred reaction mixture is slowly added a solution of 2.5 g of [1,1'-biphenyl]-2-carbonyl chloride. The reaction mixture is stirred at room temperature for 4 hours and then quenched with water. The organic layer is washed well with water and dried over anhydrous $MgSO_4$, filtered and evaporated in vacuo to a solid residue. The residue is stirred with ether, filtered and dried to give 3.0 g of the desired product: $M^+ = 332$.

Reference Example 200

6-([(1,1'-Biphenyl]-2-carbonyl)amino]pyridine-3-carboxylic Acid

20
25
30
To a stirred solution of 2.5 g of methyl 6-([(1,1'-Biphenyl]-2-carbonyl)amino]-pyridine-3-carboxylate in 50 ml of 1:1 tetrahydrofuran:methanol is added 10 ml of 5N sodium hydroxide and the mixture stirred at room temperature for 16 hours. The reaction mixture is concentrated in vacuo to a residue which is dissolved in water and neutralized with acetic acid. The separated colorless solid is filtered and air dried to give 2.0 g of the desired product: $M^+ = 318$.

Reference Example 201

Methyl 2-(2-Pyridinyl)benzoate

35
A mixture of 12 g of methyl 2-(iodomethyl)-benzoate, 20 g of n-butyl stannane and 2 g of tetrakis-(triphenylphosphine)palladium (0) are refluxed in degassed toluene for 48 hours. The reaction mixture is concentrated in vacuo to a residue which is purified by

column chromatography on silica gel by elution with 1:1 ethyl acetate:hexane to give 5.5 g of the desired product as an oil. $M^+ = 213$.

Reference Example 202

5

2-(2-Pyridinyl)benzoic Acid

A mixture of 3.0 g of methyl 2-(2-pyridinyl)-benzoate and 600 mg of sodium hydroxide in 50 ml of 9:1 methanol:water is refluxed for 4 hours. The reaction mixture is concentrated in vacuo and the residue
10 dissolved in 50 ml of cold water. The solution is neutralized with glacial acetic acid and the resulting product filtered, washed with water, and dried to give 2.5 g of the desired product: $M+1 = 200$.

15

Example 1

N-[5-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)-2-pyridinyl]-5-fluoro-2-methylbenzamide


A mixture of thionyl chloride (100 ml) and 6-[(5-fluoro-2-methylbenzoyl)amino]pyridine-3-carboxylic
20 acid (2.7 g, 10 mmol) is heated to reflux for 5 hours. At the end, excess thionyl chloride is removed and the acid chloride is dissolved in CH_2Cl_2 (100 ml). At room temperature, the methylene chloride solution of the 6-[(5-fluoro-2-methylbenzoyl)amino]pyridine-3-carbonyl
25 chloride is added slowly. The reaction mixture is stirred at room temperature for 2 hours and quenched with ice cold water. The reaction mixture is washed with 0.1 N NaOH and subsequently washed with water. The CH_2Cl_2 layer is separated; dried (MgSO_4), filtered and
30 concentrated. The product is purified by silica gel column chromatography by eluting first with 10% ethyl acetate-hexane (1 L) and then with 30% ethyl acetate-hexane. The product is crystallized from ethyl acetate-hexane. Yield 1.0 g, 46 ; mass spectrum (FAB), $M+1$ 441;
35 $M^+\text{Na}$: 462.

-222-

As described for Example 1, the following compounds are prepared (Table C).



-223-

Table C



Ex. No	R ₁	R ₂	R ₃	R ₄	R ₅	X	M+1
2	CH ₃	H	H	H	H	H	423
3	CH ₃	H	H	H	F	H	
4	CH ₃	F	H	H	H	H	441
5	H	OCH ₃	OCH ₃	OCH ₃	H	H	499
6	Cl	H	H	H	H	H	443
7	F	H	F	H	H	H	445
8	Br	H	H	H	H	H	489
9	Cl	H	F	H	H	H	461
10	Ph	H	H	H	H	H	
11	Cl	H	H	Br	H	H	
12	CH ₃	H	H	H	H	Br	502
13	CH ₃	H	H	F	H	Cl	
14	Cl	H	H	Cl	H	H	
15	CH ₃	CH ₃	H	H	H	H	
16	Cl	H	H	F	H	H	
17	Cl	H	H	CF ₃	H	H	
18	Cl	H	H	H	F	H	
19	Cl	H	H	H	Cl	H	


-224-

Ex. No	R ₁	R ₂	R ₃	R ₄	R ₅	X	H+1
20	Cl	H	H	F	H	H	
21		H	H	H	H	H	
22		H	H	H	H	H	
23	CH ₃	H	H	H	CH ₃	H	
24	Cl	H	H	F	H	Cl	
25	Cl	H	F	H	H	Cl	
26	Cl	Cl	H	H	H	H	
27	Cl	H	H	Cl	H	H	
28	-OCH ₃	H	H	H	H	H	
29	OCF ₃	H	H	H	H	H	
30	-CF ₃	H	H	H	H	H	
31	Cl	Cl	H	Cl	H	H	
32	-SCH ₃	H	H	H	H	H	
33	Cl	H	NO ₂	H	H	H	
34	CH ₃	H	H	CH ₃	H	H	
35	F	H	H	Cl	H	H	
36	Cl	H	H	NH ₂	H	H	
37	F	CF ₃	H	H	H	H	
38	-OCH ₃	H	H	Cl	H	H	
39	Cl	H	H	-SCH ₃	H	H	
40	F	H	H	H	CF ₃	H	
41	F	H	CF ₃	H	H	H	
42	CF ₃	H	F	H	H	H	
43	NO ₂	H	H	H	H	H	
44	F	H	H	H	H	H	
45	Cl	H	NH ₂	H	H	H	

Example 46N-[5-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)-2-pyridinyl]-2-methylbenzeneacetamide

A mixture of 2.0 mmol of 10,11-dihydro-10-(6-amino-3-pyridinylcarbonyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine, 2.1 mmol of 2-methylbenzeneacetyl chloride and 5 mmol of triethylamine in 10 ml of dichloromethane is stirred under argon at room temperature for 16 hours. The solvent is removed under vacuum and the residue partitioned between 50 ml of ethyl acetate and 25 ml of water. The organic layer is separated, washed with H₂O, 1 N NaHCO₃, brine and dried (Na₂SO₄). The solvent is removed and the residue chromatographed on silica gel with ethyl acetate-hexane as solvent to give the product as a solid.

As described for Example 46, the following compounds are prepared (Table D).

Table D

Ex. No.	R ₁	R ₂	R ₃	R ₄	R ₅	X
47	CH ₃	H	H	CH ₃	H	H
48	CH ₃	H	H	H	H	Br
49	CH ₃	H	H	H	H	Cl
50	Cl	H	H	H	H	H
51	Cl	H	H	H	H	Br
52	Cl	H	H	H	H	Cl
53	Cl	H	Cl	H	H	H
54	Cl	H	Cl	H	H	Br
55	Cl	H	Cl	H	H	Cl
56	-OCH ₃	H	H	H	H	H
57	-OCH ₃	H	H	H	H	Br
58	-OCH ₃	H	H	H	H	Cl
59	-OCH ₃	H	H	-OCH ₃	H	H
60	-OCH ₃	H	H	-OCH ₃	H	Br
61	-OCH ₃	H	H	-OCH ₃	H	Cl
62	H	-OCH ₃	-OCH ₃	H	H	H
63	H	-OCH ₃	-OCH ₃	H	H	Br
64	H	-OCH ₃	-OCH ₃	H	H	Cl
65	H	Cl	H	H	H	H
66	H	Cl	H	H	H	Br
67	H	Cl	H	H	H	Cl
68	H	H	Cl	H	H	H
69	H	H	Cl	H	H	Br
70	H	H	Cl	H	H	Cl
71	F	H	H	H	H	H
72	F	H	H	H	H	Br
73	F	H	H	H	H	Cl
74	H	F	H	H	H	H
75	H	F	H	H	H	Br
76	H	F	H	H	H	Cl
77	H	H	F	H	H	H
78	H	H	F	H	H	Br

-227-

Ex No.	R1	R2	R3	R4	R5	X
79	H	H	F	H	H	Cl
80	H	CH ₃	H	H	H	H
81	H	CH ₃	H	H	H	Br
82	H	CH ₃	H	H	H	Cl


Example 83

10,11-Dihydro-10-[[6-[[[2-methylphenyl]aminol-carbonyl]aminol-3-pyridinyl]carbonyl]-5H-pyrrolo[2,1-c]-[1,4]benzodiazepine

A mixture of 2.0 mmol of 10,11-dihydro-10-(6-amino-3-pyridinylcarbonyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine and 4.0 mmol of (2-methylphenyl)isocyanate in 12 ml of tetrahydrofuran is refluxed for 16 hours. The solvent is removed and the residue chromatographed on silica gel with ethyl acetate-hexane as solvent to give the product as a solid.

As described for Example 83, the following compounds are prepared (Table E).

Table E



Ex. No.	R ₁	R ₂	R ₃	R ₄	R ₅	X
84	H	CH ₃	H	H	H	H
85	H	CH ₃	H	H	H	Br
86	H	CH ₃	H	H	H	Cl
87	H	H	CH ₃	H	H	H
88	H	H	CH ₃	H	H	Br
89	H	H	CH ₃	H	H	Cl
90	Cl	H	H	H	H	H
91	Cl	H	H	H	H	Br
92	Cl	H	H	H	H	Cl
93	H	Cl	H	H	H	H
94	H	Cl	H	H	H	Br
95	H	Cl	H	H	H	Cl
96	H	H	Cl	H	H	H
97	H	H	Cl	H	H	Br

Ex. No.	R ₁	R ₂	R ₃	R ₄	R ₅	X
98	H	H	Cl	H	H	Cl
99	Cl	Cl	H	H	H	H
100	Cl	Cl	H	H	H	Br
101	Cl	Cl	H	H	H	Cl
102	Cl	H	Cl	H	H	H
103	Cl	H	Cl	H	H	Br
104	Cl	H	Cl	H	H	Cl
105	Cl	H	H	H	Cl	H
106	Cl	H	H	H	Cl	Br
107	Cl	H	H	H	Cl	Cl
108	H	Cl	Cl	H	H	H
109	H	Cl	Cl	H	H	Br
110	H	Cl	Cl	H	H	Cl
111	F	H	F	H	H	H
112	F	H	F	H	H	Br
113	F	H	F	H	H	Cl
114	F	H	H	F	H	H
115	F	H	H	F	H	Br
116	F	H	H	F	H	Cl
117	F	H	H	H	F	H
118	F	H	H	H	F	Br
119	F	H	H	H	F	Cl

Example 120

N-[5-[3-[(Dimethylamino)methyl]-5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)]-ylcarbonyl]-2-pyridinyl]-5-fluoro-2-methylbenzamide

A mixture of 0.44 g of N-[5-(5H-pyrrolo-[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)-2-pyridinyl]-5-fluoro-2-methylbenzamide, 5 ml of a 40% aqueous solution of dimethylamine and 5 ml of an aqueous solution of formaldehyde in 50 ml of tetrahydrofuran-methanol (1:1) is refluxed for 16 hours in the presence of a drop of glacial acetic acid. The mixture is concentrated under vacuum and the residue extracted with

chloroform. The extract is washed with water, dried (MgSO₄) and the solvent removed. The residue is purified by column chromatography on silica gel with 5% methanol in chloroform as eluent to give 0.45 g of solid: mass spectrum (CI) 499 (M+1).

The following Examples are prepared as described for Example 120 with formaldehyde and the appropriate amine.

Example 121

N-[5-[[3-[(Dimethylamino)methyl]-[5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)]-yl]carbonyl]-2-pyridinyl]-5-chloro-2-methylbenzamide

Example 122

N-[5-[[3-[(Dimethylamino)methyl]-[5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)]-yl]carbonyl]-2-pyridinyl]-3-fluoro-2-methylbenzamide

Example 123

N-[5-[[3-[(Dimethylamino)methyl]-[5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)]-yl]carbonyl]-2-pyridinyl]-2-chloro-4-fluorobenzamide

Example 124

N-[5-[[3-[(Dimethylamino)methyl]-[5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)]-yl]carbonyl]-2-pyridinyl]-2-chloro-5-fluorobenzamide

Example 125

N-[5-[[3-[(Dimethylamino)methyl]-[5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)]-yl]carbonyl]-2-pyridinyl]-2-chlorobenzamide

Example 126

N-[5-[[3-[(Dimethylamino)methyl]-[5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)]-yl]carbonyl]-2-pyridinyl]-2-fluoro-5-chlorobenzamide

Example 127

N-[5-[[3-[(Dimethylamino)methyl]-[5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)]-yl]carbonyl]-2-pyridinyl]-2,4-dichlorobenzamide

-231-

Example 128

N-[5-[3-(1-Pyrrolidinyl)methyl]-5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)-yl]carbonyl]-2-pyridinyl]-2-chloro-4-fluorobenzamide

Example 129

N-[5-[3-[(Dimethylamino)methyl]-5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)]-yl]carbonyl]-2-pyridinyl]-2-chlorobenzeneacetamide

Example 130

N-[2-(Dimethylamino)ethyl]-N-[5-(5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)-yl]carbonyl]-2-pyridinyl]-5-fluoro-2-methylbenzamide

To a solution of 0.75 g of 10-[[6-[2-(dimethylamino)ethylamino]-3-pyridinyl]carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine and 5 ml of diisopropylethylamine in 75 ml of dichloromethane is added (slowly) 0.35 g of 5-fluoro-2-methylbenzoyl chloride in 10 ml of dichloromethane. The mixture is stirred at room temperature for 16 hours and the solution washed well with water. The organic layer is dried (MgSO₄) and the solvent removed under vacuum. The residue is purified by column chromatography on silica gel with 30% methanol in chloroform as eluent to give 0.80 g of yellow solid; mass spectrum (CI), 511 (M+1).

Example 131

N-[3-(Dimethylamino)propyl]-N-[5-(5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)-yl]carbonyl]-2-pyridinyl]-5-fluoro-2-methylbenzamide

A solution of 6.35 g of 5-fluoro-2-methylbenzoyl chloride in 10 ml of dichloromethane is added to a solution of 2 mmol of 10-[[6-[3-(dimethylamino)propylamino]-3-pyridinyl]carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine and 5 ml of diisopropylethylamine in 75 ml of dichloromethane. The solution is stirred 16 hours at room temperature, washed with water, dried (MgSO₄) and the solvent removed. The

residue is purified by column chromatography over silica gel with 30% methanol in chloroform as eluent to give 0.75 g of solid; mass spectrum (CI) 525 (M+1).

Example 132

N-[2-(Dimethylamino)methyl]-N-5-(5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)-ylcarbonyl)-2-pyridinyl-5-fluoro-3-methylbenzamide

As described for Example 130, a solution of 2 mmol of 10-[[6-[2-(dimethylamino)methylamino]-3-pyridinyl]carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]-benzodiazepine, 8 ml of diisopropylethylamine, and 2.2 mmol of 5-fluoro-2-methylbenzoyl chloride in 100 ml of dichloromethane is stirred at room temperature for 16 hours. The solvent is removed and the product purified by chromatography on silica gel to give a solid.

Example 133

N-[5-[[3-[(Dimethylamino)methyl]-[5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)]yl]carbonyl]-2-pyridinyl]-3,4,5-trimethoxybenzamide

A mixture of 1.0 g of N-[5-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)-2-pyridinyl]-3,4,5-trimethoxybenzamide, 10 ml of 40% aqueous dimethylamine, 10 ml of 35% aqueous formaldehyde in 50 ml of tetrahydrofuran-methanol (1:1) plus 1 drop of acetic acid is refluxed for 16 hours. The mixture is concentrated and the residue extracted with chloroform. The extract is washed with water, dried (MgSO₄), concentrated and the residue purified by column chromatography (silica gel) with 5% methanol in chloroform as eluent. The fractions containing product are combined to give 0.80 g of solid; mass spectrum (CI) 556 (M+1).

Example 134


N-[5-(Pyrido[3,2-e]pyrrolo[1,2-a]pyrazin-5(6H)-ylcarbonyl)-2-pyridinyl]-5-fluoro-2-methylbenzamide

To a chilled (0°C) solution of 0.343 g of 5,6-dihydropyrido[3,2-e]pyrrolo[1,2-a]pyrazine and 1.1 ml of

triethylamine in 5 ml of dichloromethane is added 1.17 g of 6-(5-fluoro-2-methylbenzoyl)aminopyridine-3-carbonyl chloride. The mixture is stirred at room temperature for 16 hours. To the mixture is added 50 ml of dichloromethane and 20 ml of water. The organic layer is separated and washed with 20 ml each of 1 M NaHCO₃ and brine. The organic layer is dried (Na₂SO₄) and passed through a thin pad of hydrous magnesium silicate and the pad washed with dichloromethane. The filtrate is concentrated and the residue chromatographed on silica gel prep-plates with ethyl acetate-hexane (1:1) as eluent. The product is crystallized from ethyl acetate to give 0.38 g of white crystals, m.p. 226-234°C.

As described for Example 134 the following compounds are prepared (Table F).

Table F




Ex No.	R ₁	R ₂	R ₃	R ₄	R ₅	X
135	H	CH ₃	H	H	H	H
136	H	CH ₃	H	H	H	Br
137	H	CH ₃	H	H	H	Cl
138	H	H	CH ₃	H	H	H

Ex. No.	R ₁	R ₂	R ₃	R ₄	R ₅	X
139	H	H	CH ₃	H	H	Br
140	H	H	CH ₃	H	H	Cl
141	Cl	H	H	H	H	H
142	Cl	H	H	H	H	Br
143	Cl	H	H	H	H	Cl
144	H	Cl	H	H	H	H
145	H	Cl	H	H	H	Br
146	H	Cl	H	H	H	Cl
147	H	H	Cl	H	H	H
148	H	H	Cl	H	H	Br
149	H	H	Cl	H	H	Cl
150	Cl	Cl	H	H	H	H
151	Cl	Cl	H	H	H	Br
152	Cl	Cl	H	H	H	Cl
153	Cl	H	Cl	H	H	H
154	Cl	H	Cl	H	H	Br
155	Cl	H	Cl	H	H	Cl
156	Cl	H	H	H	Cl	H
157	Cl	H	H	H	Cl	Br
158	Cl	H	H	H	Cl	Cl
159	H	Cl	Cl	H	H	H
160	H	Cl	Cl	H	H	Br
161	H	Cl	Cl	H	H	Cl
162	F	H	F	H	H	H
163	F	H	F	H	H	Br
164	F	H	F	H	H	Cl
165	F	H	H	F	H	H
166	F	H	H	F	H	Br
167	F	H	H	F	H	Cl
168	F	H	H	H	F	H
169	F	H	H	H	F	Br
170	F	H	H	H	F	Cl

Example 171N-[5-(Pyrrolo[1,2-a]quinoxalin-5(4H)-ylcarbonyl)-2-pyridinyl]-5-fluoro-2-methylbenzamide

To a chilled (0°C) solution of 0.341 g of 4,5-dihydropyrrolo[1,2-a]quinoxaline and 1.11 ml of triethylamine in 5 ml of dichloromethane is added 1.17 g of 6-[(5-fluoro-2-methylbenzoyl)amino]pyridine-3-carbonyl chloride. The mixture is stirred under argon at room temperature for 16 hours. The mixture is diluted with 50 ml of dichloromethane and 20 ml of water and the organic layer is separated. The organic layer is washed with 20 ml each of 1 M NaHCO₃ and brine and dried (Na₂SO₄). The solution is filtered through a thin pad of hydrous magnesium silicate and the pad washed with dichloromethane. The filtrate is concentrated and the residue purified on silica gel prep-plates with ethyl acetate-hexane (1:1) as solvent to give a solid. The solid is crystallized from ethyl acetate to give 0.38 g of crystals, m.p. 190-196°C.

As described for Example 171 the following compounds are prepared (Table G).

Table G

EX. NO.	R1	R2	R3	R4	R5	X
EX. NO.	R1	R2	R3	R4	R5	X
172	H	CH3	H	H	H	H
173	H	CH3	H	H	H	Br
174	H	CH3	H	H	H	Cl
175	H	H	CH3	H	H	H
176	H	H	CH3	H	H	Br
177	H	H	CH3	H	H	Cl
178	Cl	H	H	H	H	H
179	Cl	H	H	H	H	Br
180	Cl	H	H	H	H	Cl
181	H	Cl	H	H	H	H
182	H	Cl	H	H	H	Br
183	H	Cl	H	H	H	Cl
184	H	H	Cl	H	H	H
185	H	H	Cl	H	H	Br
186	H	H	Cl	H	H	Cl
187	Cl	Cl	H	H	H	H
188	Cl	Cl	H	H	H	Br
189	Cl	Cl	H	H	H	Cl
190	Cl	H	Cl	H	H	H
191	Cl	H	Cl	H	H	Br
192	Cl	H	Cl	H	H	Cl
193	Cl	H	H	H	Cl	H
194	Cl	H	H	H	Cl	Br
195	Cl	H	H	H	Cl	Cl
196	H	Cl	Cl	H	H	H
197	H	Cl	Cl	H	H	Br
198	H	Cl	Cl	H	H	Cl
199	F	H	F	H	H	H
200	F	H	F	H	H	Br
201	F	H	F	H	H	Cl
202	F	H	H	F	H	H
203	F	H	H	F	H	Br

-237-


Ex No.	R ₁	R ₂	R ₃	R ₄	R ₅	X
204	F	H	H	F	H	Cl
205	F	H	H	H	F	H
206	F	H	H	H	F	Br
207	F	H	H	H	F	Cl

Example 208

N-[5-(4H-Pyrazolo[5,1-c][1,4]benzodiazepin-5(10H)-ylcarbonyl)-2-pyridinyl]-5-fluoro-2-methylbenzamide

To a chilled (0°C) solution of 0.37 g of 5,10-dihydro-4H-pyrazolo[5,1-c][1,4]benzodiazepine and 836 microliters of triethylamine in 5 ml of dichloromethane is added 0.761 g of 6-[(5-fluoro-2-methylbenzoyl)-amino]pyridine-3-carbonyl chloride. The mixture is stirred at room temperature under argon for 5 hours. An additional 420 microliters of triethylamine and 0.38 g of 6-[(5-fluoro-2-methylbenzoyl)amino]pyridine-3-carbonyl chloride is added and the mixture stirred 16 hours. The mixture is diluted with 60 ml of dichloromethane and washed with 25 ml each of H₂O, 1 M NaHCO₃, brine and dried (Na₂SO₄). The solution is filtered (twice) through a thin pad of hydrous magnesium silicate and the pad washed with dichloromethane. The filtrate is concentrated to give a yellow glass (0.68 g) which is crystallized from ethyl acetate to give 0.38 g of white crystals, m.p. 250-260°C; mass spectrum (FAB/L) 442.4 (M+H).

Table H



Ex. No.	R ₁	R ₂	R ₃	R ₄	R ₅	X
209	H	CH ₃	H	H	H	H
210	H	CH ₃	H	H	H	Br
211	H	CH ₃	H	H	H	Cl
212	H	H	CH ₃	H	H	H
213	H	H	CH ₃	H	H	Br
214	H	H	CH ₃	H	H	Cl
215	Cl	H	H	H	H	H
216	Cl	H	H	H	H	Br
217	Cl	H	H	H	H	Cl
218	H	Cl	H	H	H	H
219	H	Cl	H	H	H	Br
220	H	Cl	H	H	H	Cl
221	H	H	Cl	H	H	H
222	H	H	Cl	H	H	Br
223	H	H	Cl	H	H	Cl
224	Cl	Cl	H	H	H	H
225	Cl	Cl	H	H	H	Br
226	Cl	Cl	H	H	H	Cl

-239-

Ex No.	R ₁	R ₂	R ₃	R ₄	R ₅	X
227	Cl	H	Cl	H	H	H
228	Cl	H	Cl	H	H	Br
229	Cl	H	Cl	H	H	Cl
230	Cl	H	H	H	Cl	H
231	Cl	H	H	H	Cl	Br
232	Cl	H	H	H	Cl	Cl
233	H	Cl	Cl	H	H	H
234	H	Cl	Cl	H	H	Br
235	H	Cl	Cl	H	H	Cl
236	F	H	F	H	H	H
237	F	H	F	H	H	Br
238	F	H	F	H	H	Cl
239	F	H	H	F	H	H
240	F	H	H	F	H	Br
241	F	H	H	F	H	Cl
242	F	H	H	H	F	H
243	F	H	H	H	F	Br
244	F	H	H	H	F	Cl

Example 245


N-[5-(4H-Pyrazolo[5,1-c][1,4]benzodiazepin-5(10H)-ylcarbonyl)-2-pyridinyl]-[1,1'-biphenyl]-2-carboxamide








To a chilled (0°C) solution of 0.185 g of 5,10-dihydro-4H-pyrazolo[5,1-c][1,4]benzodiazepine and 417 µl of triethylamine in 3.5 ml of dichloromethane is added 0.35 g of 6-(2-biphenylcarbonyl)aminopyridine-3-carbonyl chloride in 1.5 ml of dichloromethane. The mixture is stirred at room temperature under argon for 16 hours, diluted with 40 ml of dichloromethane and 20 ml of water. The organic layer is separated, washed with 20 ml of brine and dried (Na₂SO₄). The solution is filtered through a thin pad of hydrous magnesium silicate. The filtrate is concentrated to dryness under vacuum to give 0.4 g of solid. The solid is purified on silica gel prep-plates with ethyl acetate-hexane (3:1)

as eluent to give 170 mg of a brown glass, m.p. 110-150°C.

As described for Example 245, the following derivatives are prepared (Table H).

Table H



Ex. No.	R ₁	X	R ₂
246	H	Cl	
247	H	H	
248	H	H	
249	H	H	
250	H	H	
251	Cl	Cl	
252	Cl	H	

-241-

253	H	Cl	
254	H	H	
255	Cl	H	
256	H	Cl	
257	H	H	
258	H	Cl	
259	H	H	
260	H	H	


Example 26110-[(6-[(2-Methylpropyl)amino]-3-pyridinyl)carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine






A mixture of 0.16 g of 10-[(6-chloro-3-pyridinyl)carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine, 40 mg of pyridine and 2 ml of 2-methylpropylamine is stirred and heated at 100°C in a sealed vessel for 1 hour. To the mixture is added 0.2 ml of N,N-dimethylpropyleneurea and the mixture is heated at 110°C for 7 hours. The volatiles are removed under vacuum and 10 ml of 0.5 N NaOH is added to the residue. The mixture is filtered and the solid washed with water and then hexane. The solid is dissolved in ethyl acetate and the solution washed with 0.5 N NaOH, brine and dried (Na₂SO₄). The solution is filtered through a thin pad of hydrous magnesium silicate and the filtrate concentrated to dryness. The residue is tri-

turated with diisopropylether-hexane to give 0.18 g of white solid; mass spectrum (CI) 361. (M+H).

As described for Example 261, the following derivatives are prepared (Table I).

Table I



Ex. No.	D	R
*262	C	-CH ₂ CH ₂ C(CH ₃) ₃
**263	C	-CH ₂ - 
264	C	
265	C	-CH ₂ CH ₂ C(CH ₃) ₂ -CH ₂ CH ₃
266	C	-CH ₂ (CH ₂) ₄ CH ₃
267	C	-CH ₂ - 
268	C	-CH ₂ CH ₂ CH(CH ₃) ₂
269	N	-CH ₂ CH ₂ C(CH ₃) ₃
270	N	-CH ₂ - 
271	N	
272	N	-CH ₂ (CH ₂) ₄ CH ₃

*mass spectrum (CI) 389 (M+1)

**mass spectrum (CI) 401 (M+1)


Example 273

10-[(6-[(Phenylmethyl)amino]-3-pyridinyl)carbonyl]-
10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine

A mixture of 0.16 g of 10-[(6-chloro-3-pyridinyl)carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine, 0.5 ml of benzylamine and 0.2 ml of N,N'-dimethylpropyleneurea is stirred and heated at 110°C for 7 hours. After cooling to room temperature, the mixture is washed with hexane (3 times 10 ml). The residue is dissolved in water and made alkaline with 1 N NaOH. The suspension is washed with H₂O and extracted with ethyl acetate. The organic extract is washed with brine, dried (Na₂SO₄) and filtered through a thin pad of hydrous magnesium silicate. The filtrate is evaporated and the residue triturated with diethyl ether-hexane to give 0.20 g of white solid; mass spectrum (CI) 395 (M+H).






As described for Example 273, the following derivatives are prepared (Table J).

Table J



Ex. No.	D	R
274	C	
275	C	
276	C	
277	C	
278	C	
279	C	
280	C	
281	N	
282	N	

-245-

283	N	
284	N	
285	N	
286	N	
287	N	


Example 288

10,11-Dihydro-10-[[6-(cyclohexylthio)-3-pyridinyl]carbonyl]-5H-pyrrolo-[2,1-cl[1,4]benzodiazepine

To a suspension of 35 mg of sodium hydride (60% in oil) in 3 ml of tetrahydrofuran is added under argon 0.10 g of cyclohexylmercaptan. A white precipitate forms and after 0.5 hour at room temperature, 1 ml of *N,N'*-dimethylpropyleneurea is added. To the mixture is added 0.13 g of 10-[(6-chloro-3-pyridinyl)-carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-*c*][1,4]benzodiazepine in 2 ml of tetrahydrofuran. The mixture is stirred at room temperature for 18 hours, quenched with water and ammonium chloride and concentrated under vacuum. The aqueous suspension is filtered and the solid washed with water and hexane. The solid is purified by chromatography on silica gel prep-plates with ethyl acetate-hexane (1:4) as eluent to give 0.13 g of white solid; mass spectrum (CI): 404 (M+H).

As described for Example 288, the following derivatives are prepared (Table K).

Table K



Ex. No.	D	R
289	C	$-\text{CH}_2-$
290	C	$-\text{CH}_2-$
291	C	$-\text{CH}_2\text{CH}_2\text{C}(\text{CH}_3)_3$
292	C	$-\text{CH}_2\text{CH}_2-$
293	C	$-\text{CH}_2\text{CH}_2-$
294	N	$-\text{CH}_2-$
295	N	$-\text{CH}_2-$
296	N	$-\text{CH}_2\text{CH}_2\text{C}(\text{CH}_3)_3$
297	N	$-\text{CH}_2\text{CH}_2-$
298	N	$-\text{CH}_2\text{CH}_2-$
299	N	$-\text{CH}_2-$

-247-

300	C	
-----	---	---

5

Example 30110,11-Dihydro-10-[[6-[(2-methylphenyl)amino]-3-pyridinyl]carbonyl]-5H-pyrrolo[2,1-c][1,4]benzodiazepine

10

15

A mixture of 0.5 g of 10-[(6-chloro-3-pyridinyl)carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]-benzodiazepine and 0.36 g of *o*-toluidine in 60 ml of *N,N*-dimethylformamide is refluxed for 16 hours. The mixture is poured into 200 ml of ice-water and extracted with three 100 ml portions of chloroform. The extract is washed with water, dried (Na₂SO₄) and the solvent removed. The residue is purified by chromatography on silica gel prep-plates with hexane-ethyl acetate (5:1) as solvent to give 0.56 g of yellow solid: mass spectrum (CI) 395.2 (M+H).

20


As described for Example 301, the following derivatives are prepared (Table L).

25

30

35

Table L



ExNo.	D	R	R ₁	R ₂	R ₃	R ₄	R ₅
302	C	H	Cl	H	H	H	H
303	C	H	Cl	H	Cl	H	H
304	C	H	Cl	H	H	F	H
305	C	H	F	H	F	H	H
306	C	H	CH ₃	H	H	F	H
307	C	H	CF ₃	H	H	H	H
308	C	CH ₃	CH ₃	H	H	H	H
309	C	H	H	H	H	H	H
310	N	H	H	H	H	H	H
311	N	CH ₃	H	H	H	H	H
312	N	H	CF ₃	H	Cl	H	H
313	N	H	CH ₃	H	H	F	H
314	N	H	F	H	F	H	H
315	N	H	Cl	H	H	F	H
316	N	H	Cl	H	Cl	H	H
317	N	H	Cl	H	H	H	H

Example 318

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)-2-methoxyphenyl][1,1'-biphenyl]-2-
carboxamide

To a solution of 0.70 g of 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine and 0.56 g of N,N-diisopropylethylamine in 50 ml of methylene chloride is added 1.35 g of 4-[[[1,1'-biphenyl]-2-carbonyl)amino]-3-methoxybenzoyl chloride followed by stirring at room temperature for 18 hours. The reaction mixture is washed with water and saturated aqueous NaHCO₃ and the organic layer dried (Na₂SO₄). The organic layer is passed through hydrous magnesium silicate and the filtrate concentrated in vacuo to give a residue which is dissolved in methylene chloride and passed through a pad of hydrous magnesium silicate two additional times to give upon concentration in vacuo to give 1.5 g of amorphous solid. M⁺=512.

Example 319

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)-3-chlorophenyl][1,1'-biphenyl]-2-carboxamide

To a solution of 0.52 g of 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine and 0.39 g of N,N-diisopropylethylamine in 25 ml of methylene chloride is added 1.1 g of 4-[[[1,1'-biphenyl]-2-carbonyl)amino]-2-chlorobenzoyl chloride followed by stirring at room temperature for 18 hours. The reaction mixture is washed with water and saturated aqueous NaHCO₃ and the organic layer dried (Na₂SO₄). The organic layer is passed through hydrous magnesium silicate and the filtrate concentrated in vacuo to give a residue which is dissolved in methylene chloride and passed through hydrous magnesium silicate two additional times to give upon concentration in vacuo 1.10 g of the desired product as a residue. M⁺=516, 518, 520.

Example 320

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)phenyl][1,1'-biphenyl]-2-carboxamide

To a solution of 0.65 g of 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine and 0.52 g of N,N-diisopropylethylamine in 25 ml of methylene chloride is added 1.34 g of 4-[[[1,1'-biphenyl]-2-carbonyl]amino]benzoyl chloride followed by stirring at room temperature for 18 hours. The reaction mixture is washed with water and saturated aqueous NaHCO₃ and the organic layer dried (Na₂SO₄). The organic layer is passed through hydrous magnesium silicate and the filtrate concentrated in vacuo to give a residue which is dissolved in methylene chloride and passed through hydrous magnesium silicate two additional times to give upon concentration in vacuo to give 1.02 g of the desired product as a residue. M⁺=482.

Example 321

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepine-10(11H)-
ylcarbonyl)phenyl]-2-(phenylmethyl)benzamide

To a solution of 0.75 g of 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine and 0.57 g of N,N-diisopropylethylamine in 50 ml of methylene chloride is added 1.53 g of 4-[[2-(phenylmethyl)benzoyl]amino]benzoyl chloride followed by stirring at room temperature for 18 hours. The reaction mixture is washed with water and saturated aqueous NaHCO₃ and the organic layer dried (Na₂SO₄). The organic layer is passed through hydrous magnesium silicate and the filtrate concentrated in vacuo to give a residue which is dissolved in methylene chloride and passed through hydrous magnesium silicate two additional times to give upon concentration in vacuo to give 1.97 g of the desired product as an amorphous solid.

-251-

Example 322

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)-3-chlorophenyl]-2-(phenylmethyl)benzamide

To a solution of 0.92 g of 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine and 0.72 g of N,N-diisopropylethylamine in 50 ml of methylene chloride is added 2.4 g of 2-chloro-4-[[[(2-phenylmethyl)benzoyl]-amino]benzoyl chloride followed by stirring at room temperature for 18 hours. The reaction mixture is washed with water and saturated aqueous NaHCO₃ and the organic layer dried (Na₂SO₄). The organic layer is passed through hydrous magnesium silicate and the filtrate concentrated in vacuo to give a residue which is dissolved in methylene chloride and passed through hydrous magnesium silicate two additional times to give upon concentration in vacuo 2.87 g of the desired product as an amorphous compound.

Example 323

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)-2-methoxyphenyl]-2-(phenylmethyl)benzamide

To a solution of 0.75 g of 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine and 0.58 g of N,N-diisopropylethylamine in 50 ml of methylene chloride is added 1.69 g of 3-methoxy-4-[[[(2-phenylmethyl)benzoyl]-amino]benzoyl chloride followed by stirring at room temperature for 18 hours. The reaction mixture is washed with water and saturated aqueous NaHCO₃ and the organic layer dried (Na₂SO₄). The organic layer is passed through hydrous magnesium silicate to give upon concentration in vacuo 1.92 g of the desired product as an amorphous solid.

Example 324

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)phenyl][4'-(trifluoromethyl)[1,1'-biphenyl]-
2-carboxamide

A solution of 1.14 g of [4'-(trifluoromethyl)-
[1,1'-biphenyl]-2-carbonyl chloride in 10 ml of
methylene chloride is added dropwise to an ice cold
solution of 1.0 g of 10,11-dihydro-10-(4-aminobenzoyl)-
5H-pyrrolo[2,1-c][1,4]benzodiazepine and 0.52 g of N,N-
diisopropylethylamine in 25 ml of methylene chloride.
The reaction mixture is stirred at room temperature for
18 hours and washed with water, saturated aqueous NaHCO₃
and the organic layer dried (Na₂SO₄). The organic layer
is passed through a pad of hydrous magnesium silicate
two times to give 1.70 g of the desired product as an
amorphous compound.

Example 325

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)-3-methoxyphenyl][4'-(trifluoromethyl)[1,1'-
biphenyl]-2-carboxamide

A solution of 1.87 g of [4'-(trifluoromethyl)-
[1,1'-biphenyl]-2-carbonyl chloride in 10 ml of
methylene chloride is added dropwise to an ice cold
solution of 0.74 g of 10,11-dihydro-10-(4-aminobenzoyl)-
5H-pyrrolo[2,1-c][1,4]benzodiazepine and 0.56 g of N,N-
diisopropylethylamine in 50 ml of methylene chloride.
The reaction mixture is stirred at room temperature for
18 hours and washed with water, saturated aqueous NaHCO₃
and the organic layer dried (Na₂SO₄). The organic layer
is passed through a pad of hydrous magnesium silicate
two times to give the desired product as a residue which
is crystallized from ethyl acetate to give 2.33 g of the
desired product, 211-212°C.

Example 326

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)-2-chlorophenyl][4'-(trifluoromethyl)[1,1'-
biphenyl]-2-carboxamide

A solution of 1.35 g of 2-chloro-4-[[4'-(trifluoromethyl)[1,1'-biphenyl]-2-carbonyl)amino]-benzoyl chloride in 10 ml of methylene chloride is added dropwise to an ice cold solution of 0.63 g of 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine and 0.48 g of N,N-diisopropylethylamine in 50 ml of methylene chloride. The reaction mixture is stirred at room temperature for 18 hours and washed with water, saturated aqueous NaHCO₃ and the organic layer dried (Na₂SO₄). The organic layer is passed through a pad of hydrous magnesium silicate two times to give 1.63 g of the desired product as a non-crystalline solid..

Example 327

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)phenyl]-2-methylpyridine-3-carboxamide

To a stirred solution of 1.0 g of 10,11-dihydro-10-(4-aminobenzoyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine and 3 ml of N,N-diisopropylethylamine in 100 ml of methylene chloride is slowly added 600 mg of 2-methylpyridine-3-carbonyl chloride dissolved in 15 ml of methylene chloride. The reaction mixture is stirred at room temperature for 2 hours. The reaction mixture is quenched with water and the organic layer washed well with water. The organic layer is dried (MgSO₄), filtered and evaporated in vacuo to a residue which is purified by column chromatography on silica gel by elution with 1:1 ethyl acetate:hexane to give 800 mg of the desired product as a pale yellow residue. M⁺=422.

Example 328

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-yl-
5 carbonyl)-3-chlorophenyl]-2-methyl-pyridine-3-
carboxamide

10 A mixture of 1.1 g of 10,11-dihydro-10-(4-amino-2-chlorobenzoyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine and 3 ml of N,N-diisopropylethylamine in 100 ml of methylene chloride is stirred while a solution of 600 mg of 2-methylpyridine-3-carbonyl chloride in 15 ml of methylene chloride is added slowly. The reaction mixture is stirred at room temperature for 2 hours. The reaction mixture is quenched with water and the organic layer washed with water, dried (MgSO₄), filtered and
15 evaporated in vacuo to a residue. The product is purified by column chromatography on silica gel by elution with 1:1 ethyl acetate:hexane to give the desired product as a pale yellow residue. M⁺=456.

Example 329

20 N-[5-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl]-2-pyridinyl]-2-methylpyridine-3-carboxamide

A mixture of 2.5 g of 6-[[3-(2-methylpyridinyl)carbonyl]amino]pyridine-3-carboxylic acid and
25 25 ml of thionyl chloride is refluxed for 3 hours and the mixture evaporated to dryness in vacuo to give a solid. A solution of the solid in 50 ml of methylene chloride is added to 2 g of 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine dissolved in 50 ml of
30 dichloromethane containing 3 ml of N,N-diisopropylethylamine at room temperature. The reaction mixture is stirred at room temperature for 2 hours and quenched with water; washed with water; dried (MgSO₄), filtered and evaporated in vacuo to a residue. The residue is
35 purified by column chromatography on silica gel by elution with 1:1 ethyl acetate:hexane to give 2.0 g of the desired product as a solid. M⁺=423.

-255-

Example 330

N-[5-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl]-2-pyridinyl]-2-methylpyridine-3-carboxamide
Hydrochloride

To a solution of 1.0 g of N-[5-(5H-pyrrolo-
[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl]-2-
pyridinyl]-2-methylpyridine-3-carboxamide in 50 ml of
methanol is added hydrogen chloride gas. The mixture is
stirred at room temperature for 30 minutes and the
solvent removed under vacuum. The residue is triturated
with ether to give 1.0 g of the desired product as a
solid: mass spectrum(CCl); 459(M⁺).

Example 331

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)phenyl]-2-[N-methylpiperazinyl]-pyridine-3-
carboxamide Hydrochloride

The method of Example 330 is used to prepare
the desired product as a solid: M⁺=543.

Example 332

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)phenyl]-2-(dimethylamino)-pyridine-3-
carboxamide Hydrochloride

The method of Example 330 is used to prepare
the desired product as a solid: M⁺=487.

Example 333

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)phenyl]-2-chloropyridine-3-carboxamide

To a stirred solution of 6.06 g of 10,11-
dihydro-10-(4-aminobenzoyl)-5H-pyrrolo[2,1-c][1,4]benzo-
diazepine and 10 ml of N,N-diisopropylethylamine is
added a solution of 4.0 g of 2-chloropyridine-3-carbonyl
chloride in 25 ml of methylene chloride. The reaction
mixture is stirred at room temperature for 1 hour. The
reaction mixture is quenched with water and the organic
layer washed well with water. The organic layer is
dried, filtered and evaporated in vacuo to a pale yellow

product which is crystallized from 1:1 ethyl acetate:hexane to give 7.0 g of the desired product; $M^+=442$.

Example 334

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-2-(methylamino)pyridine-3-carboxamide

A mixture of 1 g of N-[4-(5H-pyrrolo[2,1-c]-[1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-2-chloropyridine-3-carboxamide, 1 g of K_2CO_3 and 10 ml of a 40% solution of monomethylamine is heated in 25 ml of dimethylsulfoxide for 8 hours at 100°C. The reaction mixture is poured over water and the pale yellow solid separated. The reaction mixture is filtered and the collected solid washed well with water. After drying the solid is purified by column chromatography on silica gel by elution with 9:1 ethyl acetate:methanol to give 850 mg of the desired product as a pale yellow solid: $M^+=437$.

Example 335

N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-2-[(3-dimethylaminopropyl)amino]pyridine-3-carboxamide

Using the conditions of Example 334 and N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-2-chloropyridine-3-carboxamide and 3-(dimethylamino)propylamine gives 900 mg of the desired product: $M^+=508$.

Example 336

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-2-(1-piperidinyl)-pyridine-3-carboxamide

Using the conditions of Example 334 and 1 g of N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-2-chloropyridine-3-carboxamide and 5 ml of piperidine gives 700 mg of the desired product: $M^+=491$.

-257-

Example 337

N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)phenyl]-2-(4-methyl-1-piperazinyl)-pyridine-
3-carboxamide

Using the conditions of Example 334 and 1 g of
N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)phenyl]-2-chloropyridine-3-carboxamide and 5
ml of N-methylpiperazine gives 1 g of the desired
product: $M^+ = 500$.

Example 338

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)phenyl]-2-(dimethylamino)-pyridine-3-
carboxamide

Using the conditions of Example 334 and 1 g of
N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)-phenyl]-2-chloropyridine-3-carboxamide and
10 ml of 40% N,N-dimethylamine gives 700 mg of the
desired product: $M^+ = 451$.

Example 339

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylc
arboxyl)phenyl]-2-(morpholino)-pyridine-3-carboxamide

Using the conditions of Example 334 and 1 g of
N-[4-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)-phenyl]-2-chloropyridine-3-carboxamide and 5
ml of morpholine gives 800 mg of the desired
product: $M^+ = 493$.

Example 340

N-[5-(5H-Pyrrolo[2,1-c][1,4]-benzodiazepin-10(11H)-
ylcarbonyl)-2-pyridinyl][1,1'-biphenyl]-2-carboxamide

A mixture of 2.0 g of 6-([1,1'-biphenyl]-2-
carbonyl)amino]pyridine-3-carboxylic acid and 20 ml of
thionyl chloride is refluxed for 3 hours. The excess
thionyl chloride is removed in vacuo to a residue which
is dissolved in 50 ml of methylene chloride. This
solution is added dropwise to a stirred solution
of 2.0 g of 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzo-

-258-

5 diazepine in 50 ml of methylene chloride and 5 ml of
N,N-diisopropylethylamine. The reaction mixture is
stirred at room temperature for 2 hours and quenched
with water. The organic layer is washed well with water
and dried over anhydrous MgSO_4 . The organic layer is
concentrated in vacuo to a residue which is purified by
column chromatography on silica gel by elution with 40%
ethyl acetate:hexane to give 1.2 g of a colorless
10 solid: $M^+ = 484$.

Example 341

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)phenyl]-2-(2-pyridinyl)benzamide

15 A mixture of 1.94 g of N-[4-(5H-pyrrolo-
[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-2-
bromobenzamide, 2.95 g of 2-pyridyl tri-n-butyl tin and
400 mg of tetrakis(triphenylphosphine)palladium(O) is
refluxed for 24 hours in degassed toluene for 24 hours.
20 The reaction mixture is concentrated in vacuo to a
residue which is purified by column chromatography on
silica gel by elution with 70% ethyl acetate:hexane to
give 900 mg of the desired product as a pale yellow
solid: $M+1 = 485$.

Example 342

25 N-[5-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-
ylcarbonyl)-2-pyridinyl]-2-(2-pyridinyl)benzamide

A mixture of 484 mg of N-[5-(5H-pyrrolo-
[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)-2-
30 pyridinyl]-2-bromobenzamide, 814 mg of 4-(N,N-di-
methyl)anilino-tri-n-butyl stannane and 100 mg of tetra-
kis(triphenylphosphine)palladium (O) is refluxed in
degassed toluene for 24 hours. The reaction mixture is
concentrated in vacuo to a residue which is purified by
column chromatography on silica gel by elution with
ethyl acetate to give 200 mg of the desired product:
35 $M+1 = 528$.

Example 34310,11-Dihydro-10-(4-(4-butyloxy)benzoyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine

5 To a solution of 92 mg of 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine in 2 ml of methylene chloride is added 100 mg of triethylamine followed by 130 mg of 4-(n-butyloxy)benzoyl chloride. The reaction mixture is stirred at room temperature for 24 hours and then treated with 4 ml of 1N sodium hydroxide. The mixture is extracted with 10 ml of ethyl acetate and the extract washed with 1N sodium hydroxide and 5 ml of brine. The organic layer is dried over anhydrous sodium sulfate and filtered through hydrous magnesium silicate. The filtrate is concentrate in vacuo to a residue which is stirred with ether-hexanes to give 160 mg of the desired product as a white solid:mass spectrum(CI), 361(MH⁺).

Example 3445,10-Dihydro-2-hydroxymethyl-5-(4-(4-butyloxy)benzoyl)-4H-pyrazolo[5,1-c][1,4]benzodiazepine

20 As described for Example 343 4-(n-butyl-oxy)benzoyl chloride is reacted with 5,10-dihydro-4H-pyrazolo[5,1-c][1,4]benzodiazepine to give the desired product as a solid;mass spectrum(CI), 392(MH⁺).

Example 34510,11-Dihydro-10-(4-(5-pentyloxy)benzoyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine

30 As described for Example 343 4-(n-pentyl-oxy)benzoyl chloride is reacted with 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine to the desired product as a solid:mass spectrum(CI), 375(MH⁺).

Example 346

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-2-(4-chlorophenyl)pyridine-3-carboxamide

The conditions of Example 325 are used with 2-(4-chlorophenyl)pyridine-3-carbonyl chloride to give the desired product as a crystalline solid, m.p. 211-212°C (M+Na) = 557.3.

Example 347

N-[4-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)phenyl]-2-methyl-2-(4-chlorophenyl)propionamide

The conditions of Example 325 are used with 2-(4-chlorophenyl)-2-methylpropionyl chloride to give the desired product as a solid. M+499.

Example 348

10-[[6-(1,1-dimethylethyl)amino]-3-pyridinyl]carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine

Using the conditions of Example 273 and t-butylamine gives the desired product as a beige solid. MS(CI): 361(M+H).

Example 349

10-[[6-(1-Methylethyl)amino]-3-pyridinyl]carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine

Using the conditions of Example 273 and isopropylamine gives the desired product as a white solid. MS(CI): 347(M+H).

Example 350

10-[[6-(1-Indanyl)amino]-3-pyridinyl]carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine

Using the conditions of Example 273 and 1-aminoindan gives the desired product as a beige solid. MS(CI): 421(M+H).

-261-

Example 351

10-[[6-(2,4-Dimethoxyphenylamino)-3-pyridinyl]carbonyl]-
10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine

Using the conditions of Example 273 with 2,4-dimethoxybenzylamine gives the desired product as a light yellow solid. MS(CI): 455(M+H).

Example 352

10-[[6-(2-Bromophenylamino)-3-pyridinyl]carbonyl]-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine

Using the conditions of Example 273 and 2-bromobenzylamine gives the desired product as an off-white solid. MS(CI): 474(M+H).

Example 353

N-[5-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)-2-pyridinyl]-2-methylfurane-3-carboxamide

Using the conditions of Example 1 with Reference Example 39 to give Reference Example 86 and stirring overnight gives the desired product as white crystals after column chromatography on silica gel by elution with 1:1 ethyl acetate:hexane and crystallization from ethyl acetate, m.p. 210-212°C.

Example 354

N-[5-(5H-Pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)-2-pyridinyl]-2-aminobenzamide

A room temperature solution of 1.0 g of N-[5-(5H-pyrrolo[2,1-c][1,4]benzodiazepin-10(11H)-ylcarbonyl)-2-pyridinyl]-2-nitrobenzamide in 100 ml of ethyl alcohol is hydrogenated over 200 mg of 10% Pd/C in a Parr apparatus under 40 psi of hydrogen for 2 hours. The reaction mixture is filtered through diatomaceous earth and the cake washed with additional ethyl alcohol. The combined filtrates are concentrated in vacuo and the residue purified by crystallization from 2:1 ethyl acetate:hexane to give the desired product as pale yellow crystals: M+Na 445:M+423.

Example 355

{3-Chloro-4-[3-dimethylaminomethyl]-5H,11H-pyrrolo-
[2,1-cl[1,4]-benzodiazepine-10-carbonyl]-phenyl}-
biphenyl-2-carboxylic acid amide

To a solution of the product from Example 319, (2.23 g, 4.32 mmol) in 1:1 methanol/tetrahydrofuran (40 ml) was added N,N,N',N'-tetramethyl-diaminomethane (1.19 ml, 8.64 mmol), paraformaldehyde (0.519 g, 17.3 mmol), and acetic acid (0.516 ml, 8.6 mmol). The suspension was stirred at room temperature overnight. The solvent was removed, and the residue was dissolved in dichloromethane, washed with water, 5% sodium bicarbonate, and water. All aqueous washings were backwashed with dichloromethane. The combined organic solutions were dried (MgSO₄), and the solvent removed to give crude product (1.68 g). Purification by flash chromatography on silica gel (50 g) in 18% methanol/ethyl acetate gave the product, which was recrystallized from ethyl acetate-hexane to give pure sample (1.06 g) mp 138-141°. MS (+FAB) m/z: 575/577 (M+H).

Analysis for: C₃₂H₂₁ClN₃O₃

Calcd: C, 73.10, H: 5.43, N: 9.74.

Found C, 71.57, H: 5.21, N: 9.41.

Example 356

{3-Chloro-4-[3-(4-methylpiperazin-1-ylmethyl)5H,11H-
pyrrolo[2,1-cl[1,4]benzodiazepine-10-carbonyl]]-phenyl}-
biphenyl-2-carboxylic acid amide

To a solution of the product from Example 319, (0.54 g, 1.08 mmol) in 1:1 methanol-tetrahydrofuran (8 ml) was added N-methylpiperazine (0.48 g, 4.32 mmol), paraformaldehyde (0.194 g), and acetic acid (0.13 ml, 2.16 mmol) in that order. The mixture was allowed to stir at 60° for 21 hours. The solvent was removed under vacuum, and the residue was partitioned between dichloromethane and water. The organic phase was washed

-263-

with sodium bicarbonate and water, dried (MgSO_4), and the solvent removed to yield crude product (0.48 g). The experiment was repeated to obtain 0.43 g of the crude product. The two batches were combined (0.9 g) and purified by silica gel chromatography (25g) with methanol-ethyl acetate (1:4) to give on crystallization from ethyl acetate-hexane 0.45 g of desired product. MS (+FAB) m/z: 653 ($\text{M}+\text{Na}$)⁺.

Example 357

[4-(3-Dimethylaminomethyl-5H,11H-pyrrolo[2.1-c]-[1.4]benzodiazepine-10-carbonyl)-3-methoxy-phenyl]-biphenyl-2-carboxylic acid amide

Step a) 2-methoxy-4-nitrobenzoic acid methyl ester
Thionyl chloride (13.9 ml, 190 mmol) was added via syringe to a solution of 2-methoxy-4-nitrobenzoic acid (50 g, 250 mmol) in methanol which was stirred at room temperature for 16 hours. The volatiles were removed in vacuo. The residue dissolved in dichloromethane, washed with (1N) sodium hydroxide, and the organic layer separated and dried (MgSO_4). Evaporation in vacuo gave a light yellow solid (50 g, 93%) mp 80-81°C, which was taken directly to the next step.

Analysis for: $\text{C}_9 \text{H}_9 \text{N O}_5$
Calcd: C, 51.19; H, 4.30; N, 6.63.
Found: C, 50.97; H, 4.11; N, 6.51.

Step b) 4-amino-2-methoxy-benzoic acid methyl ester
A mixture of 2-methoxy-4-nitrobenzoic acid methyl ester (12 g, 57 mmol), palladium (10% on activated carbon), and ethanol (150 ml) was shaken at room temperature under 50psi of hydrogen for 2 hours. The reaction was filtered through diatomaceous earth, and the diatomaceous earth washed with chloroform. Evaporation of the chloroform washings gave a yellow

-264-

solid; purification by crystallization gave a light yellow crystalline solid (8.76 g, 85%) mp 148-149°C.

Analysis for: C₉ H₁₁ N O₃

Calcd: C, 59.66; H, 6.12; N, 7.73.

Found: C, 59.42; H, 6.02; N, 7.69.

Step c) 4-[(Biphenyl-2-carbonyl)-amino]-2-methoxy-benzoic acid methyl ester

Into a refluxing solution of 2-biphenyl-carboxylic acid (9.2 g, 46 mmol) in dichloromethane was added dimethylformamide (0.1 ml, 1.4 mmol) and then neat oxalyl chloride (8.1 ml, 92 mmol) via syringe. The reaction was refluxed for 10 min, then the volatiles removed in vacuo. The residue was redissolved in dichloromethane, concentrated and dried under high vacuum for 15 min. The acid chloride was dissolved in dichloromethane (50 ml) and added into a 0°C solution of 4-amino-2-methoxy-benzoic acid methyl ester (8.4 g, 46 mmol), diisopropyl ethylamine (10.5 ml, 60 mmol) and dichloromethane (200 ml). The reaction was warmed to room temperature and stirred for 16 hours. The reaction was diluted with dichloromethane, washed with water, (1N) sodium hydroxide (1N) HCl, and brine, and dried (MgSO₄). Evaporation gave a yellow foam, which was crystallized from methanol to give a light yellow solid (16.08 g, 96%) m.p. 141-142°C.

Analysis for: C₂₂ H₁₉ N O₄

Calcd: C, 73.12; H, 5.30; N, 3.88.

Found: C, 72.93; H, 5.20; N, 3.83.

Step d) 4-[(Biphenyl-2-carbonyl)-amino]-2-methoxy-benzoic acid

Sodium hydroxide (1N) (38 ml, 38 mmol) was added to a refluxing solution of 4-[(biphenyl-2-carbonyl)-amino]-2-methoxy-benzoic acid methyl ester (11.6 g, 32 mmol) in methanol (200 ml). The reaction

-265-

was refluxed for 2 hours. The volatiles were removed in vacuo and the residue taken into ethyl acetate/HCl (aq).

5 The aqueous layer was re-extracted with ethyl acetate, and the organic extracts combined and dried (MgSO₄).

Evaporation gave a pale orange foam, which was crystallized from methanol to give a colorless solid (9.33 g, 84%) m.p. 158-159°C.

10 Analysis for: C₂₁ H₁₇ N O₄

Calcd: C, 72.61; H, 4.93; N, 4.03.

Found: C, 72.20; H, 4.61; N, 3.96.

15 Step e) [3-Methoxy-4-(5H,11H-pyrrolo[2,1-c][1,4]-benzodiazepine-10-carbonyl)-phenyl]-biphenyl-2-carboxylic acid-amide

20 Into a refluxing solution of 4-[(biphenyl-2-carbonyl)-amino]-2-methoxy-benzoic acid (3.29 g, 9.5 mmol) and dichloromethane (50 ml) was added dimethylformamide (0.02 ml, 0.28 mmol) and then neat oxalyl chloride (0.87 ml, 10 mmol) via syringe. The reaction was refluxed for 10 minutes and the volatiles removed in vacuo. The residue was evaporated with

25 dichloromethane and dried under high vacuum for 15 minutes. The acid chloride was dissolved in dichloromethane (50 ml) and added to a 0°C solution of the product from reference Example 6, 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine (1.57 g, 8.55 mmol),

30 N,N-diisopropylethylamine (1.93 ml, 12.35 mmol) and dichloro-methane (200 ml). The reaction was warmed to room temperature and stirred for 2 hours. The reaction mixture was diluted with dichloromethane, washed with water, (1N) sodium hydroxide, (1N) HCl, and brine, and

35 dried (MgSO₄). Evaporation gave a yellow foam, which was crystallized from methanol to give a colorless solid (2.05 g, 73%) mp 224-226°C.

Analysis for: C₃₃ H₂₇ N₃ O₃

-266-

Calcd: C, 76.87; H, 5.35; N, 8.07.

Found: C, 76.82; H, 5.23; N, 8.04.

5

Step f) [4-(3-Dimethylaminomethyl-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-3-methoxy-phenyl]-biphenyl-2-carboxylic acid amide

10

A mixture of biphenyl-2-carboxylic acid [3-methoxy-4-(5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl]-amide (2.54 g, 4.9 mmol), paraformaldehyde (0.59 g, 19.6 mmol), N,N,N',N'-tetramethyldiaminomethane (1.35 ml, 9.8 mmol), tetrahydrofuran-methanol (1:1) (20 ml) and glacial acetic acid (0.57 ml, 9.8 mmol) was stirred at room temperature for 24 hours. The volatiles were removed in vacuo, and the residue was dissolved dichloromethane - (1N) sodium hydroxide. The organic layer was separated, washed with brine and dried (MgSO₄). Evaporation and purification by flash

15

20

chromatography (silica gel; eluting solvent chloroform-methanol 20:1) gave a colorless foam, which crystallized from ethanol to give a colorless solid (2.05 g, 73%) m.p. 196-197°C.

Analysis for: C₃₆ H₃₄ N₄ O₃ + 0.25 H₂O

25

Calcd: C, 75.17; H, 6.04; N, 9.74.

Found: C, 75.23; H, 6.06; N, 9.81.

Example 358

[3-Methoxy-4-[3-(4-methyl-piperazin-1-ylmethyl)-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl]-phenyl]-biphenyl-2-carboxylic acid amide

30

The compound of Example 358 was prepared in substantially the same manner as described in Example 357. In step 357f, N-methyl piperazine was substituted for N,N,N',N'-tetramethyldiaminomethane. The title compound was obtained as a colorless solid, m.p. 217-218°C.

35

Analysis for: C₃₉ H₃₉ N₅ O₃

Calcd: C, 74.86; H, 6.28; N, 11.19.

-267-

Found: C, 74.46; H, 6.35; N, 11.24.

Example 359

{2-Methoxy-4-[3-(4-methyl-piperazin-1-ylmethyl)-5H,11H-pyrrolo[2,1-cl[1,4]benzodiazepine-10-carbonyl]-phenyl}-biphenyl-2-carboxylic acid amide

The compound of Example 359 was prepared in substantially the same manner as described in Example 357. In step 357a, 4-nitro-3-methoxybenzoic acid was substituted for 4-nitro-2-methoxybenzoic acid. In step 357f, N-methyl piperazane was used in place of N,N,N',N'-tetramethyl-diaminomethane. The product was obtained as a colorless solid, mp 104-105°C.

Analysis for: C₃₉ H₃₉ N₅ O₃ + 1.0 H₂O

Calcd: C, 73.43; H, 6.59; N, 10.88.

Found: C, 73.01; H, 6.17; N, 10.92.

Example 360

[4-(3-Dimethylaminomethyl-5H,11H-pyrrolo[2,1-cl[1,4]benzodiazepine-10-carbonyl)-2-methoxy-phenyl]-biphenyl-2-carboxylic acid amide

The compound of Example 360 was prepared in substantially the same manner as described in Example 357. In step 357a, 4-nitro-3-methoxybenzoic acid was substituted for 4-nitro-2-methoxybenzoic acid. The title compound was obtained as a colorless solid, m.p. 114-116°C.

Analysis for: C₃₆ H₃₄ N₄ O₃ + 0.25 H₂O

Calcd: C, 75.17; H, 6.05; N, 9.74.

Found: C, 74.98; H, 5.89; N, 9.69.

Example 361

{3-Bromo-4-[3-(dimethyl-amino-methyl)-5H,11H-pyrrolo[2,1-cl[1,4]benzodiazepine-10-carbonyl]-phenyl}-biphenyl-2-carboxylic acid amide

Step a) 2-Bromo-4-nitrobenzoic acid methyl ester Thionyl chloride (3.99 ml, 54.6 mmol) was added via syringe at room temperature to a methanol solution (500 ml) of 2-bromo-4-nitrobenzoic acid (Chem.

Ber. 1961, 835) (17.9 g, 72.9 mmol). The reaction was stirred at room temperature for 16 hours. The volatiles were removed in vacuo, the residue dissolved in dichloromethane, washed with 1N sodium hydroxide, and the organic layer separated and dried (MgSO₄).

Evaporation gave a light yellow solid (10.9 g, 83%) m.p. 73-74°C, which was used without further purification in Example 361, step b.

Analysis for: C₈ H₆ Br N O₄

Calcd: C, 34.17; H, 1.64; N, 5.69.

Found: C, 33.92; H, 1.49; N, 5.67.

Step b) {3-Bromo-4-[3-(dimethyl-amino-methyl)-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl]-phenyl}-biphenyl-2-carboxylic acid amide

The compound of Example 361, step b was prepared in substantially the same manner as Example 357, following the steps b through f. In Example 357 step b, the product of Example 361, step a, was substituted for the product of Example 357, step a. Also in Example 357, step b, Raney nickel was substituted for palladium on carbon and the reaction time increased to 24 hours. The product was obtained as a colorless solid, m.p. 138-140°C.

Analysis for: C₃₅ H₃₁ Br N₄ O₂

Calcd: C, 67.85; H, 5.04; N, 9.04.

Found: C, 67.94; H, 5.24; N, 8.84.

Example 362

{3-Bromo-4-[3-(4-methyl-piperazin-1-ylmethyl)-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl]-phenyl}-biphenyl-2-carboxylic acid amide

The compound of Example 362 was prepared in substantially the same manner as described in Example 357, following the steps b through f. In Example 357 step b, the product of Example 361, step a, was substituted for the product of Example 357, step a.

-269-

Also in Example 357, step b, Raney nickel was substituted for palladium on carbon and the reaction time increased to 24 hours. In Example 357, step f, N-methylpiperazane was substituted for N,N,N',N'-tetramethyldiaminomethane. The product was obtained as a colorless solid, m.p. 149-150°C.

Analysis for: C₃₈ H₃₆ Br N₅ O

Calcd: C, 67.65; H, 5.38; N, 10.38.

Found: C, 67.28; H, 5.52; N, 10.13.

Example 363

[3-Chloro-4-(3-morpholin-4-ylmethyl-5H,11H-pyrrolo[2,1-cl[1,4]benzodiazepine-10-carbonyl)-phenyl]-biphenyl-2-carboxylic acid amide

The product from Example 319, (2.07 g, 4 mmol) was treated sequentially with morpholine (1.03 g, 12 mmol), glacial acetic acid (0.72 g, 12 mmol), and 37% aqueous formaldehyde (formalin) (4 ml, 50 mmol) in methanol (50-75 ml). After stirring for one hour at room temperature, the reaction mixture was diluted with dichloromethane (500 ml), extracted with saturated aqueous sodium bicarbonate (200 ml) and water (4 x 200 ml) and dried (Na₂SO₄). The product was purified through a short silica gel plug by gradient elution, (ethyl acetate to methanol-ethyl acetate 1:4). The appropriate fractions were combined and evaporated in vacuo, dissolved in ethyl acetate and filtered, and the solvent evaporated in vacuo to afford 2.0 g of a colorless foam. Trituration with ether and filtration afforded, after drying in vacuo overnight at 50°C, 1.7 g (2.8 mmol, 69%) of the title compound as a colorless powder, m.p. 142-145°C. MS (+FAB), m/z: 639 (M⁺Na). Analysis for: C₃₇H₃₃ClN₄O₃

Calcd: C, 72.01; H, 5.39; N, 9.08.

Found: C, 71.03, H, 5.44, N, 8.64.

Example 364

{4-[3-(2-Aminoethyl)-5H,11H-pyrrolo[2,1-c]
5 [1,4]benzodiazepine-10-carbonyl]-3-chloro-phenyl}-
biphenyl-2-carboxylic acid amide

Step a) {3-Chloro-4-[3-(2-nitroethenyl)-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl]-phenyl}-biphenyl-2-carboxylic acid amide

10 Portionwise over 10 minutes, the product from Example 319, (1.5 g, 3 mmol) was added to a stirred solution of 1-dimethylamino-2-nitroethylene (0.35 g, 3 mmol) in trifluoroacetic acid (20 ml) at 0°C. After 15 minutes the reaction was warmed to room temperature, poured into cold water, and extracted with ethyl acetate
15 (2 x 500 ml). The combined organic layer was washed with saturated aqueous sodium bicarbonate (2 x 250 ml) and water (2 x 200 ml), then dried (Na₂SO₄). The solvent was evaporated in vacuo to afford 1.5 g (2.5 mmol, 85% crude yield) of a yellow solid which was used without further purification in Example 364, step b.
20 WAY 140149

Step b) {3-Chloro-4-[3-(2-nitroethyl)-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl]-phenyl}-biphenyl-2-carboxylic acid amide
25

A stirred solution of {3-Chloro-4-[3-(2-nitroethenyl)-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl]-phenyl}-biphenyl-2-carboxylic acid amide (1.32 g, 3 mmol) in tetrahydrofuran (50 ml) was treated
30 at -12°C over 45 minutes with alternate, portionwise additions of sodium borohydride (912 mg, 24 mmol) and dropwise additions of methanol (3.20 g, 100 mmol). After 15 minutes, the reaction was neutralized to pH 7, at 0°C, with a 10% acetic acid solution. The reaction mixture was poured into water and extracted with ethyl
35 acetate (2 x 100 ml). The combined organic layer was washed with saturated aqueous sodium bicarbonate (1x), and water (3x), and dried (Na₂SO₄). The organic solution

-271-

was filtered through a silica gel plug, and evaporated
in vacuo to give 1.04 g (1.76 mmol, 59%) of a tan solid.
The product was purified by flash column chromatography
on silica gel (100:1, adsorbent-compound ratio), eluting
with ethyl acetate-hexane (1:3) to afford, after
evaporation, 1.0 g (1.69 mmol, 56%) of a bright yellow
amorphous powder, m.p. 245°C. MS (EI), m/z : 590 (M^+).
Step c) {4-[3-(2-Amino-ethyl)-5H,11H-pyrrolo[2,1-
c][1,4]benzodiazepine-10-carbonyl]-3-chloro-phenyl}-
biphenyl-2-carboxylic acid amide

A rapidly stirred solution of {3-chloro-4-[3-
(2-nitroethyl)-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-
10-carbonyl]-phenyl}-biphenyl-2-carboxylic acid amide
(875 mg, 1.48 mmol) in ethanol was treated with four
equal portions of powdered zinc metal (40 g), and
several aliquots of 6N HCl (15 ml, 90 mmol), and then
warmed gently. After 15 minutes the zinc was filtered
and the neutral filtrate evaporated in vacuo. The
residue was redissolved in ethyl acetate and the product
was purified through a short silica gel plug by gradient
elution filtration, (ethyl acetate to methanol-ethyl
acetate 1:4). The eluent was evaporated, redissolved in
ethyl acetate, refiltered, and the solvent evaporated in
vacuo to yield 500 mg (0.89 mmol, 60%) of an off-white
solid. Trituration with ether afforded, after drying in
vacuo overnight at 40°C, 300 mg (36%) of the title
compound as a colorless amorphous powder, m.p. 132-
136°C. MS (+FAB), m/z : 561 (M^+H).

Analysis for: $C_{34}H_{29}ClN_4O_2$

Calcd: C, 72.78; H, 5.21; N, 9.99.

Found: C, 71.63; H, 5.45; N, 9.18.

Example 365

N-[3-(3-Methoxy-5H,10H-pyrazolo[5,1-
c][1,4]benzodiazepine-9-carbonyl)-phenyl]-2-pyridin-2-
yl-benzamide

The title compound was prepared in substantially the same manner as described in Example 357 steps c through e. In step 357c, 1-(pyridin-2-yl)benzoic acid (G. Timari, et.al., Chem. Ber. 1992,125,929) was used in place of 2-biphenylcarboxylic acid. In step 357e 5H,10H-pyrazolo[5,1-c][1,4]benzodiazepine (L. Cecchi and G. Filacchioni, J. Heterocyclic Chem. 1983,20, 871) was used in place of 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine. The title compound was obtained as a pale pink solid (0.23 g, 37%). MS (+FAB) m/z: 516 (M+H). Analysis for: C₃₁H₂₅N₅O₃

Calcd: C, 72.22; H, 4.89; N, 13.58.
Found: C, 71.47; H, 4.63; N, 12.95.

Example 366

N-[3-Chloro-4-(5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl]-2-thiophen-2-yl-benzamide

Step a) 2-Bromobenzoyl chloride

To a solution of 2-bromobenzoic acid (1.88 g, 9.35 mmol) in anhydrous tetrahydrofuran (20 ml), under nitrogen, was added 1 drop of dimethylformamide followed by addition of oxalyl chloride (1 ml, 11.4 mmol). The mixture was stirred at room temperature until gas evolution ceased and then heated to reflux. The solution was cooled to room temperature before being concentrated in vacuo to produce a golden colored oil (1.87 g, 91%) which was used without further purification.

Step b) 2-Bromo-N-[3-chloro-4-(10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl]-benzamide

To a stirred solution of the product of 10,11-dihydro-10-(2-chloro-4-aminobenzoyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine (2.25 g, 6.66 mmol) in dichloromethane (40 ml), under nitrogen, was added triethylamine (1.19 ml, 8.53 mmol). The mixture was cooled to 0°C

before a solution of 2-bromobenzoyl chloride (1.87 g, 8.52 mmol) in dichloromethane (20 ml) was added dropwise. The cooling bath was removed and stirring was continued for 14 hours. The reaction mixture was poured into water. The organic layer was separated and sequentially washed with water, saturated aqueous sodium bicarbonate, and water. The organic solution was dried (Na_2SO_4) and concentrated in vacuo to yield a pale orange foam (2.0 g, 58%). Purification by flash chromatography on silica gel with hexane-ethyl acetate (1:1) as the mobile phase resulted in a colorless powder (1.39 g, 40%), m.p. 188-189°C. MS (EI), m/z : 519 (M^+)
Analysis for: $\text{C}_{26}\text{H}_{19}\text{BrClN}_3\text{O}_2 + 0.5 \text{H}_2\text{O}$
Calcd: C, 58.93; H, 3.80; N, 7.93.
Found: C, 59.12; H, 3.62; N, 7.75.
Step c) N-[3-Chloro-4-(5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl]-2-thiophene-2-yl-benzamide

The 2-bromo-N-[3-chloro-4-(10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl]-benzamide (1.04 g, 2.0 mmol) and thiophene-2-boronic acid (0.32 g, 2.4 mmol), and barium hydroxide octahydrate (0.88 g, 2.8 mmol) was suspended in ethylene glycol dimethyl ether (28.8 ml) and water (4.8 ml). The heterogeneous mixture was stirred at room temperature and purged with nitrogen for ten minutes before bis(triphenylphosphine) palladium (II) chloride (0.17 g, 0.24 mmol) was added. The reaction was capped with a nitrogen balloon and heated in an oil bath at 70°C. After 20 hours, additional thiophene-2-boronic acid (0.13 g, 1 mmol) was added to the reaction. After 24 hours additional bis(triphenylphosphine)-palladium(II)chloride (84 mg, 0.12 mmol) was added to the reaction flask. The reaction was cooled to room temperature and the mixture was extracted into benzene. The combined organic extracts were washed with brine,

dried (MgSO₄), filtered and concentrated in vacuo to
yield a brown solid (1.42 g). The solid was triturated
with ethyl acetate and filtered. The filtrate was
purified by flash chromatography using silica gel with
hexane-ethyl acetate (1:1) as the mobile phase to afford
a pale yellow solid (0.59 g, 56%), which was dried under
vacuum at 78°C for two days, m.p. 132-136°C. MS
(EI), m/z: 523 (M⁺).

Analysis for: C₃₀H₂₂ClN₃O₂S + 0.5 H₂O

Calcd: C, 67.53; H, 4.36; N, 7.88.

Found: C, 67.53; H, 4.08; N, 7.90.

Example 367

N-[3-Chloro-4-(5H,11H-pyrrolo[2,1-cl][1,4]benzodiazepine-10-
carbonyl)-phenyl]-2-pyridin-3-yl-benzamide

The compound of Example 367 was prepared in
substantially the same manner as described in Example 366
following the steps 366a and 365b. In Step 366a, 2-
(pyridin-3-yl)-benzoic acid was substituted for 2-
bromobenzoic acid. Preparation of 2-(pyridin-3-yl)-benzoic
acid was carried out in the manner of Timari, et al (Chem.
Ber. 1992, 125, 929) substituting 3-bromopyridine in place of
2-bromopyridine. The title compound was obtained as an off-
white powder (0.21 g, 40%) m.p. 155-158°C.

Analysis for: C₃₁H₂₃ClN₄O₂ + 0.85 H₂O

Calcd: C, 69.68; H, 4.66; N, 10.49.

Found: C, 69.69; H, 4.70; N, 10.16.

Example 368

N-[3-Chloro-4-(5H,11H-pyrrolo[2,1-cl][1,4]benzodiazepine-10-
carbonyl)-phenyl]-2-pyridin-4-yl-benzamide

The compound of Example 368 was prepared in
substantially the same manner as described in Example 366
following steps 366a and 366b. In Step 366a, 2-(pyridin-4-
yl)-benzoic acid was substituted for 2-bromobenzoic acid.
Preparation of 2-(pyridin-4-yl)-benzoic acid was carried out
in the manner of Timari, et al (Chem. Ber. 1992, 125, 929)

-275-

substituting 4-bromopyridine hydrochloride and an additional equivalent of base in place of 2-bromopyridine. The title compound was obtained as a pale yellow solid (1.21 g, 53%) m.p. 165-168°C.

Analysis for: $C_{31}H_{23}ClN_4O_2 + 0.47 H_2O$

Calcd: C, 70.59; H, 4.57; N, 10.62.

Found: C, 70.58; H, 4.50; N, 10.33.

Example 369

N-[4-(3-Methoxy-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl]-2-pyridin-2-yl-benzamide

Step a) 2-Methoxy-4-[(2-pyridin-2-ylbenzoyl)amino]benzoyl chloride

To a solution of 2-methoxy-4-[(2-pyridin-2-ylbenzoyl)amino]benzoic acid (0.92 g, 2.64 mmol) in anhydrous tetrahydrofuran (25 ml), under nitrogen, was added 1 drop of dimethylformamide followed by addition of oxalyl chloride (0.28 ml, 3.17 mmol). The mixture was stirred at room temperature until gas evolution ceased. The solution was concentrated in vacuo to produce a tan solid (1.16 g) which was used without further purification in Example 369 step b.

Step b) N-[4-(3-Methoxy-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl]-2-pyridin-2-yl-benzamide

To a stirred solution of the product from Reference Example 6, 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine (0.405 g, 2.20 mmol) in dichloromethane (30 ml), under nitrogen, was added triethylamine (0.37 ml, 2.64 mmol). The mixture was cooled to 0°C and a solution of the crude 2-methoxy-4-[(2-pyridin-2-ylbenzoyl)-amino]benzoyl chloride (1.16g) in dichloromethane (30 ml) was added dropwise. After 5 hours the reaction mixture was poured into water. The organic layer was separated and sequentially washed twice with water and aqueous sodium bicarbonate, and

-276-

once with water. The organic solution was dried
(Na_2SO_4) and concentrated in vacuo to give a marron
solid (1.1 g, 94%). Purification by flash
chromatography on silica gel with hexane-ethyl acetate-
methylene chloride-methanol (3:6:2:0.5) as a mobile
phase, followed by concentration in vacuo, resulted in a
pale purple solid (0.88 g, 76%), m.p. 138-140°C. MS
(FAB), m/z : 515 (M+H).

Analysis for: $\text{C}_{32}\text{H}_{26}\text{N}_4\text{O}_3 + 0.43 \text{ H}_2\text{O}$

Calcd: C, 73.58; H, 5.18; N, 10.73.

Found: C, 73.59; H, 5.05; N, 10.47.

Example 370

N-[4-(3-Dimethylaminomethyl-5H,11H-pyrrolo[2,1-c]
[1,4]benzodiazepine-10-carbonyl)-3-methoxy-phenyl]-2-
pyridin-2-yl-benzamide

Into a flask equipped with a reflux condenser
was placed under nitrogen product of Example 369 step b,
N-[4-(3-methoxy-5H,11H-pyrrolo[2,1-
c][1,4]benzodiazepine-10-carbonyl)-phenyl]-2-pyridin-2-
yl-benzamide (0.37 g, 0.71 mmol), N,N,N',N'-
tetramethyldiaminomethane (0.15 mg, 1.4 mmol),
paraformaldehyde (85 g, 2.8 mmol), tetrahydrofuran (5
ml) and methanol (5 ml). After stirring at room
temperature for two minutes glacial acetic acid (85m g,
1.4 mmol) was added. The solution was stirred at room
temperature for 14 hours. The reaction was concentrated
in vacuo, redissolved in dichloromethane and washed
sequentially with saturated aqueous sodium bicarbonate,
water, saturated aqueous sodium bicarbonate and water.
The organic solution was dried (Na_2SO_4) and concentrated
in vacuo to afford an off-colorless foam (0.39 g, 96%).
Purification by flash chromatography using silica gel
with dichloromethane-methanol (9:1) as the mobile phase,
afforded a colorless foam. The foam was redissolved in
dichloromethane, filtered through diatomaceous earth,
concentrated in vacuo and dried under vacuum at 78°C

-277-

overnight to afford an off-white solid (0.24 g, 59%),
m.p. 132-134°C (dec).

Analysis for: C₃₅H₃₃N₅O₃ + 0.89 H₂O

Calcd: C, 71.53; H, 5.97; N, 11.92.

Found: C, 71.52; H, 5.63; N, 11.89.

Example 371

N-[3-Bromo-4-(5H,11H-pyrrolo[2,1-cl[1,4]benzodiazepine-
10-carbonyl)-phenyl]-2-pyridin-2-yl-benzamide

Step a) 2-(Pyridin-2-yl)benzoyl chloride

A solution of 2-(pyridin-2-yl)benzoic acid
(2.85 g, 14.3 mmol) in dry tetrahydrofuran (20 ml) was
treated with 1 drop of dimethylformamide followed by
oxalyl chloride (1.5 ml, 17.1 mmol) in dry
tetrahydrofuran (5 ml). When the gas evolution ceased
the mixture was heated to reflux for 5 minutes, cooled
to room temperature and concentrated in vacuo to a
bright yellow solid. The solid was slurried with
tetrahydrofuran (20 ml) and reconcentrated. The crude
acid chloride was used in the next step without further
purification.

Step b) Methyl 2-Bromo-4-[(2-pyridin-2-yl-
benzoyl)amino] benzoate

A slurry of 2-(pyridin-2-yl)benzoyl chloride
in dichloromethane (20 ml) was added to a solution of
methyl 2-bromo-4-amino benzoate (3 g, 13 mmol) and
triethylamine (2.5 ml, 18 mmol) in dichloromethane (50
ml) which was cooled to 0°C. Stirring at room
temperature was maintained for 4 hours. The reaction
was quenched with 20% acetic acid, wash sequentially
with saturated aqueous sodium bicarbonate, water then
saturated brine solution. The solution was dried
(MgSO₄), filtered and concentrated in vacuo to give
5.23 g (97%) of a colorless foam. MS (+FAB) m/z:
411/413 (M+H)⁺.

Analysis for: C₂₀H₁₅BrN₂O₃

Calcd: C, 58.41; H, 3.68; N, 6.81.

Found: C, 57.73; H, 3.66; N, 6.54.

Step c) 2-Bromo-4-[(2-pyridin-2-yl-benzoyl)amino]benzoic acid

A solution of methyl 2-bromo-4-[(2-pyridin-2-yl-benzoyl)amino]benzoate in methanol (100 ml) was treated with 1N sodium hydroxide (15 ml, 1.2 eq). The solution was warmed to reflux for 3.5 hours and additional 1N sodium hydroxide was added (10.4 ml., 2 eq total). Reflux was maintained for 2 additional hours and the reaction was stirred at room temperature overnight. The sample was concentrated in vacuo to a syrup and diluted with water. The aqueous solution was washed with ethyl acetate and the aqueous layer was adjusted to a pH of 4.5-5 with acetic acid. The product was precipitated, filtered and air dried to give a tan solid (4.43 g, 87%). MS (EI) m/z: 397/399 (M+).

Step d) 2-Bromo-4-[(2-pyridin-2-yl-benzoyl)amino]benzoyl chloride

To a solution of 2-bromo-4-[(2-pyridin-2-yl-benzoyl)amino]benzoic acid (1.4 g, 3.52 mmol) in anhydrous tetrahydrofuran (25 ml), under nitrogen, was added 1 drop of dimethylformamide followed by the addition of oxalyl chloride (0.37 ml, 4.23 mmol). The mixture was stirred at room temperature until gas evolution ceased and then heated to reflux for 15 minutes. The reaction mixture was cooled to room temperature and concentrated in vacuo to produce a tan solid (1.385g, 95%) which was used without further purification.

Step e) N-[3-Bromo-4-(5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl]-2-pyridin-2-ylbenzamide

To a stirred solution of the product from Reference Example 6, 10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepine (0.54 g, 2.93 mmol) in dichloromethane (35 ml), under nitrogen, was added triethylamine

-279-

(0.49 ml, 3.52 mmol). The mixture was cooled to 0°C before a suspension of the crude 2-bromo-4-[(2-pyridin-2-ylbenzoyl)amino]benzoyl chloride (1.4g) in dichloromethane (5 ml) was added dropwise. After the addition was complete, the reaction mixture was allowed to warm to room temperature. After 18 hours the reaction mixture was poured into water and sequentially washed with water, saturated aqueous sodium bicarbonate, twice with 10% aqueous acetic acid, once with saturated aqueous sodium bicarbonate and once with water. The organic solution was dried (Na₂SO₄), filtered and in vacuo to yield a dark purple foam (1.73 g).

Purification by flash chromatography on silica gel with hexane-ethyl acetate (1:2) as the mobile phase, followed by concentration in vacuo, resulted in a colorless solid (1.23 g, 75%), m.p. 227.5-229°C. MS (ESI), *m/z* : 563 (M⁺).

Analysis for: C₃₁H₂₃BrN₄O₂

Calcd: C, 66.08; H, 4.11; N, 9.94.

Found: C, 65.84; H, 3.86; N, 9.85.

Example 372

[4-(3-Dimethylaminomethyl-3-hydroxy-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl]-biphenyl-2-carboxylic acid amide

Step a) [3-Hydroxy-4-(5H,11H-pyrrolo[2,1-c][1,4]diazepine-10-carbonyl)-phenyl]-biphenyl-2-carboxylic acid amide

Boron tribromide (21 ml, 21 mmol) was added via syringe to a dichloromethane (15 ml) solution at 0°C of biphenyl-2-carboxylic acid [3-methoxy-4-(5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl]-amide (3.6 g, 7 mmol) following the steps 357a through 357e. The reaction was stirred at 0°C for 30 minutes. Ice and ammonium hydroxide was added at 0°C and stirring continued until a homogeneous solution was obtained. The organic layer was separated, washed with

brine and dried (MgSO₄). Evaporation in vacuo gave a dark residue, which was adsorbed onto silica gel and purified by flash chromatography (eluting solvent
5 hexane-ethyl acetate 2:1) to give a colorless solid (2.25 g, 64%) m.p. 194-196°C.

Analysis for: C₃₂ H₂₅ N₃ O₃ + 0.25 H₂O

Calcd: C, 76.24; H, 5.10; N, 8.34.

Found: C, 76.16; H, 5.00; N, 8.31.

10 Step b) [4-(3-Dimethylaminomethyl-3-hydroxy-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl]-biphenyl-2-carboxylic acid amide

The compound of Example 371 step b was prepared in the same manner as described in Example 357
15 step f, substituting the product of Example 371 step a for the product of Example 357 step e. The product was obtained as a colorless solid, m.p. 135-137°C.

Analysis for: C₃₅ H₃₂ N₄ O₃ + 0.25H₂O

Calcd: C, 74.91; H, 5.84; N, 9.98.

Found: C, 74.61; H, 5.94; N, 9.93.

Example 373

[4-(3-[1,4'-Bipiperidinyl-1'-ylmethyl-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-3-chloro-phenyl]-biphenyl-2-carboxylic acid amide

25 The product from Example 319, (2.07 g, 4 mmol) was treated sequentially with 4-piperidinopiperidine (2.02 g, 12 mmol), trifluoroacetic acid (2.73 g, 24 mmol), and 37% aqueous formaldehyde (formalin) (4 ml, 50 mmol) in methanol (50-75 ml). After stirring for one
30 hour at room temperature, the reaction mixture was diluted with dichloromethane (500 ml), extracted with saturated aqueous sodium bicarbonate (200 ml) and water (4 x 200 ml), and dried (Na₂SO₄). The product was
35 purified through a short silica gel plug by gradient elution filtration, (ethyl acetate to methanol-ethyl acetate 1:4). The appropriate fractions were combined and evaporated, redissolved and refiltered from ethyl

-281-

acetate, and the solvent evaporated in vacuo to afford 1.34 g (1.9 mmol, 48%) of a colorless solid.

5 Trituration with ether-hexane and filtration afforded, after drying in vacuo overnight at 50°C, 1.30 g (1.86 mmol, 47%) of the title compound as a colorless, amorphous powder, m.p. 193-195°C. MS (+FAB), m/z : 720 (M⁺Na).

10 Analysis for: C₄₃H₄₄ClN₅O₂

Calcd: C, 73.96; H, 6.35; N, 10.03.

Found: C, 73.23; H, 6.31; N, 9.81.

Example 374

15 (3-Chloro-4-(3-[(2-hydroxy-1,1-bis-hydroxymethyl-ethylamino)-methyl]-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl)-biphenyl-2-carboxylic acid amide

20 Step a) (10-(4-[(Biphenyl-2-carbonyl)-amino]-2-chloro-benzoyl)-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benodiazepin-3-ylmethyl)-trimethyl-ammonium iodide

25 The product from Example 355, [3-chloro-4-(3-dimethylaminomethyl-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl]-biphenyl-2-carboxylic acid amide (2.87 g, 5 mmol) was treated with an excess iodomethane (20 ml) as the solvent and stirred at room temperature for 30 minutes. After trituration with ethyl acetate-ether (3:1), the quarternary ammonium salt (3.58 g, 100%) was filtered to give a colorless amorphous powder.

30 Step b) (3-Chloro-4-(3-[(2-hydroxy-1,1-bis-hydroxymethyl-ethylamino)-methyl]-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl)-biphenyl-2-carboxylic acid amide

35 A mixture of (10-(4-[(Biphenyl-2-carbonyl)-amino]-2-chloro-benzoyl)-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benodiazepin-3-ylmethyl)-trimethyl-ammonium iodide (3.58 g, 5 mmol) and

-282-

tris(hydroxymethyl)aminomethane (6.05 g, 50 mmol) in dimethyl sulfoxide (25 ml) was heated to 90°C for 1.5 hours. The cooled reaction mixture was diluted with dichloromethane (500 ml), extracted with water (6 x 200 ml), and dried (Na₂SO₄). The product was purified through a short silica gel plug by gradient elution filtration, (ethyl acetate to methanol-ethyl acetate 1:4). The appropriate fractions were combined and evaporated in vacuo, redissolved and refiltered from ethyl acetate, and the solvent evaporated in vacuo to afford 1.7 g (2.6 mmol, 52%) of a colorless foam. Trituration with ether and filtration afforded, after drying in vacuo overnight at 40°C, 1.4 g (2.1 mmol, 43%) of the title compound as a colorless amorphous powder, m.p. 145-147°C. MS (-ESI), m/z : 649 (M⁻H), MS (+FAB), m/z: 673 (M⁺Na).

Analysis for: C₃₇H₃₅ClN₄O₅

Calcd: C, 68.25; H, 5.42; N, 8.60.

Found: C, 66.51; H, 5.57; N, 7.91.

Example 375

[3-chloro-4-(3-((2-dimethylamino-ethyl)-methyl-aminomethyl))-5H,11H-pyrrolo[2,1-cl[1,4]benzodiazepine-10-carbonyl]-phenyl]- biphenyl-2-carboxylic acid amide

The product from Example 319, (2.07 g, 4 mmol) was treated sequentially with N, N', N'-trimethylethylenediamine (1.23 g, 12 mmol), glacial acetic acid (1.44 g, 24 mmol), and 37% aqueous formaldehyde (formalin) (4 ml, 50 mmol) in methanol (50-75 ml). After refluxing under nitrogen for 1.5 hours, the cooled reaction mixture was diluted with dichloromethane (500 ml), extracted with saturated aqueous sodium bicarbonate (200 ml) and water (4 x 200 ml), and dried (Na₂SO₄). The product was purified through a short silica gel plug by gradient elution filtration, (ethyl acetate to methanol-ethyl acetate 1:4). The appropriate fractions were combined and evaporated in vacuo, redissolved and

-283-

refiltered from ethyl acetate, and the solvent evaporated in vacuo to afford 520 mg (0.82 mmol, 21% yield) of a colorless foam. Trituration of the foam with hot ether, filtration, and evaporation in vacuo of the filtrate afforded, after drying in vacuo overnight, 200 mg (0.32 mmol, 8% yield) of the title compound as a homogeneous colorless foam, m.p. 95-97°C. MS (+FAB), m/z : 654 (M^+Na).

Analysis for: $C_{38}H_{38}ClN_5O_2$

Calcd: C, 72.19; H, 6.06; N, 11.08.

Found: C, 71.83; H, 6.09; N, 10.71.

Example 376

{3-chloro-4-[3-(4-dimethylamino-piperidin-1-ylmethyl)-5H,11H-pyrrolo[2,1-cl[1,4]benzodiazepine-10-carbonyl]-phenyl]-biphenyl-2-carboxylic acid amide

The product from Example 319 (2.07 g, 4 mmol) was treated sequentially with 4-dimethylaminopiperidine trifluoroacetate salt (1:2) (4.27 g, 12 mmol), and 37% aqueous formaldehyde (formalin) (4 ml, 50 mmol) in methanol (50-75 ml). After stirring for 0.33 hours at room temperature, the reaction mixture was diluted with dichloromethane (500 ml), extracted with saturated aqueous sodium bicarbonate (200 ml) and water (4 x 200 ml), and dried (Na_2SO_4). The product was purified through a short silica gel plug by gradient elution filtration, (ethyl acetate to methanol-ethyl acetate 1:4). The fractions were combined and evaporated in vacuo, redissolved and refiltered from ethyl acetate, and the solvent evaporated in vacuo to afford 2.4 g (3.6 mmol, 91%) of a colorless solid. Trituration with ether and filtration afforded, after drying in vacuo overnight at 50°C, 1.7 g (2.6 mmol, 65% yield) of the title compound as a colorless, amorphous powder, m.p. 163-166°C. MS (+ESI), m/z : 658 (M^+H).
Analysis for: $C_{40}H_{40}ClN_5O_2$

-284-

Calcd: C, 72.99; H, 6.13; N, 10.64.

Found: C, 72.66; H, 6.01, N, 10.45.

Example 377

N-[3-Chloro-4-(5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl]-2-pyrrol-1-yl-benzamide

A solution of 1-(2-carboxyphenyl)pyrrole (188 mg, 1 mmol) and triphenylphosphine (264 mg, 1 mmol) in dichloromethane (6 ml) was cooled to 0°C. To this solution was added, portionwise, N-chlorosuccinimide (131 mg, 0.9 mmol). The solution was stirred for 30 minutes and allowed to warm to room temperature. To this solution was added a solution of 10,11-dihydro-10-(2-chloro-4-aminobenzoyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine (338 mg, 1 mmol) and triethylamine (0.15 ml, 1.06 mmol) in 15 ml of a mixture of a tetrahydrofuran-dichloromethane (1:2). The reaction was stirred for two hours at room temperature and then was concentrated to a solid in vacuo. The solid was dissolved in ether (100 ml) and filtered. The filtrate was concentrated in vacuo and chromatographed over silica gel with ethyl acetate-hexane (1:1) as the mobile phase to afford 270 mg of the product as a yellow solid. Recrystallization from ethyl acetate-ether-hexane gave 180 mg of the product as a colorless solid. MS (EI), m/z 506/508 (M+).

Example 378

Quinoline-8-carboxylic acid [4-(5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-3-phenyl]-amide

The compound of Example 378 was prepared in substantially the same manner as described in Example 366, Steps 366a and 366b. In Step 366a, quinoline-8-carboxylic acid was substituted for 2-bromobenzoic acid. The title compound was obtained as a colorless powder (0.69 g, 37%) m.p. 230-231°C.

-285-

Analysis for: $C_{29}H_{21}ClN_4O_2 + 0.33 H_2O$

Calcd: C, 69.81; H, 4.38; N, 11.23.

Found: C, 69.81; H, 4.09; N, 11.14.

Example 379

[3-Chloro-4-(3-dimethylaminomethyl-5H,11H-pyrrolo[2,1-c]
[1,4]benzodiazepine-10-carbonyl)-phenyl]-2-phenyl-
cyclopent-1-enecarboxylic acid amide

Step a) [2-Phenyl-cyclopent-1-enecarboxylic acid]

Sodium hydroxide (1N) (10.7 ml, 11.8 mmol) was added to a refluxing solution of 2-phenyl-cyclopent-1-enecarboxylic acid methyl ester (2.32 g, 10.7 mmol) (Lin et al., J. Chin. Chem. Soc., 1993, 40, 273) in methanol (40 ml). The reaction was refluxed for 2 hours. The volatiles were removed in vacuo and the residue partitioned between ethyl acetate and (1N) HCl. The aqueous layer was re-extracted with ethyl acetate, and the combined organic extracts combined and dried (MgSO₄). Evaporation of the solution in vacuo gave a pale yellow solid, which was recrystallized from acetone-hexane to give a colorless solid (1.27 g, 63%) m.p. 145-146°C.

Analysis for: $C_{12}H_{12}O_2$

Calcd: C, 76.57; H, 6.43.

Found: C, 76.47; H, 6.35.

Step b) 2-Phenyl-cyclopent-1-enecarbonyl chloride

To solution of 2-phenyl-cyclopent-1-enecarboxylic acid (0.43 g, 2.28 mmol) in dichloromethane (20 ml) was added dimethylformamide (1 drop) and then neat oxalyl chloride (0.4 ml, 4.56 mmol). The reaction was stirred at room temperature for 2 hours and then the volatiles were removed in vacuo. The residue was redissolved in dichloro-methane, concentrated in vacuo and dried under high vacuum for 15 minutes to give an amber oil which was used directly in the next step without further purification.

Step c) [4-(5H,11H-Pyrrolo-[2,1-c][1,4]benzodiazepine-10-carbonyl)-3-chloro-phenyl]-2-phenyl-cyclopent-1-enecarboxylic acid amide

The product from Example 379 step b, 2-phenyl-cyclopent-1-enecarbonyl chloride was dissolved in dichloromethane (20 ml) was added at room temperature to a solution of the product of Reference Example 6, 10,11-dihydro-10-(2-chloro-4-aminobenzoyl)-5H-pyrrolo[2,1-c][1,4]benzodiazepine (0.77 g, 2.28 mmol), 4-dimethylaminopyridine in dichloromethane (20 ml). Triethylamine (0.38 ml, 2.74 mmol) was then added via syringe. The reaction was stirred for 16 hours, diluted with dichloromethane and washed with sodium bicarbonate, (1N) HCl, and brine. The dichloromethane solution was dried (MgSO₄) and concentrated in vacuo to give a yellow solid. Purification by flash chromatography (eluting solvent chloroform-methanol 50:1 and hexane-ethyl acetate 2:1) afforded a colorless solid (0.70 g, 60%) m.p. 121-122°C.

Analysis for: C₃₁ H₂₆ Cl N₃ O₂

Calcd: C, 73.29; H, 5.16; N, 8.27.

Found: C, 73.18; H, 5.02; N, 8.11.

Example 380

Biphenyl-2-carboxylic acid (3-chloro-4-[(3-(2-nitroethyl))-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl]-phenyl)-amide

A solution of sodium metal (115 mg, 5 mmol) dissolved in ethanol (10 ml) was treated with nitromethane (1.52 g, 25 mmol). To the resulting white suspension was added (10-(4-[(Biphenyl-2-carbonyl)-amino]-2-chloro-benzoyl)-10,11-dihydro-5H-pyrrolo[2,1-c][1,4]benzodiazepin-3-ylmethyl)-trimethyl-ammonium (1 mmol) and the mixture heated to 78°C for 75 minutes. After evaporation of the reaction mixture in vacuo, the residue was dissolved in dichloromethane, washed with 1N HCl and water, and dried (MgSO₄). Filtration through a

-287-

silica gel pad afforded, after evaporation of the
filtrate in vacuo, a yellow foam which was consistent
with the title compound as prepared in Example 364 step
b.

5

10

15

20

25

30

35

Binding Assay to Rat Hepatic V₁ Receptors

5 Rat liver plasma membranes expressing the
vasopressin V₁ receptor subtypes are isolated by sucrose
density gradient according to the method described by
Lesko et al, (1973). These membranes are quickly sus-
10 pended in 50.0 mM Tris.HCl buffer, pH 7.4, containing
0.2% bovine serum albumin (BSA) and 0.1 mM phenylmethyl-
sulfonylfluoride (PMSF) and kept frozen at -70°C until
used in subsequent binding experiments. For binding
experiments, the following is added to the wells of a
ninety-six well format microtiter plate: 100 µl of 100.0
15 mM Tris.HCl buffer containing 10.0 mM MgCl₂, 0.2% heat
inactivated BSA and a mixture of protease inhibitors:
leupeptin, 1.0 mg %; aprotinin, 1.0 mg %; 1,10-phen-
anthroline, 2.0 mg %; trypsin inhibitor, 10.0 mg % and
0.1 mM PMSF, 20.0 µl of [phenylalanyl-3,4,5,-³H] vaso-
20 pressin (S.A. 45.1 Ci/mmol) at 0.8 nM, and the reaction
initiated by the addition of 80 µl of tissue membranes
containing 20 µg of tissue protein. The plates are kept
undisturbed on the bench top at room temperature for 120
min. to reach equilibrium. Non-specific samples are
assayed in the presence of 0.1 µM of the unlabeled
25 antagonist phenylalanylvasopressin, added in 20.0 µl
volume. For test compounds, these are solubilized in
50% dimethylsulfoxide (DMSO) and added in 20.0 µl volume
to a final incubation volume of 200 µl. Upon completion
of binding, the content of each well is filtered off,
30 using a Brandel® cell Harvester (Gaithersburg, MD). The
radioactivity trapped on the filter disk by the ligand-
receptor complex is assessed by liquid scintillation
counting in a Packard LS Counter, with an efficiency of
65% for tritium. The data are analyzed for IC₅₀ values
35 by the LUNDON-2 program for competition (LUNDON
SOFTWARE, OH).

Binding Assay to Rat Kidney Medullary V₂ Receptors

Medullary tissues from rat kidneys are
5 dissected out, cut into small pieces and soaked in a
0.154 mM sodium chloride solution containing 1.0 mM EDTA
with many changes of the liquid phase, until the solu-
tion is clear of blood. The tissue is homogenized in a
10 0.25 M sucrose solution containing 1.0 mM EDTA and 0.1
mM PMSF using a Potter-Elvehjem homogenizer with a
teflon pestle. The homogenate is filtered through
several layers (4 layers) of cheese cloth. The filtrate
is rehomogenized using a dounce homogenizer, with a
tight fitting pestle. The final homogenate is centri-
15 fugal at 1500 x g for 15 min. The nuclear pellet is
discarded and the supernatant fluid recentrifuged at
40,000 x g for 30 min. The resulting pellet formed
contains a dark inner part with the exterior, slightly
pink. The pink outer part is suspended in a small
20 amount of 50.0 mM Tris.HCl buffer, pH 7.4. The protein
content is determined by the Lowry's method (Lowry et
al, J. Biol. Chem., 1953). The membrane suspension is
stored at -70°C, in 50.0 mM Tris.HCl, containing 0.2%
inactivated BSA and 0.1 mM PMSF in aliquots of 1.0 ml
25 containing 10.0 mg protein per ml of suspension until
use in subsequent binding experiments.

For binding experiments, the following is
added in μ l volume to wells of a 96 well format of a
microtiter plate: 100.0 μ l of 100.0 mM Tris.HCl buffer
30 containing 0.2% heat inactivated BSA, 10.0 mM MgCl₂ and
a mixture of protease inhibitors: leupeptin, 1.0 mg %;
aprotinin, 1.0 mg %; 1,10-phenanthroline, 2.0 mg %;
trypsin inhibitor, 10.0 mg % and 0.1 mM PMSF, 20.0 μ l of
[³H] Arginine⁸, vasopressin (S.A. 75.0 Ci/mmol) at 0.8
nM and the reaction initiated by the addition of 80.0 μ l
35 of tissue membranes (200.0 μ g tissue protein). The
plates are left undisturbed on the bench top for 120
min. to reach equilibrium. Non-specific binding is

assessed in the presence of 1.0 μM of unlabeled ligand, added in 20 μl volume. For test compounds, these are solubilized in 50% dimethylsulfoxide (DMSO) and added in 20.0 μl volume to a final incubation volume of 200 μl . Upon completion of binding, the content of each well is filtered off, using a Brandel® cell Harvester (Gaithersburg, MD). The radioactivity trapped on the filter disk by the ligand-receptor complex is assessed by liquid scintillation counting in a Packard LS Counter, with an efficiency of 65% for tritium. The data are analyzed for IC₅₀ values by the LUNDON-2 program for competition (LUNDON SOFTWARE, OH). The results of this test on representative compounds of this invention are shown in Tables 1, 2 and 3.

Radioligand Binding Experiments with Human Platelet Membranes

Platelet Source: Hudson Valley Blood Services, Westchester Medical Center, Valhalla, NY.

Platelet Membrane Preparation:

Frozen platelet rich plasma (PRP), received from the Hudson Valley Blood Services, are thawed to room temperature. The tubes containing the PRP are centrifuged at 16,000 x g for 10 min. at 4°C and the supernatant fluid discarded. The platelets resuspended in an equal volume of 50.0 mM Tris.HCl, pH 7.5 containing 120 mM NaCl and 20.0 mM EDTA. The suspension is recentrifuged at 16,000 x g for 10 min. This washing step is repeated one more time. The wash discarded and the lysed pellets homogenized in low ionic strength buffer of Tris.HCl, 5.0 mM, pH 7.5 containing 5.0 mM EDTA. The homogenate is centrifuged at 39,000 x g for 10 min. The resulting pellet is resuspended in Tris.HCl buffer, 70.0 mM, pH 7.5 and recentrifuged at 39,000 x g for 10 min. The final pellet is resuspended in 50.0 mM

-291-

Tris.HCl buffer pH 7.4 containing 120 mM NaCl and 5.0 mM KCl to give 1.0-2.0 mg protein per ml of suspension.

5 Binding to Vasopressin V₁ receptor subtype in Human Platelet Membranes:

10 In wells of 96 well format microtiter plate, add 100 µl of 50.0 mM Tris.HCl buffer containing 0.2% BSA and a mixture of protease inhibitors (aprotinin, leupeptin etc.). Then add 20 µl of [³H]Ligand (Manning or Arg⁸Vasopressin), to give final concentrations ranging from 0.01 to 10.0 nM. Initiate the binding by adding 80.0 µl of platelet suspension (approx. 100 µg protein). Mix all reagents by pipetting the mixture up and down a few times. Non specific binding is measured in the presence of 1.0 µM of unlabeled ligand (Manning or Arg⁸Vasopressin). Let the mixture stand undisturbed at room temperature for ninety (90) min. Upon this time, rapidly filter off the incubate under vacuum suction over GF/B filters, using a Brandel® Harvester. Determine the radioactivity caught on the filter disks by the addition of liquid scintillant and counting in a liquid scintillator.

20 Binding to Membranes of Mouse Fibroblast Cell Line (LV-2) Transfected with the cDNA Expressing the Human V₂ Vasopressin Receptor
25 Membrane Preparation

30 Flasks of 175 ml capacity, containing attached cells grown to confluence, are cleared of culture medium by aspiration. The flasks containing the attached cells are rinsed with 2x5 ml of phosphate buffered saline (PBS) and the liquid aspirated off each time. Finally, 5 ml of an enzyme free dissociation Hank's based solution (Specialty Media, Inc., Lafayette, NJ) is added and the flasks are left undisturbed for 2 min. The content of all flasks is poured into a centrifuge tube and the cells pelleted at 300 x g for 15 min. The Hank's based solution is aspirated off and the cells

35

homogenized with a polytron at setting #6 for 10 sec in 10.0 mM Tris.HCl buffer, pH 7.4 containing 0.25 M sucrose and 1.0 mM EDTA. The homogenate is centrifuged at 1500 x g for 10 min to remove ghost membranes. The supernatant fluid is centrifuged at 100,000 x g for 60 min to pellet the receptor protein. Upon completion, the pellet is resuspended in a small volume of 50.0 mM Tris.HCl buffer, pH 7.4. The protein content is determined by the Lowry method and the receptor membranes are suspended in 50.0 mM Tris.HCl buffer containing 0.1 mM phenylmethylsulfonylfluoride (PMSF) and 0.2% bovine serum albumin (BSA) to give 2.5 mg receptor protein per ml of suspension.

Receptor Binding

For binding experiments, the following is added in μ l volume to wells of a 96 well format of a microtiter plate: 100.0 μ l of 100.0 mM Tris.HCl buffer containing 0.2% heat inactivated BSA, 10.0 mM $MgCl_2$ and a mixture of protease inhibitors: leupeptin, 1.0 mg %; aprotinin, 1.0 mg %; 1,10-phenanthroline, 2.0 mg %; trypsin inhibitor, 10.0 mg % and 0.1 mM PMSF, 20.0 μ l of [3H] Arginine⁸, vasopressin (S.A. 75.0 Ci/mmol) at 0.8 nM and the reaction initiated by the addition of 80.0 μ l of tissue membranes (200.0 μ g tissue protein). The plates are left undisturbed on the bench top for 120 min to reach equilibrium. Non specific binding is assessed in the presence of 1.0 μ M of unlabeled ligand, added in 20 μ l volume. For test compounds, these are solubilized in 50% dimethylsulfoxide (DMSO) and added in 20.0 μ l volume to a final incubation volume of 200 μ l. Upon completion of binding, the content of each well is filtered off, using a Brandel® cell Harvester (Gaithersburg, MD). The radioactivity trapped on the filter disk by the ligand-receptor complex is assessed by liquid scintillation counting in a Packard LS Counter, with an efficiency of 65% for tritium. The

data are analyzed for IC₅₀ values by the LUNDON-2 program for competition (LUNDON SOFTWARE, OH).

Oxytocin Receptor Binding

(a) Membrane Preparation

Female Sprague-Dawley rats weighing approximately 200-250 g are injected intramuscularly (i.m.) with 0.3 mg/kg of body weight of diethylstilbestrol (DES). The rats are sacrificed 18 hours later under pentobarbital anesthesia. The uteri are dissected out, cleaned of fat and connective tissues and rinsed in 50 ml of normal saline. The tissue pooled from six rats is homogenized in 50 ml of 0.01 mM Tris.HCl, containing 0.5 mM dithiothreitol and 1.0 mM EDTA, adjusted to pH 7.4, using a polytron at setting 6 with three passes of 10 sec each. The homogenate is passed through two (2) layers of cheesecloth and the filtrate centrifuged at 1000 x g for 10 min. The clear supernatant is removed and recentrifuged at 165,000 x g for 30 min. The resulting pellet containing the oxytocin receptors is resuspended in 50.0 mM Tris.HCl containing 5.0 mM MgCl₂ at pH 7.4, to give a protein concentration of 2.5 mg/ml of tissue suspension. This preparation is used in subsequent binding assays with [³H]Oxytocin.

(b) Radioligand Binding

Binding of 3,5-[³H]Oxytocin ([³H]OT) to its receptors is done in microtiter plates using [³H]OT, at various concentrations, in an assay buffer of 50.0 mM Tris.HCl, pH 7.4 and containing 5.0 mM MgCl₂, and a mixture of protease inhibitors: BSA, 0.1 mg; aprotinin, 1.0 mg; 1,10-phenanthroline, 2.0 mg; trypsin, 10.0 mg; and PMSF, 0.3 mg per 100 ml of buffer solution. Non-specific binding is determined in the presence of 1.0 μM unlabeled OT. The binding reaction is terminated after 60 min., at 22°C, by rapid filtration through glass fiber filters using a Brandel® cell harvester (Bio-medical Research and Development Laboratories, Inc.,

Gaithersburg, MD). Competition experiments are conducted at equilibrium using 1.0 nM [³H]OT and varying the concentration of the displacing agents. The concentrations of agent displacing 50% of [³H]OT at its sites (IC₅₀) are calculated by a computer assisted LUNDON-2 program (LUNDON SOFTWARE INC., Ohio, USA).

The results of this assay on representative examples are shown in Table 4.

When the compounds are employed for the above utility, they may be combined with one or more pharmaceutically acceptable carriers, for example, solvents, diluents and the like, and may be administered orally in such forms as tablets, capsules, dispersible powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solution or suspension containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 0.05 up to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.

The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.5 to about 500 mg/kg of animal body weight, preferably given in divided doses two to four times a day, or in sustained release form. For most large mammals the total daily dosage is from about 1 to 100 mg, preferably from about 2 to 80 mg. Dosage forms

suitable for internal use comprise from about 0.5 to 500 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfactants and edible oils such as corn, peanut and sesame oils, as are appropriate to the nature of the active ingredient and the particular form of administration desired. Adjuvants customarily employed in the preparation of pharmaceutical compositions may be advantageously included, such as flavoring agents, coloring agents, preserving agents, and antioxidants, for example, vitamin E, ascorbic acid, BHT and BHA.

The preferred pharmaceutical compositions from the standpoint of ease of preparation and administration are solid compositions, particularly tablets and hard-filled or liquid-filled capsules. Oral administration of the compounds is preferred.

These active compounds may also be administered parenterally or intraperitoneally. Solutions or suspensions of these active compounds as a free base or pharmacologically acceptable salt can be prepared in water suitably mixed with a surfactant such as hydroxypropylcellulose. Dispersions can also be prepared in glycerol, liquid polyethylene glycols and mixtures thereof in oils. Under ordinary conditions of storage

and use, these preparation contain a preservative to prevent the growth of microorganisms.

5 The pharmaceutical forms suitable for injectable use include sterile aqueous solutions or dispersions and sterile powders for the extemporaneous preparation of sterile injectable solutions or dispersions. In all cases, the form must be sterile and must
10 be fluid to the extent that easy syringability exists. It must be stable under the conditions of manufacture and storage and must be preserved against the contaminating action of microorganisms such as bacteria and fungi. The carrier can be a solvent or dispersion
15 medium containing, for example, water, ethanol, polyol (e.g., glycerol, propylene glycol and liquid polyethylene glycol), suitable mixtures thereof, and vegetable oils.

20


25

30

35










Table 1

Binding Assay to Rat Hepatic V₁ Receptors and Rat Kidney Medullary V₂ Receptors or *Binding to V₁ Receptor Subtype in Human Platelet and **Binding to Membranes of Mouse Fibroblast Cell Line (LV-2) Transfected with the cDNA Expressing the Human V₂ Receptor











Ex. No.	D	X	R	V ₁ IC ₅₀ (μM)	V ₂ IC ₅₀ (μM)
1	C	H		0.033 *0.020	0.004 **0.005
5	C	H		*51% at 10 μM	**47% at 10 μM
4	C	H		*0.044	0.001
261	C	H	-CH ₂ CH(CH ₃) ₂	65% at 1 μM	32% at 1 μM
208	N	H		0.087	0.011








-298-

Ex. No.	LD	K	R	V1 IC50 (μM)	V2 IC50 (μM)
273	C	H		0.190	0.082
262	C	H	$-\text{CH}_2\text{CH}_2\text{C}(\text{CH}_3)_2$	64% at 1 μM	50% at 1 μM
263	C	H		0.200	0.360
12	C	Br		0.210	0.024
7	C	H		32% at 1 μM	58% at 10 μM
6	C	H		0.011	0.0018
8	C	H		0.007	0.0016
301	C	H		94% at 10 μM	91% at 10 μM
33	C	H		0.450	0.030
9	C	H		0.006	0.0011 **0.0009
261	C	H	$-\text{CH}_2\text{CH}(\text{CH}_3)_2$	89% at 10 μM	55% at 10 μM

-299-

Exc No.	D	X	R	V ₁ IC ₅₀ (μM)	V ₂ IC ₅₀ (μM)
274	C	H		90% at 1 μM	97% at 10 μM
10	C	H		96% at 1 μM	95% at 1 μM
11	C	H		100% at 1 μM	93% at 1 μM
342	C	H			
352	C	H		0.088	0.059
348	C	H	-C(CH ₃) ₃	0.08	43% at 1 μM
350	C	H		0.015	0.034
245	N	H		0.019	0.001
329	C	H		0.31	0.07


-300-

Ex. No.	D	X	R	V ₁ IC ₅₀ (μM)	V ₂ IC ₅₀ (μM)
330	C	H		89% at 1 μM	79% at 1 μM
353	C	H		93% at 1 μM	86% at 1 μM
43	C	H		93% at 1 μM	
351	C	H		73% at 1 μM	56% at 1 μM
354	C	H		29% at 1 μM	86% at 1 μM
14	C	H		100% at 1 μM	99% at 1 μM
18	C	H		98% at 1 μM	94% at 1 μM

-301-







Table 1A

Binding Assay to Rat Hepatic V₁ Receptors and Rat Kidney
Medullary V₂ Receptors or *Binding to V₁ Receptor
Subtype in Human Platelet and **Binding to Membranes of
Mouse Fibroblast Cell Line (LV-2) Transfected with the
cDNA Expressing the Human V₂ Receptor







Ex.No.	X	R	V ₁ IC ₅₀ (μM)	V ₂ IC ₅₀ (μM)
341	H		0.02	0.004
327	H		0.35	0.028
347	H		0.18	0.42
328	Cl		3.3	0.019

-302-

Ex.No.	X	R	V ₁ IC ₅₀ (μM)	V ₂ IC ₅₀ (μM)
324	H		0.42	0.12
333	H		0.25	0.41
338	H		0.037	0.0048
332	H		0.031	0.0034
337	H		1.3	0.65
331	H		87% at 10 μM	43% at 1 μM

-303-

Ex.No.	X	R	V1 IC ₅₀ (μM)	V2 IC ₅₀ (μM)
336	H		99% at 1 μM	69% at 1 μM
334	H		15% at 1 μM	79% at 1 μM
339	H		41% at 1 μM	55% at 1 μM
346	H		44% at 10 μM	76% at 10 μM

-304-












Ex.No.	X	R	V1 IC ₅₀ (μM)	V2 IC ₅₀ (μM)
326	Cl		41% at 10 μM	91% at 10 μM
319	Cl		0.016	0.0015
320	H		0.0034	0.0026
321	H		0.018	0.0051
322	Cl		0.67	0.011
335	H		*100% at 1 μM	60% at 1 μM

Table 2

Binding Assay to Rat Hepatic V₁ Receptors and Rat Kidney
Medullary V₂ Receptors or *Binding to V₁ Receptor
Subtype in Human Platelet and **Binding to Membranes of
Mouse Fibroblast Cell Line (LV-2) Transfected with the
cDNA Expressing the Human V₂ Receptor

Ex. No.	Structure	V ₁ IC ₅₀ (μM)	V ₂ IC ₅₀ (μM)
171		630	31
288		83% at 10 μM 49% at 1 μM	54% at 10 μM
131		66% at 10 μM	82% at 1 μM


-306-

Ex. No.	Structure	V ₁ EC ₅₀ (μM)	V ₂ IC ₅₀ (μM)
130		98% at 10 μM	92% at 10 μM
134		23% at 10 μM	94% at 10 μM

-307-

Table 3

Binding Assay to Rat Hepatic V₁ Receptors and Rat Kidney
 Medullary V₂ Receptors or *Binding to V₁ Receptor
 Subtype in Human Platelet and **Binding to Membranes of
 Mouse Fibroblast Cell Line (LV-2) Transfected with the
 cDNA Expressing the Human V₂ Receptor



Ex. No.	X	R	V ₁ IC ₅₀ (μM)	V ₂ IC ₅₀ (μM)
133	H		*11% at 10 μM	21% at 10 μM
120	H		99	33

-308-

Ex. No.	Dose (μ M)	% Inhibition	IC ₅₀ (μ M)
---------	-----------------	--------------	-----------------------------

Table 4
Oxytocin Binding Assay

5	Ex. No.	Dose (μ M)	% Inhibition	IC ₅₀ (μ M)
	1	10	92	0.20
	5	10	93	
	344	1	58	3.8
10	4	10	100	0.67
	133	10	59	
	261			0.15
	120	1	8	
	208	10	95	0.73
15	273	2.5	95	0.056
	262	10	76	1.6
	263	10	98	0.38
	171	10	73	1.1
	12	10	98	0.8
20	7	10	66	
	6	1	90	0.14
	8	1	89	0.15
	301	10	89	0.86
25	288	10	94	1.36
	33	10	95	0.51
	9	2.5	96	0.17
	131	10	60	
	130	10	57	
30	134	1	63	
	341	1	74	
	327	1	56	
	347	10	86	
	328	10	85	0.57
35	324	1	45	
	333	10	98	0.88
	338	10	98	0.72

-309-

Exc. No.	Dose (μ M)	% Inhibition	IC ₅₀ (μ M)
332	10	98	0.83
337	1	16	
331	1	13	
336	10	94	1.63
334	1	5	
339	10	48	8.56
346	1	0	
326	1	0	
352	1.25	96	0.105
348	10	95	0.71
350	10	95	0.205
240	10	98	0.61
329	10	91	0.19
330	10	93	0.99
353	10	83	2.05
43	10	99	0.92
351	1	0	
354	1	7	
14	10	96	0.58
18	5	97	0.31

Effects on the Antagonism of Endogenous Arginine
Vasopressin Antidiuretic (V₂) Response in Conscious Rats
with Free Access to Water Drinking Before but not During
the Experiment:

Male or female normotensive Sprague-Dawley rats
(Charles River Laboratories, Inc., Kingston, NY) of 400-
450 g body weight were supplied with Laboratory Rodent
Feed #5001 (PMI Feeds, Inc., Richmond, IN) and water ad
libitum. On the day of test, rats were placed indivi-
dually into metabolic cages equipped with stainless
steel screens (to separate the feces from the urine) and
funnels for collection of urine. Vehicle or reference
agent was given at various oral doses. During the test,
rats were not provided with water or food. Urine was
collected for four hours after dosing of the test
compound. At the end of four hours, urine volume was
measured. Urinary osmolality was determined using a
Fiske One-Ten Osmometer (Fiske Associates, Norwood, MA
02062) or an Advanced CRYOMATIC Osmometer, Model 3C2
(Advanced Instruments, Norwood, MA). Determinations of
Na⁺, K⁺ and Cl⁻ ion were carried out using ion specific
electrodes in a Beckman SYNCHRON EL-ISE Electrolyte
System analyzer. In the following results, increased
urine volume and decreased osmolality relative to AVP-
control indicates activity. The results of this test on
representative compounds of this invention are shown in
Table 5.

TABLE 5

5 Rat Urine Volume Data* and Binding Assay to Membranes of Mouse
Fibroblast Cell Line (LV-2) Transfected with the cDNA Expressing
the Human V2 Receptor

Example Number	Urine Volume (ml/4 hrs) 10 mg/kg rat p.o.	Vasopressin Binding Human V2 Receptor nM
10		
	372	30.3
	373	15.9
	374	15.6
	375	16.5
	376	44.2
	377	23.8
	378	4.5
15	379	69.1
		12.3

*Volume of urine produced in a 4 hour time period by the oral administration of 10 mg/kg dose to rats,

20 The compounds of the present invention can be
used in the form of salts derived from pharmaceutically
or physiologically acceptable acids or bases. These
salts include, but are not limited to, the following:
salts with inorganic acids such as hydrochloric acid,
sulfuric acid, nitric acid, phosphoric acid and, as the
25 case may be, such organic acids as acetic acid, oxalic
acid, succinic acid, and maleic acid. Other salts
include salts with alkali metals or alkaline earth
metals, such as sodium, potassium, calcium or magnesium
or with organic bases. The compounds can also be used
30 in the form of esters, carbamates and other conventional
"pro-drug" forms, which, when administered in such form,
convert to the active moiety in vivo.

35 When the compounds are employed for the above
utilities, they may be combined with one or more
pharmaceutically acceptable carriers, for example, sol-
vents, diluents and the like, and may be administered
orally in such forms as tablets, capsules, dispersible

powders, granules, or suspensions containing, for example, from about 0.05 to 5% of suspending agent, syrups containing, for example, from about 10 to 50% of sugar, and elixirs containing, for example, from about 20 to 50% ethanol, and the like, or parenterally in the form of sterile injectable solutions or suspensions containing from about 0.05 to 5% suspending agent in an isotonic medium. Such pharmaceutical preparations may contain, for example, from about 25 to about 90% of the active ingredient in combination with the carrier, more usually between about 5% and 60% by weight.

The effective dosage of active ingredient employed may vary depending on the particular compound employed, the mode of administration and the severity of the condition being treated. However, in general, satisfactory results are obtained when the compounds of the invention are administered at a daily dosage of from about 0.5 to about 500 mg/kg of animal body weight, preferably given in divided doses two to four times a day, or in a sustained release form. For most large mammals the total daily dosage is from about 1 to 100 mg, preferably from about 2 to 80 mg. Dosage forms suitable for internal use comprise from about 0.5 to 500 mg of the active compound in intimate admixture with a solid or liquid pharmaceutically acceptable carrier. This dosage regimen may be adjusted to provide the optimal therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.

These active compounds may be administered orally as well as by intravenous, intramuscular, or subcutaneous routes. Solid carriers include starch, lactose, dicalcium phosphate, microcrystalline cellulose, sucrose and kaolin, while liquid carriers include sterile water, polyethylene glycols, non-ionic surfac-

5 tants and edible oils such as corn, peanut and sesame
oils, as are appropriate to the nature of the active in-
gredient and the particular form of administration de-
sired. Adjuvants customarily employed in the prepara-
tion of pharmaceutical compositions may be advan-
tageously included, such as flavoring agents, coloring
agents, preserving agents, and antioxidants, for
example, vitamin E, ascorbic acid, BHT and BHA.

10 The preferred pharmaceutical compositions from
the standpoint of ease of preparation and administration
are solid compositions, particularly tablets and hard-
filled or liquid-filled capsules. Oral administration
of the compounds is preferred.

15 These active compounds may also be adminis-
tered parenterally or intraperitoneally. Solutions or
suspensions of these active compounds as a free base or
pharmacologically acceptable salt can be prepared in
water suitably mixed with a surfactant such as hydrox-
20 ypropylcellulose. Dispersions can also be prepared in
glycerol, liquid, polyethylene glycols and mixtures
thereof in oils. Under ordinary conditions of storage
and use, these preparations contain a preservative to
prevent the growth of microorganisms.

25 The pharmaceutical forms suitable for in-
jectable use include sterile aqueous solutions or dis-
persions and sterile powders for the extemporaneous
preparation of sterile injectable solutions or disper-
sions. In all cases, the form must be sterile and must
30 be fluid to the extent that easy syringability exists.
It must be stable under conditions of manufacture and
storage and must be preserved against the contaminating
action of microorganisms such as bacterial and fungi.
The carrier can be a solvent or dispersion medium con-
35 taining, for example, water, ethanol (e.g., glycerol,
propylene glycol and liquid polyethylene glycol),
suitable mixtures thereof, and vegetable oil.

5 The new tricyclic non-peptide vasopressin antagonists of this invention are useful in treating conditions where decreased vasopressin levels are desired, such as in congestive heart failure, in disease conditions with excess renal water reabsorption and in conditions with increased vascular resistance and coronary vasoconstriction.

10 In particular, the vasopressin antagonists of this invention are therapeutically useful in the treatment and/or prevention of hypertension, cardiac insufficiency, coronary vasospasm, cardiac ischemia, renal vasospasm, liver cirrhosis, congestive heart failure, nephritic syndrome, brain edema, cerebral
15 ischemia, cerebral hemorrhage-stroke, thrombosis-bleeding and abnormal states of water retention.

20 In particular, the oxytocin antagonists of this invention are useful in the prevention of preterm labor and premature birth which is a significant cause of infant health problems and infant mortality.

25


30

35

-315-

What is claimed is:


1. A compound selected from those of the formula:



5

wherein Y is CH₂;

A-B is a moiety selected from




and the moiety:



10

represents phenyl or substituted phenyl optionally substituted by one or two substituents selected from (C₁-C₃)lower alkyl, halogen, amino, (C₁-C₃)lower alkoxy or (C₁-C₃)lower alkylamino;








15 the moiety:



is a five membered aromatic (unsaturated) nitrogen containing heterocyclic ring wherein D, E and F are selected from carbon and nitrogen and wherein the carbon atoms may be optionally substituted by a substituent selected from halogen, (C₁-C₃)lower alkyl, hydroxy, -COCCl₃, -COCF₃,

20

-316-



- CHO, amino, (C₁-C₃) lower alkoxy, (C₁-C₃) lower alkylamino, CONH-lower alkyl (C₁-C₃), and -CON[lower alkyl (C₁-C₃)]₂; q is one or two;


-317-

R_b is independently selected from hydrogen, -CH₃ or -C₂H₅;


R_e is H, lower alkyl(C₁-C₃), hydroxyethyl, -CH₂CO₂R⁵⁰, -CH₂C(CH₂OH)₃;

5 R⁵⁰ is H or lower alkyl(C₁-C₄);

R³ is a moiety of the formula:



wherein Ar is a moiety selected from the group consisting of



10











R⁴ is selected from hydrogen, lower alkyl(C₁-C₃); -CO-lower alkyl(C₁-C₃);

R¹ and R² are independently selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, hydroxy and

15 halogen; R⁵ is selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;


R⁶ is selected from (a) moieties of the formula:

-318-




-319-


wherein cycloalkyl is defined as C₃ to C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently selected from hydrogen, -CH₃, -C₂H₅,



- 5 -(CH₂)_q-O-lower alkyl(C₁-C₃) and -CH₂CH₂OH, q is one or two, and R₁, R₂ and R_b are as hereinbefore defined;
 (b) moieties of the formula:




- 10 wherein R⁷ is lower alkyl(C₃-C₈), lower alkenyl(C₃-C₈),
 -(CH₂)_p-cycloalkyl(C₃-C₆),








-320-

wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R¹ and R² are as hereinbefore defined;
 (c) a moiety of the formula:




- 5 wherein J is R_a, lower alkyl(C₃-C₈) branched or unbranched, lower alkenyl(C₃-C₈) branched or unbranched, O-lower alkyl(C₃-C₈) branched or unbranched, -O-lower alkenyl(C₃-C₈) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties:



10


or -CH₂-K' wherein K' is (C₁-C₃) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:






-321-

wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C₁-C₃)lower alkyl, hydroxy, -CO-lower alkyl(C₁-C₃), CHO, (C₁-C₃)lower alkoxy, -CO₂-
 5 lower alkyl(C₁-C₃), and R_a and R_b are as hereinbefore defined;

(d) a moiety of the formula:




wherein R_c is selected from halogen, (C₁-C₃) lower alkyl, -O-lower alkyl(C₁-C₃), OH,




and R_a and R_b are as hereinbefore defined wherein Ar' is
 10 selected from moieties of the formula:

-322-



wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);


- 5 R^8 and R^9 are independently selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),






- 10 $-N(R_b)(CH_2)_vN(R_b)_2$, and CF₃ wherein v is one to three and;
 R^{10} is selected from hydrogen, halogen and lower alkyl(C₁-C₃);

R¹⁴ is


-O-lower alkyl (C₃-C₈) branched or unbranched ,



-NH lower alkyl (C₃-C₈) branched or unbranched ,



-324-



q is 1 or 2;






wherein n is 0 or 1;

-325-

R_a is hydrogen, $-CH_3$ or $-C_2H_5$; R' is hydrogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy and halogen;

R^{45} is hydrogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy and halogen;


5 R^{20} is hydrogen, halogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy, NH_2 , $-NH(C_1-C_3)$ lower alkyl, $-N-[(C_1-C_3)$ lower alkyl] $_2$,



and the pharmaceutically acceptable salts, esters and
10 pro-drug forms thereof.

2. A compound according to Claim 1 wherein the moiety A-B is:

-326-




wherein R^3 is as defined in Claim 1.

3. A compound according to Claim 1 wherein R^3 is the moiety:




5

and Ar is




wherein R^1 , R^2 and R^{14} are as defined in Claim 1.

4. A compound according to Claim 1 wherein R^3 is the moiety:



10

and Ar is




wherein R^1 , R^2 , and R^6 are as defined in Claim 1.

15


5. A compound selected from those of the formula:

-327-



wherein Y is CH₂;

A-B is a moiety selected from




5 and the moiety:




represents phenyl or substituted phenyl optionally substituted by one or two substituents selected from (C₁-C₃)lower alkyl, halogen, amino, (C₁-C₃)lower alkoxy
10 or (C₁-C₃)lower alkylamino;

the moiety:



is a five membered aromatic (unsaturated) nitrogen containing heterocyclic ring wherein D, E and F are
15 carbon and wherein the carbon atoms may be optionally substituted by a substituent selected from halogen, (C₁-C₃)lower alkyl, hydroxy, -COCCl₃, -COCF₃,

-328-



5 -CHO, amino, (C₁-C₃) lower alkoxy, (C₁-C₃) lower alkylamino, CONH-lower alkyl (C₁-C₃), and -CON[lower alkyl (C₁-C₃)]₂; q is one or two;


-329-

R_b is independently selected from hydrogen, -CH₃ or -C₂H₅;


R_e is H, lower alkyl(C₁-C₃), hydroxyethyl, -CH₂CO₂R⁵⁰, -CH₂C(CH₂OH)₃;

5 R⁵⁰ is H or lower alkyl(C₁-C₄);

R³ is a moiety of the formula:



wherein Ar is a moiety selected from the group consisting of




10

R⁴ is selected from hydrogen, lower alkyl(C₁-C₃); -CO-lower alkyl(C₁-C₃);


R¹ and R² are independently selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, hydroxy and

15 halogen; R⁵ is selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;


R⁶ is selected from (a) moieties of the formula:




wherein cycloalkyl is defined as C₃ to C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently selected from hydrogen, -CH₃, -C₂H₅,



- 5 $-(CH_2)_q-O$ -lower alkyl (C_1-C_3) and $-CH_2CH_2OH$, q is one or
two, and R_1 , R_2 and R_b are as hereinbefore defined;
 (b) moieties of the formula:




- 10 wherein R⁷ is lower alkyl(C₃-C₈), lower alkenyl(C₃-C₈),
-(CH₂)_p-cycloalkyl(C₃-C₆),








-332-

wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R¹ and R² are as hereinbefore defined;
 (c) a moiety of the formula:




- 5 wherein J is R_a, lower alkyl(C₃-C₈) branched or unbranched, lower alkenyl(C₃-C₈) branched or unbranched, O-lower alkyl(C₃-C₈) branched or unbranched, -O-lower alkenyl(C₃-C₈) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties:



10


or -CH₂-K' wherein K' is (C₁-C₃) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:





-333-

wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C₁-C₃)lower alkyl, hydroxy, -CO-lower alkyl(C₁-C₃), CHO, (C₁-C₃)lower alkoxy, -CO₂-
 5 lower alkyl(C₁-C₃), and R_a and R_b are as hereinbefore defined;

(d) a moiety of the formula:




wherein R_c is selected from halogen, (C₁-C₃) lower alkyl, -O-lower alkyl(C₁-C₃), OH,




and R_a and R_b are as hereinbefore defined wherein Ar' is
 10 selected from moieties of the formula:

-334-



wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);


- 5 R^8 and R^9 are independently selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),






- 10 -N(R_b)(CH₂)_vN(R_b)₂, and CF₃ wherein v is one to three and;
 R^{10} is selected from hydrogen, halogen and lower alkyl(C₁-C₃); R^{14} is

-335-


-O-lower alkyl (C₃-C₈) branched or unbranched ,



-NH lower alkyl (C₃-C₈) branched or unbranched ,



-336-








q is 1 or 2;

wherein n is 0 or 1;

-337-

R_a is hydrogen, $-CH_3$ or $-C_2H_5$; R' is hydrogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy and halogen;
 R^{45} is hydrogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy and halogen;


- 5 R^{20} is hydrogen, halogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy, NH_2 , $-NH(C_1-C_3)$ lower alkyl, $-N-[(C_1-C_3)$ lower alkyl] $_2$,




- and the pharmaceutically acceptable salts, esters and
 10 pro-drug forms thereof.

6. A compound according to Claim 5 wherein R^3 is the moiety:

-338-




and Ar is




wherein R¹, R² and R¹⁴ are as defined in Claim 5.

- 5 7. A compound according to Claim 5 wherein R³ is the moiety:




and Ar is



- 10 wherein R¹, R² and R⁶ are as defined in Claim 5.


8. A compound selected from those of the formulae:



wherein Y is CH₂;

- 15 A-B is a moiety selected from


-339-



and the moiety:









- represents phenyl or substituted phenyl optionally
 5 substituted by one or two substituents selected from
 (C₁-C₃)lower alkyl, halogen, amino, (C₁-C₃)lower alkoxy
 or (C₁-C₃)lower alkylamino;
 the moiety:



- 10 is a five membered aromatic (unsaturated) nitrogen
 containing heterocyclic ring wherein D, E and F are
 carbon and wherein the carbon atoms may be optionally
 substituted by a substituent selected from halogen, (C₁-
 C₃)lower alkyl, hydroxy, -COCCl₃, -COCF₃,

-340-



-CHO, amino, (C₁-C₃)lower alkoxy, (C₁-C₃)lower
 5 alkylamino, CONH-lower alkyl(C₁-C₃), and -CON[lower
 alkyl(C₁-C₃)]₂; q is one or two;

-341-

R_b is independently selected from hydrogen, -CH₃ or -C₂H₅;


R_e is H, lower alkyl(C₁-C₃), hydroxyethyl, -CH₂CO₂R⁵⁰, -CH₂C(CH₂OH)₃;

5 R⁵⁰ is H or lower alkyl(C₁-C₄);

R³ is a moiety of the formula:



wherein Ar is a moiety selected from the group consisting of




10

R⁴ is selected from hydrogen, lower alkyl(C₁-C₃); -CO-lower alkyl(C₁-C₃);


15 R² is selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, hydroxy and halogen; R⁵ is selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;

R⁶ is selected from (a) moieties of the formula:




-343-



wherein cycloalkyl is defined as C₃ to C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently selected from hydrogen, -CH₃, -C₂H₅,



- 5 $-(\text{CH}_2)_q-\text{O}$ -lower alkyl(C₁-C₃) and $-\text{CH}_2\text{CH}_2\text{OH}$, q is one or two, and R₁, R₂ and R_b are as hereinbefore defined;
(b) moieties of the formula:




- 10 wherein R⁷ is lower alkyl(C₃-C₈), lower alkenyl(C₃-C₈), $-(\text{CH}_2)_p$ -cycloalkyl(C₃-C₆),








-344-

wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R¹ and R² are as hereinbefore defined;
 (c) a moiety of the formula:




- 5 wherein J is R_a, lower alkyl(C₃-C₈) branched or unbranched, lower alkenyl(C₃-C₈) branched or unbranched, O-lower alkyl(C₃-C₈) branched or unbranched, -O-lower alkenyl(C₃-C₈) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties:



10


or -CH₂-K' wherein K' is (C₁-C₃) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:





-345-

wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C₁-C₃)lower alkyl, hydroxy, -CO-lower alkyl(C₁-C₃), CHO, (C₁-C₃)lower alkoxy, -CO₂-
 5 lower alkyl(C₁-C₃), and R_a and R_b are as hereinbefore defined;

(d) a moiety of the formula:




wherein R_c is selected from halogen, (C₁-C₃) lower alkyl, -O-lower alkyl(C₁-C₃), OH,




and R_a and R_b are as hereinbefore defined wherein Ar' is
 10 selected from moieties of the formula:

-346-



wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);


- 5 R⁸ and R⁹ are independently selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),






- 10 -N(R_b)(CH₂)_vN(R_b)₂, and CF₃ wherein v is one to three and;
R¹⁰ is selected from hydrogen, halogen and lower alkyl(C₁-C₃); R¹⁴ is

-347-


-O-lower alkyl (C_3-C_8) branched or unbranched ,



-NH lower alkyl (C_3-C_8) branched or unbranched ,



-348-



q is 1 or 2;

-349-





wherein n is 0 or 1;

R_a is hydrogen, -CH₃ or -C₂H₅; R' is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;

R⁴⁵ is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy

5 and halogen;


R²⁰ is hydrogen, halogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, NH₂, -NH(C₁-C₃)lower alkyl, -N-[(C₁-C₃)lower alkyl]₂,



10 and the pharmaceutically acceptable salts, esters and pro-drug forms thereof.


9. A compound according to Claim 8 wherein A-B is a moiety:

-350-



where R^3 is as defined in Claim 8.

10. The compound according to Claim 8 wherein A-B is the moiety:




5

R^3 is a moiety of the formula:




wherein Ar is:




10 wherein R^2 and R^6 are defined in Claim 8.

11. The compound according to Claim 8 wherein A-B is the moiety:




R^3 is a moiety of the formula:



15


wherein Ar is:

-351-



wherein R^2 and R^{14} are defined in Claim 8.


12. A compound selected from those of the formula:



5

wherein Y is CH_2 ;

A-B is a moiety selected from




and the moiety:



10

represents phenyl or substituted phenyl optionally substituted by one or two substituents selected from $(\text{C}_1\text{-C}_3)$ lower alkyl, halogen, amino, $(\text{C}_1\text{-C}_3)$ lower alkoxy or $(\text{C}_1\text{-C}_3)$ lower alkylamino;






15 the moiety:





is a five membered aromatic (unsaturated) nitrogen containing heterocyclic ring where D is carbon and E and

-352-

F are selected from carbon and nitrogen and wherein the carbon atoms may be optionally substituted by a substituent selected from halogen, (C₁-C₃) lower alkyl, hydroxy, -COCCl₃, -COCF₃,



5



-353-

-CHO, amino, (C₁-C₃)lower alkoxy, (C₁-C₃)lower alkylamino, CONH-lower alkyl(C₁-C₃), and -CON[lower alkyl(C₁-C₃)]₂; q is one or two;

R_b is independently selected from hydrogen, -CH₃ or -C₂H₅;

R_e is H, lower alkyl(C₁-C₃), hydroxyethyl, -CH₂CO₂R⁵⁰, -CH₂C(CH₂OH)₃;


R⁵⁰ is H or lower alkyl(C₁-C₄);

R³ is a moiety of the formula:



10

wherein Ar is a moiety selected from the group consisting of




15 R⁴ is selected from hydrogen, lower alkyl(C₁-C₃); -CO-lower alkyl(C₁-C₃);

R² is selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, hydroxy and halogen; R⁵ is selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy


20 and halogen;

R⁶ is selected from (a) moieties of the formula:




-355-


wherein cycloalkyl is defined as C₃ to C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently selected from hydrogen, -CH₃, -C₂H₅,




- 5 - (CH₂)_q-O-lower alkyl (C₁-C₃) and -CH₂CH₂OH, q is one or two, and R₁, R₂ and R_b are as hereinbefore defined;
 (b) moieties of the formula:






- 10 wherein R⁷ is lower alkyl (C₃-C₈), lower alkenyl (C₃-C₈), - (CH₂)_p-cycloalkyl (C₃-C₆),



wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R¹ and R² are as hereinbefore defined;
 (c) a moiety of the formula:




- 5 wherein J is R_a, lower alkyl(C₃-C₈) branched or unbranched, lower alkenyl(C₃-C₈) branched or unbranched, O-lower alkyl(C₃-C₈) branched or unbranched, -O-lower alkenyl(C₃-C₈) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties:



10


or -CH₂-K' wherein K' is (C₁-C₃) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:






-357-

wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C₁-C₃)lower alkyl, hydroxy, -CO-lower alkyl(C₁-C₃), CHO, (C₁-C₃)lower alkoxy, -CO₂-
 5 lower alkyl(C₁-C₃), and R_a and R_b are as hereinbefore defined;

(d) a moiety of the formula:




wherein R_c is selected from halogen, (C₁-C₃) lower alkyl, -O-lower alkyl(C₁-C₃), OH,




and R_a and R_b are as hereinbefore defined wherein Ar' is
 10 selected from moieties of the formula:

-358-



wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);


- 5 R⁸ and R⁹ are independently selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),






- 10 -N(R_b)(CH₂)_vN(R_b)₂, and CF₃ wherein v is one to three and;
R¹⁰ is selected from hydrogen, halogen and lower alkyl(C₁-C₃); R¹⁴ is

-359-









-O-lower alkyl (C_3-C_8) branched or unbranched ,



-NH lower alkyl (C_3-C_8) branched or unbranched ,



-360-








q is 1 or 2;

wherein n is 0 or 1;

-361-

R_a is hydrogen, -CH₃ or -C₂H₅; R' is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;
 R⁴⁵ is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;


- 5 R²⁰ is hydrogen, halogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, NH₂, -NH(C₁-C₃)lower alkyl, -N-[(C₁-C₃)lower alkyl]₂,




and the pharmaceutically acceptable salts, esters and
 10 pro-drug forms thereof.

13. The compound according to Claim 12
 wherein A-B is the moiety:


-362-



R³ is a moiety of the formula:



wherein Ar is:




5


wherein R² and R¹⁴ are defined in Claim 12.

14. The compound according to Claim 12


wherein A-B is the moiety:



10 R³ is a moiety of the formula:



wherein Ar is:



wherein R² and R¹⁴ are defined in Claim 12.

15. The compound according to Claim 1,
[4-(3-Dimethylaminomethyl-3-hydroxy-5H,11H-pyrrolo
[2,1-c][1,4]benzodiazepine-10-carbonyl)-phenyl]-
5 biphenyl-2-carboxylic acid amide.

16. The compound according to Claim 1,
[4-(3-[1,4']Bipiperidiny1-1'-ylmethyl-5H,11H-
pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl)-3-
chloro-phenyl]-biphenyl-2-carboxylic acid amide.

10 17. The compound according to Claim 1,
(3-Chloro-4-{3-[(2-hydroxy-1,1-bis-hydroxymethyl-
ethylamino)-methyl]-5H,11H-pyrrolo[2,1-c][1,4]benzo-
diazepine-10-carbonyl)-phenyl)-biphenyl-2-carboxylic
acid amide.

15 18. The compound according to Claim 1,
[3-chloro-4-(3-[(2-dimethylamino-ethyl)-methyl]-amino)-
methyl]-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-
carbonyl)-phenyl]-biphenyl-2-carboxylic acid amide.

20 19. The compound according to Claim 1,
(3-chloro-4-[3-(4-dimethylamino-piperidin-1-ylmethyl)-
5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl]-
phenyl)-biphenyl-2-carboxylic acid amide.

25 20. The compound according to Claim 1,
N-[3-Chloro-4-(5H,11H-pyrrolo[2,1-c][1,4]benzo-
diazepine-10-carbonyl)-phenyl]-2-pyrrol-1-yl-benzamide.

21. The compound according to Claim 1,
Quinoline-8-carboxylic acid [4-(5H,11H-pyrrolo[2,1-c]
[1,4]benzodiazepine-10-carbonyl)-3-phenyl]-amide.


30 22. The compound according to Claim 1,
[3-Chloro-4-(3-dimethylaminomethyl-5H,11H-pyrrolo[2,1-c]
[1,4]benzodiazepine-10-carbonyl)-phenyl]-2-phenyl-
cyclopent-1-enecarboxylic acid amide.

23. The compound according to Claim 1,

-364-


Biphenyl-2-carboxylic acid {3-chloro-4-[3-(2-nitro-ethyl)-5H,11H-pyrrolo[2,1-c][1,4]benzodiazepine-10-carbonyl]-phenyl}-amide.

24. A compound selected from those of the
5 formula:



wherein Y is CH₂;


A-B is



10 and the moiety:






represents phenyl or substituted phenyl optionally
substituted by one or two substituents selected from
(C₁-C₃)lower alkyl, halogen, amino, (C₁-C₃)lower alkoxy
15 or (C₁-C₃)lower alkylamino;
the moiety:



is a five membered aromatic (unsaturated) nitrogen
containing heterocyclic ring wherein D, E and F are
20 carbon wherein the carbon atoms may be optionally
substituted by a substituent selected from

-365-




-CHO, and (C₁-C₃) lower alkylamino;


q is one or two;

- 5 R_b is independently selected from hydrogen, -CH₃ or -C₂H₅;

R³ is a moiety of the formula:



wherein Ar is a moiety selected from the group
10 consisting of




R⁴ is selected from hydrogen, lower alkyl (C₁-C₃); -CO-lower alkyl (C₁-C₃);


-366-

R^1 and R^2 are independently selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, hydroxy and halogen; R^5 is selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;

5 R^6 is selected from (a) moieties of the formula:




Ar' is selected from moieties of the formula:



10 wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);

R^8 and R^9 are independently selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃,
15 -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),

-367-




$-\text{N}(\text{R}_b)(\text{CH}_2)_v\text{N}(\text{R}_b)_2$, and CF_3 wherein v is one to three and;

R^{10} is selected from hydrogen, halogen and lower


5 alkyl(C_1-C_3);

wherein cycloalkyl is defined as C_3 to C_6 cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently selected from hydrogen, $-\text{CH}_3$, $-\text{C}_2\text{H}_5$,




10 $-(\text{CH}_2)_q-\text{O}-\text{lower alkyl}(\text{C}_1-\text{C}_3)$ and $-\text{CH}_2\text{CH}_2\text{OH}$, q is one or two, and R_1 , R_2 and R_b are as hereinbefore defined;

(b) moieties of the formula:




15 wherein R^7 is lower alkyl(C_3-C_8), lower alkenyl(C_3-C_8), $-(\text{CH}_2)_p$ -cycloalkyl(C_3-C_6),

-368-




wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R^1 and R^2 are as hereinbefore defined;
 (c) a moiety of the formula:




5

wherein J is R_a , lower alkyl(C₃-C₈) branched or unbranched, lower alkenyl(C₃-C₈) branched or unbranched, O-lower alkyl(C₃-C₈) branched or unbranched, -O-lower alkenyl(C₃-C₈) branched or unbranched, tetrahydrofuran,
 10 tetrahydrothiophene, the moieties:

-369-



or $-CH_2-K'$ wherein K' is (C_1-C_3) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:




5

wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C_1-C_3) lower alkyl, hydroxy, $-CO-$ lower alkyl (C_1-C_3) , CHO, (C_1-C_3) lower alkoxy, $-CO_2-$ lower alkyl (C_1-C_3) , and R_a and R_b are as hereinbefore defined;




10

(d) a moiety of the formula:


-370-



wherein R_c is selected from halogen, (C_1-C_3)
lower alkyl, $-O$ -lower alkyl (C_1-C_3) , OH ,




and R_a and R_b are as hereinbefore defined;



-371-





wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);

- R⁸ and R⁹ are independently selected from hydrogen,
 5 lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen,
 -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃,
 -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),











- N(R_b)(CH₂)_vN(R_b)₂, and CF₃ wherein v is one to three
 10 and;
 R¹⁰ is selected from hydrogen, halogen and lower
 alkyl(C₁-C₃);

-372-

 R^{14} is-O-lower alkyl (C_3-C_8) branched or unbranched ,-NH lower alkyl (C_3-C_8) branched or unbranched ,

-373-



q is 1 or 2;





-374-

wherein n is 0 or 1;

R_a is hydrogen, -CH₃ or -C₂H₅; R' is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;

R⁴⁵ is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy
5 and halogen;


R²⁰ is hydrogen, halogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, NH₂, -NH(C₁-C₃)lower alkyl, -N-[(C₁-C₃)lower alkyl]₂,



10 and the pharmaceutically acceptable salts, esters and pro-drug forms thereof.


25. The compound according to Claim 24 wherein Ar is:

-375-



wherein R¹, R² and R⁶ are defined in Claim 24.


26. The compound according to Claim 24
wherein Ar is:



5


wherein R¹, R² and R¹⁴ are defined in Claim 24.

27. A compound selected from those of the
formula:



10 wherein Y is CH₂;

A-B is




and the moiety:






15 represents phenyl or substituted phenyl optionally
substituted by one or two substituents selected from

-376-

(C₁-C₃)lower alkyl, halogen, amino, (C₁-C₃)lower alkoxy
or (C₁-C₃)lower alkylamino;
the moiety:



- 5 is a five membered aromatic (unsaturated) nitrogen containing heterocyclic ring wherein D, E and F are carbon wherein the carbon atoms may be optionally substituted by a substituent selected from




10

-CHO, and (C₁-C₃)lower alkylamino;

q is one or two;


R_b is independently selected from hydrogen, -CH₃ or -C₂H₅;

- 15 R³ is a moiety of the formula:



-377-

wherein Ar is a moiety selected from the group consisting of




R⁴ is selected from hydrogen, lower alkyl(C₁-C₃); -CO-

5 lower alkyl(C₁-C₃);


R¹ and R² are independently selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, hydroxy and halogen; R⁵ is selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;

10 R⁶ is selected from (a) moieties of the formula:




Ar' is selected from moieties of the formula:

-378-




wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);

- 5 R^8 and R^9 are independently selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),




- 10 $-N(R_b)(CH_2)_vN(R_b)_2$, and CF₃ wherein v is one to three and;
 R^{10} is selected from hydrogen, halogen and lower alkyl(C₁-C₃);
 wherein cycloalkyl is defined as C₃ to C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently
 15 selected from hydrogen, -CH₃, -C₂H₅,

-379-




- (CH₂)_q-O-lower alkyl (C₁-C₃) and -CH₂CH₂OH, q is one or two, and R₁, R₂ and R_b are as hereinbefore defined;

(b) moieties of the formula:




5

wherein R⁷ is lower alkyl (C₃-C₈), lower alkenyl (C₃-C₈), - (CH₂)_p-cycloalkyl (C₃-C₆),








10 wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R¹ and R² are as hereinbefore defined;
(c) a moiety of the formula:


-380-



wherein J is R_a , lower alkyl (C₃-C₈) branched or unbranched, lower alkenyl (C₃-C₈) branched or unbranched, O-lower alkyl (C₃-C₈) branched or unbranched, -O-lower alkenyl (C₃-C₈) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties:



or -CH₂-K' wherein K' is (C₁-C₃) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:




wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C₁-C₃) lower alkyl, hydroxy,




-381-

-CO-lower alkyl(C₁-C₃), CHO, (C₁-C₃)lower alkoxy, -CO₂-lower alkyl(C₁-C₃), and R_a and R_b are as hereinbefore defined;


(d) a moiety of the formula:



wherein R_c is selected from halogen, (C₁-C₃) lower alkyl, -O-lower alkyl(C₁-C₃), OH,




and R_a and R_b are as hereinbefore defined;



wherein W' is selected from O, S, NH, N-lower alkyl(C_1 - C_3), NHCO-lower alkyl(C_1 - C_3), and NSO₂lower alkyl(C_1 - C_3);

R^8 and R^9 are independently selected from hydrogen, lower alkyl(C_1 - C_3), -S-lower alkyl(C_1 - C_3), halogen, -NH-lower alkyl(C_1 - C_3), -N-[lower alkyl(C_1 - C_3)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C_1 - C_3),




-N(R_b)(CH₂)_vN(R_b)₂, and CF₃ wherein v is one to three and;




R^{10} is selected from hydrogen, halogen and lower alkyl(C_1 - C_3);

R¹⁴ is









-O-lower alkyl (C₃-C₈) branched or unbranched,



-NH lower alkyl (C₃-C₈) branched or unbranched,



-384-



q is 1 or 2;

-385-







wherein n is 0 or 1;

R_a is hydrogen, -CH₃ or -C₂H₅; R' is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;

R⁴⁵ is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy

5 and halogen;


R²⁰ is hydrogen, halogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, NH₂, -NH(C₁-C₃)lower alkyl, -N-[(C₁-C₃)lower alkyl]₂,



10 and the pharmaceutically acceptable salts, esters and pro-drug forms thereof.


-386-

28. The compound according to Claim 27
wherein Ar is:




and R² and R⁶ are defined in Claim 27.

5 29. The compound according to Claim 27
wherein Ar is:




and R² and R¹⁴ are as defined in Claim 27.

10 30. A compound selected from those of the
formula:



wherein Y is CH₂;

A-B is a moiety selected from




15 and the moiety:




represents phenyl or substituted phenyl optionally
substituted by one or two substituents selected from

-387-

(C₁-C₃)lower alkyl, halogen, amino, (C₁-C₃)lower alkoxy
or (C₁-C₃)lower alkylamino;
the moiety:




- 5 is a five membered aromatic (unsaturated) nitrogen containing heterocyclic ring wherein D, E and F are carbon and wherein the carbon atoms may be optionally substituted by a substituent selected from ,
-CH=CH-NO₂, -(CH₂)_qNO₂,




10

- q is one or two;
R_b is independently selected from hydrogen, -CH₃ or -C₂H₅;
R_e is H, lower alkyl(C₁-C₃), hydroxyethyl, -CH₂CO₂R⁵⁰,
15 -CH₂C(CH₂OH)₃;
R⁵⁰ is H or lower alkyl(C₁-C₄);
R³ is a moiety of the formula:







-388-

wherein Ar is a moiety selected from the group consisting of



- R⁴ is selected from hydrogen, lower alkyl (C₁-C₃); -CO-
 5 lower alkyl (C₁-C₃);
 R¹ and R² are independently selected from hydrogen, (C₁-C₃) lower alkyl, (C₁-C₃) lower alkoxy, hydroxy and halogen; R⁵ is selected from hydrogen, (C₁-C₃) lower alkyl, (C₁-C₃) lower alkoxy and halogen;
 10 R⁶ is selected from (a) moieties of the formula:

-389-



$-\text{NH}-\text{C}(=\text{O})-\text{O}-\text{lower alkyl (C}_3\text{-C}_8\text{) straight or branched,}$

$-\text{NH}-\text{C}(=\text{O})-\text{lower alkyl (C}_3\text{-C}_8\text{) straight or branched,}$

$-\text{NHSO}_2-\text{lower alkyl (C}_3\text{-C}_8\text{) straight or branched,}$


$-\text{NH}-\text{C}(=\text{O})-\text{O}-\text{lower alkenyl (C}_3\text{-C}_8\text{) straight or branched,}$

$-\text{NH}-\text{C}(=\text{O})-\text{lower alkenyl (C}_3\text{-C}_8\text{) straight or branched,}$


$-\text{NHSO}_2-\text{lower alkenyl (C}_3\text{-C}_8\text{) straight or branched,}$

-390-



wherein cycloalkyl is defined as C₃ to C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently selected from hydrogen, -CH₃, -C₂H₅,



- 5 $-(CH_2)_q-O$ -lower alkyl(C₁-C₃) and $-CH_2CH_2OH$, q is one or two, and R₁, R₂ and R_b are as hereinbefore defined;
(b) moieties of the formula:




- 10 wherein R⁷ is lower alkyl(C₃-C₈), lower alkenyl(C₃-C₈), $-(CH_2)_p$ -cycloalkyl(C₃-C₆),








-391-

wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R¹ and R² are as hereinbefore defined;
 (c) a moiety of the formula:




- 5 wherein J is R_a, lower alkyl(C₃-C₈) branched or unbranched, lower alkenyl(C₃-C₈) branched or unbranched, O-lower alkyl(C₃-C₈) branched or unbranched, -O-lower alkenyl(C₃-C₈) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties:




10

or -CH₂-K' wherein K' is (C₁-C₃) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:






wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C₁-C₃) lower alkyl, hydroxy, -CO-lower alkyl (C₁-C₃), CHO, (C₁-C₃) lower alkoxy, -CO₂- lower alkyl (C₁-C₃), and R_a and R_b are as hereinbefore defined;

(d) a moiety of the formula:




wherein R_c is selected from halogen, (C₁-C₃) lower alkyl, -O-lower alkyl (C₁-C₃), OH,




and R_a and R_b are as hereinbefore defined wherein Ar' is selected from moieties of the formula:

-393-



wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);


- 5 R⁸ and R⁹ are independently selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),






- 10 -N(R_b)(CH₂)_vN(R_b)₂, and CF₃ wherein v is one to three and;
R¹⁰ is selected from hydrogen, halogen and lower alkyl(C₁-C₃);

R¹⁴ is


-O-lower alkyl (C₃-C₈) branched or unbranched ,



-NH lower alkyl (C₃-C₈) branched or unbranched ,



-395-






q is 1 or 2;

wherein n is 0 or 1;

-396-

R_a is hydrogen, $-CH_3$ or $-C_2H_5$; R' is hydrogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy and halogen;
 R^{45} is hydrogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy and halogen;


- 5 R^{20} is hydrogen, halogen, (C_1-C_3) lower alkyl, (C_1-C_3) lower alkoxy, NH_2 , $-NH(C_1-C_3)$ lower alkyl, $-N-[(C_1-C_3)$ lower alkyl] $_2$,



- and the pharmaceutically acceptable salts, esters and
 10 pro-drug forms thereof.


-397-

31. A compound selected from those of the formula:



wherein Y is CH₂;


5 A-B is a moiety selected from





and the moiety:




represents phenyl or substituted phenyl optionally
 10 substituted by one or two substituents selected from
 (C₁-C₃)lower alkyl, halogen, amino, (C₁-C₃)lower alkoxy
 or (C₁-C₃)lower alkylamino;
 the moiety:



15 is a five membered aromatic (unsaturated) nitrogen
 containing heterocyclic ring wherein D, is carbon and E
 and F are selected from carbon or nitrogen and wherein
 the carbon atoms may be optionally substituted by a
 substituent selected from



-398-




q is one or two;

R_b is independently selected from hydrogen, -CH₃ or
 5 -C₂H₅;

R_e is H, lower alkyl(C₁-C₃), hydroxyethyl, -CH₂CO₂R⁵⁰,
 -CH₂C(CH₂OH)₃;


R⁵⁰ is H or lower alkyl(C₁-C₄);

R³ is a moiety of the formula:



10

wherein Ar is a moiety selected from the group
 consisting of



R⁴ is selected from hydrogen, lower alkyl(C₁-C₃); -CO-
 15 lower alkyl(C₁-C₃);


R¹ and R² are independently selected from hydrogen, (C₁-
 C₃)lower alkyl, (C₁-C₃)lower alkoxy, hydroxy and

-399-

halogen; R^5 is selected from hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;


R^6 is selected from (a) moieties of the formula:

-400-




-401-


wherein cycloalkyl is defined as C₃ to C₆ cycloalkyl, cyclohexenyl or cyclopentenyl; R_a is independently selected from hydrogen, -CH₃, -C₂H₅,



- 5 - (CH₂)_q-O-lower alkyl (C₁-C₃) and -CH₂CH₂OH, q is one or two, and R₁, R₂ and R_b are as hereinbefore defined;
 (b) moieties of the formula:




- 10 wherein R⁷ is lower alkyl (C₃-C₈), lower alkenyl (C₃-C₈),
 -(CH₂)_p-cycloalkyl (C₃-C₆),








-402-

wherein p is one to five and X is selected from O, S, NH, NCH₃; wherein R¹ and R² are as hereinbefore defined;
 (c) a moiety of the formula:




- 5 wherein J is R_a, lower alkyl(C₃-C₈) branched or unbranched, lower alkenyl(C₃-C₈) branched or unbranched, O-lower alkyl(C₃-C₈) branched or unbranched, -O-lower alkenyl(C₃-C₈) branched or unbranched, tetrahydrofuran, tetrahydrothiophene, the moieties:



10


or -CH₂-K' wherein K' is (C₁-C₃) lower alkoxy, halogen, tetrahydrofuran, tetrahydrothiophene or the heterocyclic ring moiety:






-403-

wherein D, E, F and G are selected from carbon or nitrogen and wherein the carbon atoms may be optionally substituted with halogen, (C₁-C₃)lower alkyl, hydroxy, -CO-lower alkyl(C₁-C₃), CHO, (C₁-C₃)lower alkoxy, -CO₂-
 5 lower alkyl(C₁-C₃), and R_a and R_b are as hereinbefore defined;

(d) a moiety of the formula:




wherein R_c is selected from halogen, (C₁-C₃) lower alkyl, -O-lower alkyl(C₁-C₃), OH,




and R_a and R_b are as hereinbefore defined wherein Ar' is
 10 selected from moieties of the formula:

-404-



wherein W' is selected from O, S, NH, N-lower alkyl(C₁-C₃), NHCO-lower alkyl(C₁-C₃), and NSO₂lower alkyl(C₁-C₃);


- 5 R^8 and R^9 are independently selected from hydrogen, lower alkyl(C₁-C₃), -S-lower alkyl(C₁-C₃), halogen, -NH-lower alkyl(C₁-C₃), -N-[lower alkyl(C₁-C₃)]₂, -OCF₃, -OH, -CN, -S-CF₃, -NO₂, -NH₂, O-lower alkyl(C₁-C₃),






- 10 -N(R_b)(CH₂)_vN(R_b)₂, and CF₃ wherein v is one to three and;
 R^{10} is selected from hydrogen, halogen and lower alkyl(C₁-C₃);

R^{14} is









-O-lower alkyl (C_3 - C_8) branched or unbranched ,



-NH lower alkyl (C_3 - C_8) branched or unbranched ,



-406-



q is 1 or 2;

-407-





wherein n is 0 or 1;

R_a is hydrogen, -CH₃ or -C₂H₅; R' is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy and halogen;

R⁴⁵ is hydrogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy

5 and halogen;

R²⁰ is hydrogen, halogen, (C₁-C₃)lower alkyl, (C₁-C₃)lower alkoxy, NH₂, -NH(C₁-C₃)lower alkyl, -N-[(C₁-C₃)lower alkyl]₂,



10 and the pharmaceutically acceptable salts, esters and pro-drug forms thereof.

32. A pharmaceutical composition useful for treating disease in a mammal characterized by excess renal reabsorption of water, the pharmaceutical composition comprising an effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt, ester or prodrug form thereof, and a suitable pharmaceutical carrier.

33. The pharmaceutical composition of Claim 32 wherein the disease in a mammal characterized by excess renal reabsorption of water is congestive heart failure, nephrotic syndrome, hyponatremia, coronary vasospasm, cardiac ischemia, renal vasospasm, liver cirrhosis, brain edema, cerebral ischemia, or cerebral hemorrhage-stroke.

34. A method for treating disease in a mammal characterized by excess renal reabsorption of water, the method comprising administering to a mammal in need thereof an effective amount of a compound of Claim 1, or a pharmaceutically acceptable salt, ester or prodrug form thereof, and a suitable pharmaceutical carrier.

35. The method of Claim 34 wherein the disease in a mammal characterized by excess renal reabsorption of water is congestive heart failure, nephrotic syndrome, hyponatremia, coronary vasospasm, cardiac ischemia, renal vasospasm, liver cirrhosis, brain edema, cerebral ischemia, or cerebral hemorrhage-stroke.

36. A compound as claimed in any one of Claims 1 to 31 for use in the treatment of disease characterised by excess renal reabsorption of water.

37. The use of a compound as claimed in any one of Claims 1 to 31 in the manufacture of a medicament for the treatment of disease characterised by excess renal reabsorption of water.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/US 97/10736

A. CLASSIFICATION OF SUBJECT MATTER

IPC 6 C07D487/04 A61K31/55 //(C07D487/04,243:00,209:00),
(C07D487/04,243:00,231:00)

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	EP 0 636 625 A (AMERICAN CYANAMID) 1 February 1995 see claims 1,9	1,32
A	--- US 5 521 173 A (VENKATESAN) 28 May 1996 see claims 1,26	1,32
P,X	--- US 5 536 718 A (ALBRIGHT) 16 July 1996 see claims 1,34 -----	1,32

☐ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"Z" document member of the same patent family

Date of the actual completion of the international search

14 October 1997

Date of mailing of the international search report

24. 10. 97

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2.
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,
Fax: (+31-70) 340-3016

Authorized officer

Alfaro Faus, I

INTERNATIONAL SEARCH REPORT

information on patent family members

Int: International Application No

PCT/US 97/10736

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 636625 A	01-02-95	AU 6877794 A	09-02-95
		CA 2128956 A	30-01-95
		CN 1106812 A	16-08-95
		CZ 9401799 A	15-02-95
		FI 943543 A	30-01-95
		HU 71495 A	28-11-95
		JP 7157486 A	20-06-95
		NO 942816 A	30-01-95
		PL 304498 A	06-02-95
		SK 88194 A	12-04-95
		US 5516774 A	14-05-96
		US 5624923 A	29-04-97
		ZA 9405603 A	09-03-95

US 5521173 A	28-05-96	AU 4656696 A	07-08-96
		WO 9622292 A	25-07-96

US 5536718 A	16-07-96	AU 4769896 A	07-08-96
		WO 9622293 A	25-07-96
		US 5610156 A	11-03-97
		US 5612334 A	18-03-97
